logo

業績一覧

講　演

  1. 林雅人，水谷友紀，大原有紗，徳重真一，齊藤裕史，西岡真理子，岡野尚弘，廣中秀一：食道癌に対するシスプラチン＋5-FU＋ペムブロリズマブ療法中に可逆性後白質脳症症候群をきたした1例．医学生・研修医・専攻医の日本内科学会ことはじめ2023．東京．2023年4月15日．
  2. 齊藤裕史，水谷友紀，前園知宏，林雅人，西岡真理子，河合桐男，岡野尚弘，藤原正親，平田佳史，橘啓盛：肺腺癌術後緩徐に増大する単発の胸膜再発に対して外科的切除で長期生存を得た1例．医学生・研修医・専攻医の日本内科学会ことはじめ2023．東京．2023年4月15日．
  3. 長島文夫：がん薬物療法の進歩．第9回杏林医学会市民公開フォーラム．三鷹．2023年5月27日.
  4. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T：Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial. ASCO. USA・ June 3rd-5th. 2023.
  5. Ikeda M, Ueno M, Furukawa M , Morizane C, Takehara T, Nishina T, Todaka A, Okano N, Hara K, Nakai Y, Ohkawa K, Sasaki T, Sugimori K, Yokoyama N, Yamamoto K, Furuse J : Subgroup analysis of double-blind, placebo-controlled Ph. 2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC): Patients with high LAT1 expression and response to nanvuranlat. ASCO. USA・ June 3rd-5th. 2023.
  6. Shoji H, Makiyama A, Katsuya H, Okano N, Negoro Y, Kito Y, Akiyoshi K, Shinozaki K, Yamamoto Y, Kawakami T, Tsuji Y, Kirishima T, Hirao M, Shimura T, Takeshita S, Funakoshi S, Shimokawa M, Yamazaki K, Hironaka S, Muro K : A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G. The 15th International Gastric Cancer Congress 2023. Yokohama. June 14th-17th. 2023.
  7. 長島文夫：支持療法の医工連携．第8回日本がんサポーティブケア学会．奈良．2023年6月22日.
  8. 長島文夫：がん薬物療法におけるポリファーマシー．第28回日本緩和医療学会学術大会．神戸．2023年6月30日.
  9. 菊地茉莉，滝智彦，中村雄，大塚弘毅，北村盾二，小倉航，道津千春，岡野尚弘，桶川隆嗣，関口久美子，中村能章，桑田健，福原浩，市川弥生子，大西宏明：がんゲノムプロファイリング検査を実施した去勢抵抗性前立腺癌の二次的所見への対応．第47回遺伝カウンセリング学会学術集．松本・オンライン．2023年7月7日．
  10. 岡野尚弘：治癒切除不能な胆道がんの新たな治療．山梨 胆道がん治療サミット．オンライン．2023年7月7日．
  11. 長島文夫：超高齢社会を迎えた我が国のがん治療．第53回腎癌研究会．札幌．2023年7月8日.
  12. 岡野尚弘：治癒切除不能な胆道癌薬物療法最新の知見．Hokkaido Gastrointestinal Cancer Symposium. オンライン．2023年7月11日．
  13. 阪本良弘，松木亮太，岡野尚弘，川口翔平，蓮井宣宏，百瀬博一，小暮正晴，鈴木裕，阿部展次,須並英二：URLA vs BR-A7膵がん―術前化療と予後―URLA vs BR-A pancreatic cancer -Preoperative chemotherapy and prognosis of patients-. 第78回消化器外科学会総会．函館・オンライン．2023年7月12日-14日．
  14. 丸木雄太池，澤賢治，佐々木満仁，小林智，三木生也，津村英隆，戸高明子，岡野尚弘，寺島健志,山下竜也，川本泰之，小島康志，今岡大，細井寛子，森実千種，上野誠，池田公史，奥坂拓志：MSI-High膵癌の臨床的特徴とペムブロリズマブの治療効果．第54回日本膵臓学会大会．福岡・オンライン．2023年7月21日-22日.
  15. 長島文夫：消化器がん薬物療法の進歩．杏林大学医学部付属病院がんと共にすこやかに生きる講演会．三鷹．2023年7月22日.
  16. 岡野尚弘：切除不能胆道癌に対する薬物療法～イミフィンジ併用の意義と使用経験を含めて～．胆道がんエキスパートWebシンポジウム.オンライン. 2023年8月21日.
  17. 長島文夫：高齢者のがん治療．第26回癌治療学会教育コース．オンライン．2023年8月26日.
  18. Mizutani T, Takei H, Kunitoh H, Wakabayashi M, Sekino Y, Tsuboi M, Ikeda N, Asamura H, Okada M, Takahama M, Ohde Y, Okami J, Shiono S, Aokage K. Watanabe S：Functional Independence of Older Adults after Lung Cancer Surgery: Final Analysis of a Prospective Observational Study. .2023 World Conference on Lung Cancer. Singapore. September 9th-12th. 2023.
  19. 岡野尚弘：新時代の肝細胞癌，胆道癌薬物療法．第6回あんず肝胆膵外科 オンライン．2023年9月21日.
  20. Kikuchi M, Ohtsuka K, Nakamura Y, Kitamura J, Miyakawa J, Doutsu C, Taki T, Ogura W, Okegawa T, Shibahara J, Hironaka S, Fukuhara H, Ichikawa Y, Ohnishi H：Clinical applications of comprehensive genomic profiling tests for castration-resistant prostate cancer. 日本人類遺伝学会第68回大会．東京・オンライン．2023年10月11日-14日．
  21. 池田公史，肱岡範，伊藤鉄英，松本繁巳，本間義崇，上野誠，岡野尚弘，青木琢，古瀬純司：膵神経内分泌腫瘍に対する治療選択MAPの有用性を検討する多施設共同研究．日本神経内分泌腫瘍研究会．栃木．2023年10月14日.
  22. 長島文夫：超高齢社会におけるがん診療．第61回日本癌治療学会学術集会．横浜．2023年10月20日．
  23. Sato T, Nishioka M, Okano N, Mizutani T, Nagashima F, Hironaka S : A case of heavily treated metastatic colon cancer with EGFR gene amplification and rearrangements, benefited from panitumumab monotherapy. 第61回日本癌治療学会学術集会．横浜・オンライン．2023年10月19日-21日.
  24. Muro K, Kawakami H, Kadowaki S, Makiyama A, Tsuda M, Hirata K, Sugimoto N, Machida N, Hara H, Hirano H, Esaki T, Komatsu Y, Hironaka S：A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7). ESMO Congress 2023. Spain・ October 20th-24th. . 2023.
  25. Mizutani T, Uemura K, Sato F：Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review. ESMO Congress 2023. Spain・ October 20th-24th. . 2023.
  26. Satake T, Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Ogawa G, Sano Y, Imaoka H, Kobayashi S, Terashima T, Ikeda M, Okano N, Yamaguchi K, Sato T, Mizuno N, Kitagawa Y, Terashima M, Ueno M：Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: an exploratory analysis of JCOG1213. ESMO Congress 2023. Spain・ October 20th-24th. . 2023.
  27. Ohba A, Ozaka M, Ogawa G, Okusaka T, Kobayashi S, Yamashita T, Ikeda M, Yasuda I, Sugimori K, Sasahira N, Ikezawa K, Miki I, Okano N, Mizuno N, Furukawa M, Shirakawa H, Sano Y, Katayama H, Furuse J, Ueno M：Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial. ESMO Congress 2023. Spain・ October 20th-24th. 2023.
  28. Kudo-Saito C, Boku N, Shoji H, Imazeki H, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Aoki K, Muro K：The FSTL1-DIP2A axis as a promising target in the anti-PD1 therapy of advanced gastric cancer. SITC 2023. USA・ November 1st-5th. 2023.
  29. 長島文夫：高齢者における胃癌薬物療法と高齢者機能評価の考え方．Medical Oncology Meet the Experts in Tokyo．東京．2023年11月10日．
  30. 岡野尚弘：高齢者膵癌に対するオニバイドの使用経験． Pancreatic Cancer Seminar. 武蔵野．2023年11月13日．
  31. 岡野尚弘：新時代の肝細胞癌薬物療法. Gastrointestinal Cancer Seminar. 横須賀. 2024年11月16日.
  32. 岡野尚弘：最新の胆道癌1次治療．みんなで考えるHCC・BTC Seminar in Ibaraki. オンライン．2023年12月1日．
  33. 長島文夫，廣中秀一，近藤晴彦：がん薬物療法における高齢者機能評価と在宅フォローの取り組み．第21回世田谷区医師会医学会．東京．2023年12月2日.
  34. Narita Y, Komori A, Hironaka S, Kawakami H, Furuta M, Kawakami T, Makiyama A, Sugiyama K, Takegawa N, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Yoshimura K, Muro K：A Prospective Observational Study of MSI Screening in Unresectable Chemotherapy-Naïve Advanced Gastric Cancer/Gastroesophageal Junction Cancer: WJOG13320GPS. ESMO Asia Congress 2023. Singapore・ December 1st-3rd. 2023.
  35. 岡野尚弘：胆道癌1次治療におけるNewスタンダード．第2回秋田県胆道癌治療講演会．秋田．2023年12月7日.
  36. 岡野尚弘：免疫チェックポイント阻害薬時代の胆道癌・肝細胞癌治療．Hepato-Biliary-Pancreatic Seminar. オンライン．2023年12月8日．
  37. 岡野尚弘：切除不能な肝細胞癌に対する1次治療レジメンの再考～STRIDEレジメンに適した患者背景～. Immuno-Oncology Web Symposium. オンライン．2023年12月14日．
  38. 長島文夫：脆弱ながん患者における全身状態評価と治療・支援と今後の課題．中国・四国広域がんプロ養成コンソーシアムがん看護インテンシブコース．オンライン．2023年12月16日．
  39. 岡野尚弘：新たな時代が到来した胆道癌薬物療法．三鷹市薬剤師会勉強会．オンライン．2023年12月20日.
  40. 岡野尚弘：胆道癌治療の進化と深化．新時代を迎えた切除不能胆道癌治療～TOPAZ-１レジメンの臨床での疑問を解決する～．オンライン．2023年12月21日．
  41. Hirata K, Kawakami H, Kadowaki S, Makiyama A, Tsuda M, Sugimoto N, Machida N, Hara H, Hirano H, Esaki T, Komatsu Y, Hironaka S, Chiba Y, Muro K：Relationship between the number of positive MSI markers and the efficacy of NIVO+IPI therapy in MSI-H gastric cancer: A subgroup analysis of NO LIMIT study (WJOG13320G/CA209-7W7). ASCO-GI. USA・ January 18th-20th. 2024.
  42. Tsushima T, Hironaka S, Tsubosa Y, Kato K, Nomura M, Hara H, Kitagawa Y, Koyanagi K, Kajiwara T, Takegawa N, Matsubara H, Baba H, Morita M, Masuzawa T, Hasegawa H, Kojima T, Machida R, Sasaki K, Takeuchi H, Kadowaki S：A randomized phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE). ASCO-GI. USA・ January 18th-20th. 2024.
  43. Maruki Y, Ikezawa K, Sasaki M, Kobayashi S, Todaka A, Tsumura H, Okano N, Terashima T, Yamashita T, Kawamoto Y, Kojima Y, Imaoka H, Hosoi H, Morizane C , Ueno M, Ikeda M, Okusaka T：Clinical characteristics and course of hepatobiliary and pancreatic malignant tumors with high microsatellite instability after pembrolizumab: A multi-center observational study. ASCO-GI. USA・ January 18th-20th. 2024.
  44. Asama H, Okuyama H, Kawamoto Y, Umemoto K, Yamai T, Kobayashi S, Watanabe M, Hamamoto Y, Furukawa T, Kitano Y, Motoya M, Suzuki Y, Ohba A, Watanabe K, Okano N, Shioji K, Kobayashi N, Imaoka H, Terashima T, Ueno M：Safety and efficacy of chemotherapy for patients (pts) with unresectable pancreatic cancer (uPC) concomitant with collagen disease: A multicenter retrospective observational study. ASCO-GI. USA・ January 18th-20th. 2024.
  45. Shibuki T, Nakamura Y, Ueno M, Furukawa M, Kawamoto Y, Itoh S, Umemoto K, Sudo K, Satoh T, Mizuno N, Asagi A, Okano N, Shimizu S, Bekaii-Saab T, Strickler J, Fujisawa T, Bando H, Yoshino T, Morizane C, Ikeda M：Prognostic effects of co-occurring TP53 and KRAS alterations in patients with advanced biliary tract cancer. ASCO-GI. USA・ January 18th-20th. 2024.
  46. Okano N, Nagashima F, Nishioka M, Kusaka H, Yamamoto K, Furuse J：Treatment outcomes by stratifying the N-acetyl transferase 2 phenotype in pre-treated advanced refractory biliary tract cancer patients treated by nanvuranlat: an L-type amino acid transporter inhibitor, an ad-hoc analysis of a randomized, double-blind, placebo-controlled Phase 2 study. ASCO-GI. USA・ January 18th-20th. 2024.
  47. Hashimoto T, Fujisawa T, Machida N, Makiyama A, Boku S, Kadowaki S, Takahashi N, Oki E, Morizane C, Sunakawa Y, Komatsu Y, Okano N, Esaki T, Ohta T, Sato T, Ozaki H, Iida N, Yoshiaki Nakamura1 Y, Bando H, Yoshino T : Efficacy of biomarker-matched therapy in clinical trials for advanced gastrointestinal cancers: A pooled analysis of SCRUM-Japan studies. ASCO-GI. USA・ January 18th-20th. 2024.
  48. 長島文夫：老年腫瘍学の概論．第42回日本口腔腫瘍学会総会．札幌．2024年1月26日．
  49. 長島文夫：超高齢社会を迎えた我が国のがん治療．第8回京都泌尿器腫瘍講演会．京都．2024年2月2日．
  50. 岡野尚弘：胆道癌薬物療法Precision Medicine. 多摩GIオンコロジーカンファレンス．オンライン．2月2日．
  51. 町田望，門脇重憲，仁科智裕，砂川優，前北隆雄，松本繁巳，西岡真理子，後藤知之，浜本康夫，安井久晃，古田光寛，梶原猛史，新井裕之，北野雅之，長島文夫，川邉里紗，岡田昌史，武藤学，室圭：Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology®: A feasibility study. 第21回日本臨床腫瘍学会学術集会．名古屋・オンライン．2024年2月22日
  52. Ozaka M, Ohba A, Mizusawa J, Okusaka T, Kobayashi S, Yamashita T, Ikeda M, Yasuda I, Sugimori K, Sasahira N, Ikezawa K, Miki I, Okano N, Mizuno N, Furukawa M, Shirakawa H, Sano Y, Katayama H, Furuse J, Ueno M：GnP vs. mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: Additional data from the GENERATE (JCOG1611) trial. 第21回日本臨床腫瘍学会学術集会.名古屋・オンライン. 2024年2月22日-24日.
  53. 清水大輔，岡野尚弘，西岡真理子，齊藤裕史，佐藤太龍，長島文夫，廣中秀一：局所進行膵癌とEGFR遺伝子変異陽性IV期肺腺癌の重複癌に対してゲムシタビン＋ナブパクリタキセル療法にオシメルチニブを併用し治療し得た一例．第21回日本臨床腫瘍学会学術集会．名古屋・オンライン．2024年2月22日-24日.
  54. Ikezawa K, Maruki Y, Kai Y, Takada R, Sasaki M, Kobayashi S, Todaka A, Tsumura H, Okano N, Terashima T, Yamashita T, Kawamoto Y, Kojima Y, Imaoka H, Hosoi H, Morizane C, Ueno M, Ikeda M, Okusaka T：Clinical characteristics of MSI-H hepatobiliary and pancreatic cancer: A multicenter observational study. 第21回日本臨床腫瘍学会学術集会．名古屋・オンライン．2024年2月22日-24日.
  55. Hashimoto T, Nakamura Y, Komatsu Y, Takahashi N, Okano N, Morizane C, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Fujisawa T, Bando H, Yoshino T：The utility of circulating tumor DNA in gastrointestinal stromal tumor–a pooled analysis of SCRUM-Japan trials–. 第21回日本臨床腫瘍学会学術集会．名古屋・オンライン．2024年2月22日-24日.
  56. Sato T, Saito Y, Nishioka M, Okano N, Mizutani T, Nagashima F, Hisamatsu T, Hironaka S. A case of metastatic colon cancer with EGFR gene amplification and KRAS mutation benefited from panitumumab rechallenge. 第21回日本臨床腫瘍学会学術集会．名古屋．2024年2月22日-24日．
  57. Shibuki T, Nakamura Y, Ueno M, Furukawa M, Kawamoto Y, Itoh S, Umemoto K, Sudo K, Satoh T, Mizuno N, Asagi A, Okano N, Shimizu S, Ohtsubo K, Matsumoto T, Fujisawa T, Bando H, Yoshino T, Morizane C, Ikeda M：Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes. 第21回日本臨床腫瘍学会学術集会．名古屋・オンライン．2024年2月22日-24日．
  58. 長島文夫，廣中秀一，近藤晴彦：がん薬物療法副作用対応の工夫（超高齢社会の在宅フォローを含めて）．第6回調布医学会．調布．2024年3月10日.
  59. 長島文夫：高齢者の化学療法について．東京都がん診療連携協議会研修部会2023年度がんの薬物療法研修会．オンライン．2024年3月23日.
  60. Sakamoto Y, Momose H, Okano N, Matsuki R, Hasui H, Kogure M, Suzuki Y, Hironaka S. Impact of aggressive surgical resection of initially unresectable hepatocellular carcinoma after lenvatinib or atezolizumab plus bevacizumab treatment. APASL 2024 Kyoto. Kyoto. March 27th-31st. 2024.

論　文

欧文

  1. Ura T, Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, Fushiki K, Chin K, Tomori A, Okuno T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Seki S, Kitagawa Y: Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. Esophagus. 20(2). 272-280. 2023.
  2. Hashimoto T, Otsu S, Hironaka S, Takashima A, Mizusawa J, Kataoka T, Fukuda H, Tsukamoto S, Hamaguchi T, Kanemitsu Y: Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future Oncol. 19(23). 1593-1600. 2023.
  3. Kitamura H, Nakazawa J, Nagashima F, Andou M, Furuse J（Department of Medical Oncology, Kyorin University School of Medicine）：The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study. Intern Med. 62(11). 1573-1580.2023.
  4. Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka S, Boku N, Muro K: Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G). BMC Cancer. 23(1). 726. 2023.
  5. Muro K, Shitara K, Yamaguchi K, Yoshikawa T, Satake H, Hara H, Sugimoto N, Machida N, Goto M, Kawakami H, Amagai K, Omuro Y, Esaki T, Hironaka S, Nishina T, Komatsu Y, Matsubara H, Shiratori S, Han S, Satoh T, Ohtsu A: Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer. J Gastrointest Cancer. 54(3). 951-961. 2023.
  6. Otsu S, Hironaka S: Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer. Cancers (Basel). 15(18). 4564. 2023.
  7. Okuyama A, Mizutani T, Tachibana K, Higashi T, Ogawa A: Treatment Patternsand Postoperative Activities of Daily Living in Patients with Non-small CellLung Cancer: A Retrospective Study Using Nationwide Health Services UtilizationData in Japan. Ann Surg Oncol. 31(5). 3409-3416. 2023. Epub ahead of print.
  8. Matsuoka A, Mizutani T, Kaji Y, Yaguchi-Saito A, Odawara M, Saito J, FujimoriM, Uchitomi Y, Shimazu T: Barriers and facilitators to implementing geriatricassessment in daily oncology practice in Japan: A qualitative study using an implementation framework. J Geriatr Oncol. 14(8). 101625. 2023.
  9. Takei H, Kunitoh H, Wakabayashi M, Kataoka T, Sekino Y, Mizutani T, Tsuboi M, Ikeda N, Asamura H, Okada M, Takahama M, Ohde Y, Okami J, Shiono S, Aokage K, Watanabe SI; Lung Cancer Surgical Study Group of the Japan Clinical OncologyGroup, Japan: Prospective, Multi-Institutional Observational Study of Deterioration in Activities of Daily Living in Elderly Patients After Lung Cancer Surgery. JTO Clin Res Rep. 4(8). 100550. 2023.
  10. Harada T, Tsuji T, Tanaka M, Konishi N, Yanagisawa T, Koishihara Y, Ueno J,Mizutani T, Nishiyama N, Soeda R, Hijikata N, Ishikawa A, Hayashi R: Priority of the basic and instrumental activities of daily living in older patients with cancer prescribed rehabilitation: a cross-sectional survey. Support Care Cancer. 31(8). 503. 2023.
  11. Ishiki H, Kikawa Y, Terada M, Mizusawa J, Honda M, Iwatani T, Mizutani T, Mori K, Nakamura N, Miyaji T, Yamaguchi T, Ando M, Nakamura K, Fukuda H, Kiyota N; PRO/QOL research Committee of Japan Clinical Oncology Group: Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy. Jpn J Clin Oncol. 53(3). 195-202. 2023.
  12. Imai M, Nakamura Y, Denda T, Komatsu Y, Yuki S, Nishina T, Hamamoto Y, Hara H, Esaki T, Kawakami H, Kato K, Satoh T, Okano N, Sunakawa Y, Taniguchi H, Yamaguchi K, Yamada T, Miki I, Wakabayashi M, Kuwata T, Shitara K, Yoshino T: Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis. ESMO Gastrointestinal Oncology . 2023. DOI:10.1016/j.esmogo.2023.08.007.
  13. Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kanazawa A, Ando K, Horita Y, Goto M, Okano N, Moriwaki T, Satoh T, Tsuji A, Yamashita K, Asano C, Abe Y, Nomura S, Yoshino T: Plasma angiogenic factors as predictors of the efficacy of second-line chemotherapy combined with angiogenesis inhibitors in metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit Study. Clin Colorectal Cancer . 2024. DOI : 10.1016/j.clcc.2024.01.003. Epub ahead of print.
  14. Imaoka H, Ikeda M, Nomura N, Morizane C, Okusaka T, Ozaka M, Shimizu S, Yamazaki K, Okano O, Sugimori K, Shirakawa H, Mizuno N, Satoi S, Yamaguchi H, Sugimoto R, Gotoh K, Sano K, Asagi A, Nakamura K, Ueno M: Development of a nomogram to predict survival in advanced biliary tract cancer. Sci Rep. 13(1). 21548. 2023.
  15. Todaka A, Sasaki M, Ueno H, Goto T, Murohisa G, Mizuno M, Ozaka M, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Nanami S, Boku N: FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia – Nationwide study analysis. Anticancer Res. 43(9). 4115-4123. 2023.
  16. Kawabata R, Chin K, Takahari D, Hosaka H, Muto O, Shindo Y, Nagata N, Yabusaki H, Imamura H, Endo S, Kashiwada T, Nakamura M, Jun Hihara J, Michiya Kobayashi M, Sagawa T, Saito S, Sato A, Yamada T, Okano N, Shimada K, Matsushima M, Kataoka M, Matsumoto S, Goto M, Kotaka M, Shiraishi T, Yamai H, Nagashima F, Ishizuka N, Yamaguchi K: Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study. Gastric Cancer. 26(6). 1020-1029. 2023.
  17. Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, Nishina T, Yamada T, Yuki S, Narita Y, Hara H, Ohta T, Esaki T, Hamamoto Y, Kato K, Yamamoto Y, Minashi K, Ohtsubo K, Izawa N, Kawakami H, Kato T, Satoh T, Okano N, Tsuji A, Yamazaki K, Yoshino T, Maehara Y, Oki E: Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study). Br J Cancer. 129(6). 1032-1039. 2023.
  18. Imaoka H, Ikeda M, Umemoto K, Sunakawa Y, Ueno M, Ueno H, Ozaka M, Kuwahara T, Okano N, Kanai M, Hisano T, Suzuki Y, Asagi A, Shioji K, Todaka A, Tsuji K, Ikezawa K, Miki I, Komatsu Y, Akutsu N, Yamashita T, Okuyama H, Furuse J, Nagano H: Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment. Jpn J Clin Oncol. 53(9). 764-773. 2023.
  19. Aoki Y, Nakamura Y, Denda T, Ohta T, Esaki T, Shiozawa M, Yamaguchi K, Yamazaki K, Sunakawa Y, Kato T, Okano N, Taniguchi H, Sato T, Oki E, Nishina T, Komatsu Y, Matsuhashi N, Goto M, Yasui H, Ohtsubo K, Moriwaki T, Takahashi N, Horita Y, Boku S, Wakabayashi M, Ikeno T, Mitani R, Yuasa M, Yoshino T: Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy. JCO Precis Oncol. 2023. DOI : 10.1200/PO.22.00688.
  20. Mizuno N, Ioka T, Ogawa G, Nakamura S, Hiraoka N, Ito Y, Katayama H, Takada R, Kobayashi S, Ikeda M, Miwa H, Okano N, Kuramochi H, Sekimoto M, Okusaka T, Ozaka M, Todaka A, Gotoh K, Tobimatsu K, Yamaguchi H, Nakagohri T, Kajiura S, Sudo K, Okamura K, Shimizu S, Shirakawa H, Kato N, Sano K, Iwai T, Fujimori N, Ueno M, Ishii H, Furuse J; Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG): Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106. Jpn J Clin Oncol. 53(8). 704-713. 2023.
  21. Kato N, Kudo M, Tsuchiya K, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Okano N, Ikeda M, Morimoto M, Kuroda S, Kimura A: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study. Hepatol Res. 53(5). 409-416. 2023.
  22. Kito Y, Kawakami H, Mitani S, Nishina S, Matsumoto T, Tsuzuki T, Shinohara Y, Shimokawa H, Kumanishi R, Ohta T, Katsuya H, Kawakami T, Nishina T, Hasegawa H, Akiyoshi K, Chiba Y, Yamazaki K, Hironaka S, Muro K: Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). Oncologist. 29(3). e330-e336. 2024
  23. Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T: A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA Oncol. 10(1). 95-102. 2024.
  24. Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K: A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G. Target Oncol. 19(2). 181-190. 2024.
  25. Okano N, Morizane C, Okusaka T, Sadachi R, Kataoka T, Kobayashi S, Ikeda M, Ozaka M, Mizutani T, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Gotoh K, Yamaguchi H, Ishii H, Ohba A, Furuse J, Ueno M; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG): Early tumor shrinkage and depth of response as predictors of survival for advanced biliary tract cancer: an exploratory analysis of JCOG1113. Oncologist. 29(1). e97-e107. 2024.
  26. Nishioka M, Okano N, Wakabayashi M, Ikeno T, Hayashi M, Mizutani T, Nagashima F, Furuse J: A retrospective study of gemcitabine plus nab-paclitaxel for advanced pancreatic cancer refractory to gemcitabine monotherapy. Anticancer Res. 44(3). 1233-1239. 2024.

和文

  1. 長島文夫：がん薬物療法の進歩．杏林医学会雑誌．54巻4号．213-216．2023．
  2. 山本圭一郎，水谷友紀，岩谷胤生：医療者が考える医療経済の落とし穴 医療者が医療資源の配分について論じる前に知って欲しいこと．臨床薬理．54巻2号．63-70．2023．
  3. 岡野尚弘：膵癌の遠隔転移 免疫チェックポイント阻害薬．胆と膵．44巻11号．1587-1592．2023．
  4. 水谷友紀，柳川まどか，山本寛，濱口哲弥，福元剛，松岡歩，西山菜々子，原田剛志，清水奈緒美，渡邉雄貴，浦久保安輝子，岡野尚弘，小川朝生：多職種による老年腫瘍ケースカンファレンス 日本老年腫瘍研究会の試み．腫瘍内科．32巻1号．97-102．2023．

著書

  1. 水谷友紀(分担執筆)：分子標的薬 ALK阻害薬 ロルラチニブ．YORi-SOUがんナーシング別冊がん化学療法の薬-抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬-はや調べノート2023・2024年版．上野誠，古瀬純司 監修．メディカ出版．2023．134-135.
  2. 水谷友紀(分担執筆)：分子標的薬 EGFR阻害薬 ダコミチニブ水和物．YORi-SOUがんナーシング別冊がん化学療法の薬-抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬-はや調べノート2023・2024年版．上野誠，古瀬純司 監修．メディカ出版．2023．134-135．
  3. 岡野尚弘(分担執筆)：胆道がん．新臨床腫瘍学 改訂第7版．日本臨床腫瘍学会 編．南江堂．2024．454-458．

その他

  1. 長島文夫：杏林大学地域総合研究所紀要巻頭言．2023年4月．

講　演

  1. 長島文夫：Vulnerable症例への治療戦略 診療ガイドラインを参考に．第8回お茶の水Cancer Conference．オンライン．2022年4月7日．
  2. 廣田玲，岡野尚弘，林雅人，西岡真理子，前園知宏，河合桐男，關里和，川村直弘，水谷友紀，長島文夫：5次治療のアテゾリズマブ/ベバシズマブ併用療法によりmodified RECISTでcomplete responseが得られた肝細胞癌の一例，第369回日本消化器病学会関東支部例会．東京・オンライン．2022年5月14日．
  3. 岡野尚弘：高頻度マイクロサテライト不安定性高齢者膵癌にペムブロリズマブを投与した1例．第64回日本老年医学会．大阪・オンライン．2022年6月3日．
  4. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T : Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). 2022 ASCO Annual Meeting. USA・ June 3rd-7th. 2022.
  5. 松井敏史，木棚究，山中崇，長島文夫．：ロボットによる認知症高齢者の介護支援．日本老年医学会．大阪・オンライン．2022年6月4日．
  6. 松井敏史，須藤珠水，永田あかね，前野聡子，長島文夫，木棚究，山中崇：排泄支援ロボット「ラップポン」の自立支援排泄ケアプランへの組み込み．日本老年医学会．大阪・オンライン．2022年6月4日．
  7. 松井敏史，須藤珠水，永田あかね，水木麻衣子，木棚究，山中崇，長島文夫．：移動支援ロボット「RT-2」の疾患イベント後の在宅使用での3次予防効果の検証．日本老年医学会．大阪・オンライン．2022年6月4日．
  8. 長島文夫：胃がん治療ガイドラインと最新の薬物治療について．武蔵野消化器・肝疾患医療連携懇談会．オンライン．2022年6月21日．
  9. 長島文夫：全身状態の把握とそれに基づく治療の考え方．高齢者の口腔がん治療を考える会．オンライン．2022年7月8日．
  10. 長島文夫：高齢者のがん治療の考え方．Gastric Cancer Leaders Meeting．オンライン．2022年8月31日．
  11. Ueno M, Morizane C, Ikeda M, Ozaka M, Nagashima F, Kataoka T, Mizusawa J, Ohba A, Kobayashi S, Imaoka H, Kasuga A, Okano N, Nagasaka Y, Kurishita K, Tomatsuri S, Sasaki M, Shibata T, Nakamura K, Furuse J, Okusaka T : Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE). ESMO Congress 2022. France・ September 9th-13th. 2022.
  12. Shoji H, Boku N, Kudo-Saito C , Nagashima K , Tsugaru K , Takahashi N , Kawakami T, Amanuma Y, Wakatsuki T , Okano N , Narita Y, Yamamoto Y, Kizawa R , Imazeki H , K Aoki K, Muro K : Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study) . ESMO Congress 2022. France・ September 9th-13th. 2022.
  13. Boku N, Kudo-Saito C, Imazeki H, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K : Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study). ESMO Congress 2022. France・ September 9th-13th. 2022.
  14. 岡野尚弘：消化器がんに対する最新の化学療法-がん治療医とかかりつけ医の連携の重要性. 東大和市医師会学術講演会．オンライン．2022年9月9日．
  15. 長島文夫：食道がん・胃がんの薬物療法．杏林大学がん看護研修会．オンライン．2022年9月24日．
  16. Okano N, Inoue Y, Kawai M, Ueno M, Yu X, Takahashi S, Wang W, Takahashi H, Yukiyasu Okamura Y, Morinaga S, Matsumoto I, Shimizu Y, Yoshida K, Yamamoto T, Ohtsuka M, Inokawa Y, Esaki M, Yamamoto K, Yamaue H, Furuse J : Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery was planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel
    (PC-CURE-1). 33rd IASGO World Congress. TURKEY. September 29th. 2022.
  17. 林雅人，岡野尚弘，鈴木裕，廣田玲，西岡真理子，前園知宏，河合桐男，水谷友紀，松木亮太，小暮正晴，杉山政則，柴原純二，阪本良弘，長島文夫：遠位胆管癌術後肝転移に対して化学療法後に肝切除を行い長期生存が得られた1例．第58回日本胆道学会学術集会．横浜・オンライン．2022年10月14日．
  18. 廣中秀一：食道がん1次化学療法のNew Strategy～Nivo+Ipi, Nivo+Chemo併用療法～．食道がん1次治療 オプジーボ併用療法WEBライブセミナー -IO併用療法におけるirAEマネジメント．オンライン．2022年10月17日．
  19. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T : Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancers (BTCs) : An investigator-initiated multicenter phase 2 trial (HERB trial). 第60回日本癌治療学会学術集会．神戸・オンライン．2022年10月20日-22日.
  20. Mizutani T: Interpretation of Randomized Clinical Trials. SIOG 2022 Annual Conference. October 30th. 2022.
  21. 廣中秀一：進行・再発食道がんに対する一次化学療法～ペムブロリズマブ併用でどう変わる？～．食道がん治療セミナー．オンライン．2022年11月10日．
  22. 廣中秀一：進行再発食道がん～最新の化学療法と支持療法～．第19回HEMCO．オンライン．2022年11月15日．
  23. 岡野尚弘：GISTに対する薬物療法の進歩新宿消化器がんフォーラム2022．新宿．2022年11月15日．
  24. 廣中秀一：更なる治療成績向上を目指した新たな胃癌薬物療法シークエンス．第52回胃外科・術後障害研究会．沼津．2022年11月19日．
  25. 廣中秀一：胃癌に対する化学療法～エビデンスから考える治療戦略～．Gastric Cancer Web Seminar．オンライン．2022年11月22日．
  26. 廣中秀一：進行・再発食道がんに対する一次化学療法～ペムブロリズマブ併用でどう変わる?～．Esophageal Cancer Seminar．オンライン．2022年12月2日．
  27. 岡野尚弘：消化器がんにおけるエドルミズの役割．GI Cancer Seminar in TAMA．オンライン．2022年12月2日．
  28. 廣中秀一：進行・再発食道がんに対する一次化学療法～ペムブロリズマブ併用でどう変わる?～．Esophageal Cancer Clinical Seminar．徳島．2022年12月6日．
  29. 廣中秀一：切除不能・再発胃癌に対する化学療法 ～ニボルマブによる新しい治療シークエンス～．第７回長岡胃癌講演会．オンライン．2022年12月16日．
  30. 廣中秀一：進行・再発食道がんに対する一次化学療法～ペムブロリズマブ併用でどう変わる?～．Shizuoka Esophageal Cancer Seminar．オンライン．2022年12月20日．
  31. Imazeki H, Kudo-Saito C, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N,Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Muro K, Aoki K, Boku N : CD11b+ myeloid subsets as significant prognostic biomarkers in the nivolumab therapy of gastric cancer. 国際がん研究シンポジウム．オンライン．2023年1月14日．
  32. Mitani S, Kito Y, Kawakami H, Nishina S, Matsumoto T, Tsuzuki T, Shinohara Y, Shimokawa H, Kumanishi R, Ohta T, Kimura S, Kawakami T, Nishina T, Hasegawa H, Akiyoshi K, Chiba Y, Yamazaki K, Hironaka S, Muro K : Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT). 2023 ASCO Gastrointestinal Cancers Symposium. USA・ January19th-21st. 2023.
  33. Suzuki Y, Morizane C, Mizusawa J, Sano Y, Kobayashi S, Imaoka H, Terashima T, Ikeda M, Okano N, Sugimori K, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Wada K, Tobimatsu K, Katanuma A, Okusaka T, Ozaka M, Ueno M: Comparison of clinical features by primary sites in patients with biliary tract cancer who received gemcitabine-based chemotherapy: an exploratory analysis of JCOG1113. 2023 ASCO Gastrointestinal Cancers Symposium. USA・ January 19th-21st. 2023.
  34. Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Kamei K, Yanagibashi H, Mizuno N, Gotoh K, Kawamoto Y, Shirakawa H, Okano N, Nomura T, Makino I, Takahashi A, Anbo Y, Ohta K, Katayama H, Konishi M, Ueno M, Hepatobiliary and Pancreatic Oncology Study Group of Japan Clinical Oncology Group (JCOG) : Effects of gene expressions of 5-FU metabolic pathway in a phase III trial evaluating adjuvant S-1 compared to surgery alone following curative resection for biliary tract cancer (JCOG1202A1). 2023 ASCO Gastrointestinal Cancers Symposium. USA・Online. January 19th-21st. 2023.
  35. Furuse J, Ikeda M, Ueno M, Furukawa M, Morizane C, Takehara T, Nishina T, Todaka A, Okano N, Hara K, Nakai Y, Ohkawa K, Sasaki T, Sugimori K, Yokoyama N, Yamamoto K : Nanvuranlat,an L-type amino acid transporter (LAT1) inhibitor, for pre-treated patientswith advanced, refractory biliary tract cancers (BTC): Primary endpoint results of arandomized, double-blind, placebo-controlled Phase 2 study. 2023 ASCO Gastrointestinal Cancers Symposium. USA・Online. January 19th-21st. 2023.
  36. Tsugaru K, Boku N, Kudo-Saito C, Shoji H, Imazeki H, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K : Increased LAG3-related factors predict poor prognosis after nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study). 2023 ASCO Gastrointestinal Cancers Symposium. USA・Online. January 19th-21st. 2023.
  37. Ohba A, Takumoto Y, Terashima T, Ueno M, Kobayashi S, Ikezawa K, Okano N, Fujimori N, Tsumura H, Murohisa G, Ohya A, Yamashita T, Ozaka M, Ikeda M, Okusaka T, Morizane C, Narimatsu H, Akazawa M, Shiroiwa T, Furuse J : patient-reported outcome measured in patients with pancreatic cancer receiving second-line chemotherapy : A multicenter prospective observational study. ASCO Gastrointestinal Cancers Symposium. Online・USA. January 19th-21st. 2023.
  38. Okano N, Sakamaki K, Mie T, Watanabe K, Kobayashi S, Todaka A, Suzuki Y, Kitamura H, Tanaka K, Nakagawa K, Kamei K , Umemoto K, Azemoto N, Kawamoto Y, Yanagimoto H, Tsuji K, Imaoka H, Terashima T, Ueno M, Furuse J : Outcomes of FOLFIRINOX and gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 : A propensity score-matching analysis. ASCO Gastrointestinal Cancers Symposium. Online・USA. January 19th-21st. 2023.
  39. 長島文夫：みんなでつくろう！がん情報迷路の羅針盤～がん情報/教育の現状と課題～．World Cancer Week 2023．オンライン．2023年2月5日.
  40. 岡野尚弘：肝細胞癌．肝胆膵エビデンス Update2023 Winter．オンライン．2023年2月11日.
  41. 陳勁松，川端良平，保坂尚志，武藤理，進藤吉明，永田直幹，藪崎裕，今村博司，遠藤俊治，柏田知美，中村将人，檜原淳，小林道也，長島文夫，高張大亮，石塚直樹，山口研成：高齢者転移進行胃癌に対するCapeOX第2相試験(TCOG GI-1601) G8/Mini-Cogを用いた探索的解析．日本胃癌学会．札幌．2023年2月24日．
  42. 廣中秀一，菊香準史，牧野怜奈，石田武浩，君嶋悠矢，西山英児，松田祐子，Tejada Mariella，Carroll Robert，吉川貴己：診療データベースを用いた実診療下における胃がん患者の術後補助化学療法及び再発後の治療パターンの解析．第95回日本胃癌学会総会．札幌．2023年2月25日．
  43. Shoji H, Boku N, Kudo-Saito C, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Imazeki H, Aoki K, Muro K : Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer. 第95回日本胃癌学会総会．札幌．2023年2月25日.
  44. Kawakami T, Boku N, Kudo-Saito C, Shoji H, Nagashima K, Tsugaru K, Takahashi N, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Imazeki H, Aoki K, Muro K : Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer. 第95回日本胃癌学会総会．札幌．2023年2月25日．
  45. 廣中秀一：進行胃癌に対する化学療法～エビデンスと有害事象マネジメント～．地域で診る消化器疾患連携セミナー．オンライン．2023年3月10日．
  46. 長島文夫，中島恵美子，橋詰崇：「がん教育」がつなぐ地域の健康と次世代への教育．地域総合研究所フォーラム．三鷹．2023年3月11日．
  47. 庄司広和，木藤陽介，山崎健太郎，山田武史，對馬隆浩，三谷誠一郎，白石和寛，安井久晃，原浩樹，下嵜啓太郎，江崎泰斗，下川穂積，築木隆雄，舛石俊樹，馬場英司．吉村健一，川上尚人，廣中秀一，室圭：WJOG9216G（RECAST）：切除不能大腸がん一次治療例に対するFOLFIRI＋ラムシルマブとFOLFOXIRI＋ラムシルマブのランダム化第II相試験．第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日．
  48. 仁科慎一，木藤陽介，川上尚人，三谷誠一郎，築木隆雄，松本俊彦，下川穂積，篠原雄大，熊西亮介，太田高志，木村晋也，川上武志，仁科智裕，長谷川裕子，秋吉宏平，千葉康敬，廣中秀一，山崎健太郎，室圭：WJOG14520G（TWILIGHT）：前治療歴を有するVulnerableな切除不能大腸がん患者に対するFTD/TPI＋ベバシズマブの多施設レトロ研究．第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日．
  49. 中村真穂，下嵜啓太郎，平田堅郎，三谷誠一郎，杉山圭司，廣田玲，有山寛，杉本直俊，井澤直樹，山本祥之，高山歳三，篠原雄大，国枝献治，安藤孝将，長島健悟，佐藤泰憲，山崎健太郎，廣中秀一，高石官均，室圭：BRAF V600E変異型切除不能・再発大腸癌に対するFOLFOXIRI+/-Bevacizumab療法とDoublet療法の有効性および安全性に関する後方視的検討．第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日．
  50. 菊香順史，廣中秀一，牧野怜奈，石田武浩，君嶋悠矢，西山英児，松田祐子，Tejada Mariella，Carroll Robert，吉川貴己：診療データベースを用いた実診療下における胃がん患者の術後補助化学療法及び再発後の治療パターンの解析．第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日．
  51. 牧山明資，庄司広和，川上尚人，田村孝雄，杉山圭司，原浩樹，長瀬通隆，西川和夫，江崎泰斗，伊澤直樹，中村将人，安藤孝将，三浦裕司，成田有季哉，下川元継，山崎健太郎，廣中秀一，朴成和，兵頭一之介，室圭：高齢者切除不能・再発胃癌に対するS-1単剤療法とS-1/L-OHP併用（SOX）療法のランダム化第II相試験．第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日．
  52. Shoji H, Boku N, Kudo-Saito C, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Imazeki H, Aoki K, Muro K : Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study). 第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日-18日.
  53. Kawakami T, Boku N, Kudo-Saito C, Shoji H, Nagashima K, Tsugaru K, Takahashi N, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Imazeki H, Aoki K, Muro K : Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study). 第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日-18日．
  54. Nishioka M, Okano N, Onozawa S, Miyauchi R, Hayashi M, Maesono T, Mizutani T, Seki S, Kawamura N, Kuroki K, Nagashima F, Furuse J : 4Vp4 hepatocellular carcinoma with Child-Pugh B treated with lenvatinib plus hepatic intra-arterial cisplatin infusion. 第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月16日-18日．
  55. 岡野尚弘：治癒切除不能な胆道癌の新たな一次治療．肝胆Network Seminar．オンライン．2023年3月16日．
  56. 水谷友紀：世界の高齢がん診療の実態：SIOG National Representative‘s Survey第20回日本臨床腫瘍学会学術集会．福岡・オンライン．2023年3月18日．

論　文

欧文

  1. Tsukamoto Y1, Kurogi S1, Shibata T1, Suzuki K1, Hirashita Y1, Fumoto S1, Yano S1, Yanagihara K1, Nakada C1, Mieno F1, Kinoshita K1, Fuchino T1, Mizukami K1, Ueda, Y1, Etoh T1, Uchida T1, Hanada T1, Takekawa M2, Daa T1, Shirao K1, Hironaka S1, Murakami K1, Inomata M1, Hijiya N1, Moriyama M (1Oita University, 2University of Tokyo) : Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids. Lab Invest. 102(12). 1355-1366. 2022.
  2. Takeuchi H1, Ito Y2, Machida R3, Kato K4, Onozawa M5, Minashi K6, Yano T5, Nakamura K3, Tsushima T7, Hara H8, Okuno T9, Hironaka S6, Nozaki I10, Ura T11, Chin K12, Kojima T5, Seki S13, Sakanaka K14, Fukuda H3, Kitagawa Y15, Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. (1Department of Surgery, Hamamatsu University School of Medicine, 2Department of Radiation Oncology, Showa University School of Medicine, 3JCOG Data Center, 4Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, 6Clinical Trial Promotion Department, Chiba Cancer Center, 7 Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 8Department of Gastroenterology and Endoscopy, Shizuoka Cancer Center, 9Division of Gastrointestinal Oncology, Saitama Cancer Center, 10Division of Gastroenterology, Department of Internal Medicine, Graduate School of Medicine,, Kobe University, 11Department of Gastroenterological Surgery, Shikoku Cancer Center, 12 Department of Clinical Oncology, Aichi Cancer Center, 13Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 14Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 15Department of Surgery, National Hospital Organization Tokyo Medical Center, 16 Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 17Department of Surgery, Keio University) : A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys. 114(3). 454-462. 2022.
  3. Yoshida Y1, Kobayashi S2, Ueno M2, Morizane C3, Tsuji K4, Maruki Y3, Mori K5, Watanabe K6, Ohba A3, Furuta M7, Todaka A8, Tsujimoto A9, Ozaka M10, Okano N11, Yane K12, Umemoto K13, Kawamoto Y14, Terashima T15,Tsumura H16, Doi K17, Shioji K18, Asagi A19,Kojima Y20, Suzuki E21, Toshiyama R22, Furukawa M23, Naganuma A24,Suzuki R25, Miwa H26, Ikeda M6, Furuse J27 (1Division of Oncology and Hematology, Okinawa Chubu Hospital,2Department of Gastroenterology, Kanagawa Cancer Center, 3Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 4Department of Gastroenterology, Ishikawa Prefectural Central Hospital, 5Department of Biostatistics, Clinical Research Support Center, Shizuoka Cancer Center, 6Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 7Department of Gastroenterology, Kanagawa Cancer Center, 8Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 9Division of Gastroenterology, Chiba Cancer Center, 10Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 11Department of Medical Oncology, Kyorin University Faculty of Medicine, 12Center for Gastroenterology, Teine Keijinkai Hospital, 13 Department of Clinical Oncology, St. Marianna University School of Medicine, 14Division of Cancer Center, Hokkaido University Hospital, 15Department of Gastroenterology, Kanazawa University, 16Department of Gastroenterological Oncology, Hyogo Cancer Center, 17Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 18Department of Internal Medicine, Niigata Cancer Center Hospital, 19 Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, 20Department of Gastroenterology, National Center for Global Health and Medicine, 21Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 22Department of Surgery, National Hospital Organization Osaka National Hospital, 23Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, 24Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, 25Department of Gastroenterology, Fukushima Medical University, School of Medicine, 26 Gastroenterological Center, Yokohama City University Medical Center, 27Department of Gastroenterology, Kanagawa Cancer Center, Department of Medical Oncology, Kyorin University Faculty of Medicine) : Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis. Pancreatology. 22(8). 1159-1166. 2022.
  4. Matsuki R1, Okano N2, Hasui N1, Kawaguchi S1, Momose H1, Kogure M1, Suzuki Y1, Nagashima F2, Sakamoto Y1(1 Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, 2 Department of Medical Oncology, Kyorin University Faculty of Medicine) : Trends in the surgical treatment for pancreatic cancer in the last 30 years. BioScience Trends. 16(3). 198-206. 2022.
  5. Mizutani T (Department of Medical Oncology, Kyorin University Faculty of Medicine) : Practical management of older adults with cancer: geriatric oncology in Japan. Jpn J Clin Oncol. 52(10). 1073-1081. 2022.
  6. Kajiwara T1, Nishina T2, Nakasya A2, Yamashita N3, Yamashita R4, Nakamura Y5, Shiozawa M6,Yuki S7, Taniguchi H8, Hara H9, Ohta T10, Esaki T11, Shinozaki E12, Takashima A13, Moriwaki T14,Denda T15, Ohtsubo K16, Sunakawa Y17, Horita Y18, Kawakami H19, Kato T20, Satoh T21, Ando K22, Mizutani T23, Yasui H24, Goto M25, Hiroyuki Okuyama H26, Yamazaki K27, Yoshino T5, Hyodo I2 (1Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, 2 Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, 3 Clinical Research Center, National Hospital Organization Shikoku Cancer Center, 4 Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 5 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6 Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 7 Department of Gastroenterology and Hepatology, Hokkaido University Hospital, 8 Department of Clinical Oncology, Aichi Cancer Center Hospital, 9 Department of Gastroenterology, Saitama Cancer Center, 10Department of Clinical Oncology, Kansai Rosai Hospital, 11 Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, 12Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 13Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 14Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, 15 Division of Gastroenterology, Chiba Cancer Center, 16 Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 17Department of Clinical Oncology, St. Marianna University School of Medicine, 18Department of Medical Oncology, Saitama Medical University International Medical Center, 19Department of Medical Oncology, Kindai University Faculty of Medicine, 20Department of Surgery, National Hospital Organization Osaka National Hospital, 21Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 22 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 23Department of General Medicine, Department of Medical Oncology, Kyorin University Faculty of Medicine, 24Department of Medical Oncology, Kobe City Medical Center General Hospital, 25Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, 26:Department of Clinical Oncology, Kagawa University Hospital, 27Division of Gastrointestinal Oncology, Shizuoka Cancer Center) : NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Ja
  7. Matsuki R1, Okano N2, Hasui N1, Kawaguchi S1, Momose H1, Kitahama K3, Nagahama K3, Kogure M1, Suzuki Y1, Nagashima F2, Shibahara J3, Mori H4, Sakamoto Y1 (1 Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, 2 Department of Medical Oncology, Kyorin University Faculty of Medicine, 3Department of Pathology, Kyorin University School of Medicine, 4Department of Hepatology and Gastroenterology, Kyorin University Faculty of Medicine): Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression. Liver Cancer. 180-183. 2022.
  8. Ohba A1 , Morizane C1, Ueno M2, Kobayashi S2, Kawamoto Y3, Komatsu Y4, Ikeda M5, Sasaki M5, Okano N6, Furuse J6, Hiraoka N7, Yoshida H7, Kuchiba A8, Sadachi R8, Nakamura K9, Matsui N9, Nakamura Y10, Okamoto W11, Yoshino T10, Okusaka T1 (1Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital, 2Division of Hepatobiliary & Pancreatic Oncology, Kanagawa Cancer Center, 3Department of Gastroenterology & Hepatology, Hokkaido University Hospital, 4Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, 5Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, 6Department of Medical Oncology, Kyorin University Faculty of Medicine, 7Division of Pathology & Clinical Laboratories, National Cancer Center Hospital, 8Biostatistics Section, Clinical Research Support Office, National Cancer Center Hospital/Biostatistics Division, Center for Research Administration & Support, National Cancer Center, 9Clinical Research Support Office, National Cancer Center Hospital, 10Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, 11Cancer Treatment Center, Hiroshima University Hospital): Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 18(19). 2351-2360. 2022.
  9. Mizusawa J1, Ohba A2, Ozaka M3, Katayama H1, Okusaka T2, Kobayashi S4, Ikeda M5, Terashima T6, Sasahira N3, Okano N7, Miki I8, Kaneko T9, Mizuno N10 Todaka A11, Furukawa M12, Kajiura S13, Kataoka T1, Fukuda H1, Furuse J4, Ueno M4, and Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group(1JCOG Data Center/Operations Office, NationalCancerCenterHospital, 2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 3Department of Gastroenterology, Cancer Institute Hospital, 4Department of Gastroenterology, Kanagawa Cancer Center, 5Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6Department of Gastroenterology, Kanazawa University Hospital, 7Department of Medical Oncology, Kyorin University Faculty of Medicine, 8DepartmentofGastroenterology,HyogoCancerCenter, 9Gastroenterological Center,Yokohama City University Medical Center, 10Department of Gastroenterology, Aichi Cancer Center Hospital, 11Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 12Department of Hepato-Biliary-Pancreatology, National Kyushu Cancer Center, 13 Third Department of Internal Medicine, University of Toyama Hospital): Protocol of a randomized phaseII/IIIstudy of gemcitabine plus nabpaclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer:JCOG1611(GENERATE). Japanese Journal of Clinical Oncology. 53(1). 80-84. 2022.
  10. Morizane C1, Machida N 2, Honma Y1, Okusaka T1, Boku N1, Kato K1, Nomura S3,4, Hiraoka N1, Sekine S1, Taniguchi H1, Okano N5, Yamaguchi K6, Sato T7, Ikeda M8, Mizuno N9, Ozaka M6, Kataoka T3, Ueno M2, Kitagawa Y10, Terashima M11, Furuse J5, for the Japan Clinical Oncology Group (JCOG) (1 National Cancer Center Hospital, 2Kanagawa Cancer Center, 3Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, 4The University of Tokyo, 5Kyorin University Faculty of Medicine, 6Cancer Institute Hospital of Japanese Foundation for Cancer Research, 7Kochi Health Sciences Center, 8National Cancer Center Hospital East, 9Aichi Cancer Center Hospital, 10Keio University School of Medicine、11 Shizuoka Cancer Center): Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 8(10). 1447-1455. 2022.
  11. Kobayashi S1, Suzuki M2, Ueno M1, Maruki Y3, Okano N4, Todaka A5, Ozaka M6, Tsuji K7, Shioji K8, Doi K9, Kojima Y10, Tsumura H11, Tanaka K12, Higuchi H13, Kawabe K14, Imaoka H15, Yamashita T16, Miwa H17, Nagano H18, Arima S19, Hayashi H20, Naganuma A21, Yamaguchi H22, Hisano T23, Umemoto K24, Ishii S25, Nakashima K26, Suzuki R27, Kitano Y28, Misumi T2, Furuse J4, Ishii H29 （1Department of Gastroenterology, Kanagawa Cancer Center, 2 Department of Data Science, National Cancer Center Hospital East, 3Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, National Cancer Center Hospital, 4Department of Medical Oncology, Kyorin University Faculty of Medicine, 5Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 6Department of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 7Department of Gastroenterology, Ishikawa Prefectural Central Hospital, 8Department of Internal Medicine, Niigata Cancer Center Hospital, 9 Department of Therapeutic Oncology, Kyoto University, Graduate School of Medicine, 10 Department of Gastroenterology, National Center for Global Health and Medicine, 11 Department of Gastroenterological Oncology, 12 Center for Gastroenterology, Teine Keijinkai Hospital, 13 Department of Clinical Oncology, International University of Health and Welfare, Narita Hospital, 14Department of Gastroenterology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 15Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 16 Department of Gastroenterology, Kanazawa University Graduate School of Medicine Sciences, 17Gastroenterological Center, Yokohama City University Medical Center, 18 Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 19 Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 20Genomics Unit, Keio Cancer Center, Keio University School of Medicine, 21Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, 22Department of Surgery, Jichi Medical University, 23 Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, 24Department of Clinical Oncology, St. Marianna University School of Medicine, 25Department of Gastroenterology and Hepatology, Osaka General Medical Center, 26Department of Clinical Oncology, University of Miyazaki Hospital, 27Department of Gastroenterology, Fukushima Medical University, 28Division of Metabolism and Biosystemic Science, Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 29Clinical Research Center, Chiba Cancer Center）: Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Oncologist. 27(10). e774-e782. 2022.
  12. Ohba A1, Ueno H1, Shiba S1, Okano N2, Kobayashi T2, Nagashima F2, Sasahira N3, Sasaki M4, Imaoka H4, Sakamoto Y1, Kondo S1, Morizane C1, Ozaka M3, Ikeda M4, Furuse J2, Okusaka T1(1Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 3Department of Medical Oncology, Kyorin University Faculty of Medicine,4Department of Gastroenterology, Cancer Institute Hospital, 5 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East) : Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b doseescalation and dose-expansion clinical trial. Eur J Cancer. 174. 40-47. 2022.
  13. Ozaka M1, Nakachi K2, Kobayashi S3, Ohba A4, Imaoka H5, Terashima T6, Ishii H7, Mizusawa J8, Katayama H9, Kataoka T10, Okusaka T11, Ikeda M12, Sasahira N13, Miwa H14, Mizukoshi E15, Okano N16, Mizuno N17, Yamamoto T18, Komatsu Y19, Todaka A20, Kamata K21, Furukawa M22, Fujimori N23, Katanuma A24, Takayama Y25, Tsumura H26, Fukuda H27, Ueno M28, Furuse J29, Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG) (1Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 2Department of Medical Oncology, Tochigi Cancer Center, 3Department of Gastroenterology, Kanagawa Cancer Center, 4Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6Department of Gastroenterology, Kanazawa University Hospital, 7Clinical Research Center, Chiba Cancer Center, 8Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, 9Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 10Department of Gastroenterology, Yokohama City University Medical Center, 11Department of Medical Oncology, Kyorin University Faculty of Medicine, 12Department of Gastroenterology, Aichi Cancer Center Hospital, 13Department of Surgery, Kansai Medical University Hospital,14Department of Gastroenterology, Hokkaido University Hospital, 15Divison of Gastrointestinal Oncology, Shizuoka Cancer Center, 16Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine,17Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, 18Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 19Center for Gastroenterology, Teine-Keijinkai Hospital, 20 Department of Gastroenterology, Tokyo Women’s Medical University, 21Department of Gastroenterological Oncology, Hyogo Cancer Center, 22Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan; Department of Medical Oncology, Kyorin University Faculty of Medicine)：A randomised phase II study of modified FOLFIRINOXversus gemcitabine plus nab-paclitaxel for locallyadvanced pancreatic cancer (JCOG1407). European Journal of Cancer. 181. 135-144. 2023.
  14. Okano N1, Matsuki R 2, Toki M 3, Gondo K3, Ochiai K3, Watanabe S3, Tateishi H4, Kogure M2, Suzuki Y2, Sugiyama M5, Nagashima F1, Shibahara J6, Sakamoto Y2, Furuse J1 (1Department of Medical Oncology, Kyorin University Faculty of Medicine, 2 Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, 3 Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, 4 Department of Radiology, Kyorin University Faculty of Medicine, 5Tokyo Rosai Hospital, 6Department of Pathology, Kyorin University Faculty of Medicine) : A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Intern Med. 62(3). 327-334. 2023.
  15. Takahara N1, Nakai Y2, Isayama H3, Sasaki T4, Morine Y5, Watanabe K6, Ueno M7, Ioka T8, Kanai M9, Kondo S10, Okano N11, Koike K1（1Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 2Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, 3Department of Gastroenterology, Graduate School of Medicine, Juntendo University, 4Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research,5Department of Surgery, Graduate School of Biomedical Sciences, Tokushima University, 6 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East,7Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, 8Oncology Center, Yamaguchi University Hospital, 9Department of Therapeutic Oncology Graduate School of Medicine, Kyoto University, 10Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital Tokyo, 11Department of Medical Oncology, Faculty of Medicine, Kyorin University）: A prospective multicenter phase II study of FOLFIRINOX as a first‑line treatment for patients with advanced and recurrent biliary tract cancer. Invest New Drugs. 41(1). 76-85. 2023.
  16. Umemoto K1, Sunakawa Y2, Ueno M3, Furukawa M4, Mizuno N5, Sudo K6, Kawamoto Y7, Kajiwara T8, Ohtsubo K9, Okano N10, Matsuhashi N11, Itoh S12, Matsumoto T13, Shimizu S14, Otsuru T15, Hasegawa H16, Okuyama H17, Ohama H18, Moriwaki T 19, Ohta T20, Odegaard J21, Nakamura Y22,23, Bando H22, Yoshino T22, Ikeda M24 and Morizane C25(1 Department of Clinical Oncology, St. Marianna University School of Medicine, 2 Department of Clinical Oncology, St. Marianna University School of Medicine, 3 Department of Gastroenterology, Kanagawa Cancer Center, 4Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center,5 Department of Gastroenterology, Aichi Cancer Center Hospital, 6Department of Gastroenterology, Chiba Cancer Center, 7Division of Cancer Center, Hokkaido University Hospital, 8Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, 9Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 10Department of Medical Oncology, Kyorin University Faculty of Medicine, 11Department of Gastroenterological Surgery, Gifu University, 12 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 13Department of Medical Oncology, Kobe City Medical Center General Hospital, 14Department of Gastroenterology, Saitama Cancer Center, 15Osaka University Graduate School of Medicine, 16Department of Gastroenterology and Hepatology, National Hospital Organization, 17Department of Clinical Oncology, Kagawa University, 18Department of Gastroenterology, Osaka Medical College, 19Department of Gastroenterology, University of Tsukuba Hospital, 20Department of Clinical Oncology, Kansai Rosai Hospital, 21Guardant Health, Redwood City, 22Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 23Translational Research Support Section, National Cancer Center Hospital East, 24Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 25 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital) : Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Br J Cancer. 128(8). 2023. Epub

和文

  1. 廣中秀一：【実地医家が知っておくべきがんの薬物療法 がんの薬物療法の必要性・重要性】各がん種の最新情報と知っておくべき標準治療 食道がん．Medical Practice．39(10)．1481-1486．2022．
  2. 水谷友紀：【がん・がん治療の合併症と対策】高齢がん患者に対する有害事象マネジメント．腫瘍内科．30(3)．272-277．
  3. 岡野尚弘.：【膵癌ConversionSurgeryへの挑戦】コラム 転移性膵癌に対するConversion Surgeryの適応と至適タイミング～腫瘍内科医の立場から～．胆と膵．44(2)．159-162．2023．

著　書

  1. 岸千鶴，長島文夫（分担執筆）：分子標的薬 抗EGFR抗体 セツキシマブ．これだけは押さえておきたい がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2023・2024年版．上野誠，古瀬純司 監修．メディカ出版．2023年．22-23．
  2. 岸千鶴，長島文夫．（分担執筆）：分子標的薬 抗EGFR抗体 パニツムマブ．これだけは押さえておきたい がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2023・2024年版．上野誠，古瀬純司 監修．メディカ出版．2023年．26-27．
  3. 岸千鶴，長島文夫．（分担執筆）：分子標的薬 抗VEGF抗体 ベバシズマブ．これだけは押さえておきたい がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2023・2024年版．上野誠，古瀬純司 監修．メディカ出版．2023年．38-39．
  4. 長島文夫（分担執筆）：第１章高齢がん患者の特徴?非高齢者と何が違うのか?１）疫学１病因．よくわかる老年腫瘍学．日本がんサポーティブケア学会．金原出版．2023年．2-6．
  5. 水谷友紀（分担執筆）：第5章老年腫瘍学領域における研究手法1）高齢者を対象としたがんの臨床試験．よくわかる老年腫瘍学．日本がんサポーティブケア学会．金原出版．2023年292-300.
  6. 水谷友紀（分担執筆）：ダコミチニブ水和物．がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．86-87．
  7. 水谷友紀（分担執筆）：ロルラチニブ がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．134-135．
  8. 岡野尚弘（分担執筆）：レゴラフェニブ．がん化学療法の薬はや調べノート．メディカ出版．2023年．114-115．
  9. 岡野尚弘（分担執筆）：バンテダニブ．がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．116-117．
  10. 岡野尚弘（分担執筆）：ゲムシタビン．がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．250-251．
  11. 岡野尚弘（分担執筆）：パクリタキセル．がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．280-281．
  12. 岡野尚弘（分担執筆）：ナブパクリタキセル．がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．280-281．
  13. 岡野尚弘（分担執筆）：ドセタキセル．がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．284-285．
  14. 岡野尚弘（分担執筆）：オラパリブ．がん化学療法の薬はや調べノート．古瀬純司 編著．メディカ出版．2023年．164-165．
  15. 岡野尚弘（分担執筆）：腫瘍．ナーシング・グラフィカ 疾病の成り立ちと促進（１）病態生理学．山内豊明 編．メディカ出版．2023年．49-58．
  16. 岡野尚弘（分担執筆）：第8章 症例でわかる！膵癌薬物療法．6 一次治療以降の治療をどのように選択すべきか?．あらゆる症例に対応できる！消化器がん薬物療法 第3版．室圭，加藤健，池田公史 編集．羊土社．2023年．389-392.
  17. 岡野尚弘（分担執筆）：第8章 症例でわかる！膵癌薬物療法．7 術後補助化学療法としてS-1施行後に再発した膵がんに対する薬物療法は?．あらゆる症例に対応できる！消化器がん薬物療法 第3版．室圭，加藤健，池田公史 編集．羊土社．2023年．393-395．
  18. 岡野尚弘（分担執筆）：第8章 症例でわかる！膵癌薬物療法．8 BRCA遺伝子検査や遺伝子パネル検査はいつ行い，どんな治療選択をすべきか?．あらゆる症例に対応できる！ 消化器がん薬物療法．室圭，加藤健，池田公史 編集．羊土社．2023年．396-399．
  19. 岡野尚弘（分担執筆）：第8章 症例でわかる！膵癌薬物療法. 9 悪性腹水が貯留している膵がん．あらゆる症例に対応できる! 消化器がん薬物療法第3版．室圭，加藤健，池田公史 編集. 羊土社．2023年．400-402．
  20. 岡野尚弘（分担執筆）：第8章 症例でわかる！膵癌薬物療法．10 浸潤性膵管がん以外の特殊ながんにどのような薬物療法を選択すべきか?．あらゆる症例に対応できる！ 消化器がん薬物療法第3版．室圭，加藤健，池田公史 編集．羊土社．2023年．403-405．

その他

  1. 廣中秀一：後期ラインを見据えた胃癌化学療法 －実臨床における治療移行率－．オンライン（https://www.medicalcommunity.jp/products/brand/enhertu/gastric_cancer/disease）．2023年3月1日．
  2. 長島文夫，梅田恵：今こそ考えたい！高齢のがん患者を取り巻く課題・解決策（対談）．CNJ Speakers27号（2023年Winter）．

講　演

  1. 古瀬純司：肝内胆管癌に対する個別化治療のアプローチ．インサイト・バイオサイエンシズ・ジャパン主催．オンライン．2021年4月8日．
  2. 古瀬純司：多様化・高齢化を迎えた肝細胞癌の薬物治療戦略．オンライン．日本イーライリリー主催．2021年5月10日．
  3. 古瀬純司：実臨床でのエドルミズ適正使用を考える．－膵がん治療医の立場から．小野薬品主催．オンライン．2021年5月17日.
  4. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポートを目指して－．アナモレリン適正使用セミナー in Osaka．オンライン．2021年5月27日．
  5. 古瀬純司：肝胆膵領域におけるがんゲノム医療の現状と展望．第33回日本肝胆膵外科学会学術集会．大阪・オンライン．2021年6月2日．
  6. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポートを目指して－．Cancer Supportive Care Web Seminar．オンライン．2021年6月3日．
  7. Valle JW, Hollebecque A, Furuse J, Goyal L, Meric-Bernstam F, Epstein RS, Salimi T, Wacheck V, Liu M, Benhadji KA, Bridgewater JA : FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements. 2021 ASCO Annual Meeting. USA・ June4th-10th. 2021.
  8. Kobayashi S, Suzuki M, Ueno M, Maruki Y, Furuse J, Todaka A, Ozaka M, Tsuji K, Shioji K, Doi K, Kojima Y, Tsumura H, Tanaka K, Higuchi H, Kawabe K, Yamanaka T, Ishii H: Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study. 2021 ASCO Annual Meeting. 2021 ASCO Annual Meeting. USA・ June4th-10th. 2021.
  9. Ozaka M, Ueno M, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Miwa H, Kaneko S, Maesono T, Mizuno N, Yamamoto T, Kawamoto Y, Todaka A, Kamata K, Hisano T, Fujimori N, Furuse J : Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). 2021 ASCO Annual Meeting. 2021 ASCO Annual Meeting. USA・ June4th-10th. 2021.
  10. 古瀬純司：がん悪液質とアナモレリン（エドルミズ錠®）のエビデンス．医療研究会．オンライン．2021年6月18日.
  11. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポ－トを目指して－．第1回がん悪液質セミナ－in多摩．オンライン．2021年6月24日.
  12. 古瀬純司：がん悪液質の新たな展開－アナモレリンのエビデンスからプラクティスへ－．エドルミズ適正使用セミナー．オンライン．2021年6月28日．
  13. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポートを目指して－．Cachexia Web Live Seminar．オンライン．2021年6月30日．
  14. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポートを目指して－．がん悪液質治療セミナーin北海道．オンライン．2021年7月5日．
  15. Furuse J : Sponsored Seminar. Optimising the treatment of metastatic pancreatic cancer patients: From scientific evidence to clinical practice. 6th Annual Scientific Meeting of Singapore Society of Oncology. Online. July 10th. 2021.
  16. 岡野尚弘：大腸癌の治療の変遷～レジメンから知ろう！初級編～．Southern Kitatama Cancer Care Management Seminar．オンライン．2021年7月15日．
  17. 古瀬純司：膵癌治療の最前線-がんゲノム医療の動向．第21回臨床腫瘍夏期セミナー．オンライン．2021年7月16日．
  18. 古瀬純司：がん悪液質の新たな展開－アナモレリンのエビデンスからプラクティスへ－．エドルミズ適正使用セミナー．オンライン．2021年7月29日．
  19. 古瀬純司：がん悪液質の新たな展開－アナモレリンのエビデンスからプラクティスへ－．エドルミズ適正使用セミナー．オンライン．2021年8月6日．
  20. 古瀬純司，上野誠，木村綾，福田治彦：臨床試験と患者市民参画．2021 Japan Cancer Forum. Cancer Net Japan．オンライン．2021年8月21日.
  21. 古瀬純司：多様化する肝細胞癌の薬物治療～最適な治療選択を目指して～．Lilly HCC Web Conference．オンライン．2021年9月1日．
  22. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポートを目指して－．エドルミズ錠適正使用セミナーin県北エリア．オンライン．2021年9月3日．
  23. 古瀬純司：がん治療の全体像．第3回JCOG患者・市民セミナー．オンライン．2021年9月4日．
  24. 古瀬純司：肝胆膵がんに対する薬物療法－最新の話題と今後の展望．中外製薬主催．オンライン．2021年9月4日．
  25. 古瀬純司：肝胆膵領域におけるがんゲノム医療の現状と展望．遺伝子パネル検査WEBセミナー～肝胆膵～．オンライン．021年9月8日．
  26. 古瀬純司：肝細胞がんの薬物療法－新たな治療戦略の時代に－．東大和市医師会学術講演会．オンライン．2021年9月10日．
  27. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポートを目指して－．がん悪液質 Discussion Meeting in NAGANO．オンライン．2021年9月13日．
  28. 古瀬純司：がん悪液質の新たな展開－アナモレリンのエビデンスからプラクティスへ－．がん悪液質治療セミナー．オンライン．2021年9月16日．
  29. 矢那瀬拓哉，片岡功，吉敷智和，小嶋幸一郎，飯岡愛子，麻生喜洋，若松喬，金翔哲，石井俊，磯部聡史，岡野尚弘，古瀬純司，川村直弘，森秀明，久松理一，小野澤志郎，黒木一典，阪本良弘，阿部展次，須並英二：結腸人工肛門に発症した出血性人工肛門静脈瘤に対して経皮的静脈瘤硬化療法が奏功した１例．日本消化器病学会関東支部例．オンライン．2021年9月18日．
  30. 丸木雄太，髙見澤重賢，森実千種，池田公史，上野誠，古瀬純司，奥坂拓志：膵悪性腫瘍におけるLynch症候群例の臨床的特徴．シンポジウム4・膵癌のゲノム医療の現状と展望．第52回日本膵臓学会大会．東京・オンライン．2021年9月23日．
  31. 松木亮太，岡野尚弘，吉田智幸，新井孝明，権藤興一，渡邉俊介，小暮正晴，土岐真朗，鈴木裕，古瀬純司，阪本良弘：局所進行膵癌に対する化学療法後の外科的切除は積極的に導入すべきか？膵癌治療のパタダイムシフトに向けた展望．第52回日本膵臓学会大会．東京・オンライン．2021年9月23日．
  32. 古瀬純司：がん悪液質を取り巻くエビデンス－がん患者のベストサポートを目指して－．エドルミズ膵癌WEB講演会．オンライン．2021年9月30日．
  33. 古瀬純司：肝細胞がんの薬物療法－Atezo+Bevの特徴とガイドラインでの位置づけ－．第62回三多摩肝臓談話会．オンライン．2021年10月1日．
  34. 古瀬純司：がん悪液質の新たな展開－アナモレリンのエビデンスからプラクティスへ－．オンライン．2021年10月8日．
  35. 古瀬純司：胆道癌に対する化学療法の最前線．胆道癌化学療法の歴史と現状．第57回日本胆道学会学術集会．東京・オンライン．2021年10月8日．
  36. 古瀬純司：がん悪液質に対するアナモレリン治療の意義について．エドルミズ®錠 適正使用セミナー～がん悪液質治療のベストプラクティス～．オンライン．2021年10月11日．
  37. 古瀬純司：肝癌に対する薬物療法ー肝細胞癌と肝内胆管癌の動向．第41回千葉癌化学療法研究会．オンライン．2021年10月15日．
  38. 仲雅弘，喜多村憲章，眞島喜幸，白川玲子，渡辺安李，福井澄恵，古瀬純司：膵臓がん患者を対象とした患者報告アウトカムに関する観察研究：治療、副作用・症状に関する患者評価と認知度．第59回日本癌治療学会学術集会．横浜・オンライン．2021年10月21日-23日．
  39. Uchino J, Naito T, Kojima T, Matano Y, Minato K, Yoshimasa S, Mizukami T, Atagi S, Higashiguchi T, Muro K, Takayama K, Furuse J, Morishima E, Takiguchi T, Tamura K: Efficacy and safety of anamorelin in low body mass index, cachectic patients with advanced non-small-cell lung cancer and gastrointestinal cancer. 第59回日本癌治療学会学術集会．横浜・オンライン．2021年10月23日.
  40. Okano N, Kawai M, Ueno M, Yamanaka T, Yamaue H, Furuse J: Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery is planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel therapy (PC-CURE-1). 9th International Conference of Federation of Asian Clinical Oncology (FACO 2021). 横浜・オンライン．2021年10月23日．
  41. 古瀬純司：肝細胞がんの薬物療法－新たな治療戦略の時代に－．鹿児島肝癌フォーラム．オンライン．2021年10月28日．
  42. 古瀬純司：膵がん薬物療法の解説～再発と転移、どう治療する？．パンキャンジャパン クリスマス勉強会．オンライン．2021年12月25日.
  43. Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, Toni END, Rimassa L, Breder VV, Vasilyev A, Heurgue A, Tam V, Mody K, Thungappa SC, He P, Negro A, Sangro B: Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  44. Ikeda M, Nakachi K, Konishi M, Nomura S, Katayama H, Kataoka T, Uesaka K, Yanagimoto H, Morinaga S, Wada H, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J: Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT). Rapid Abstract Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  45. Kobayashi S, Nakachi K, Ikeda M, Konishi M, Ogawa G, Uesaka K, Yanagimoto H, Morinaga S, Wada H, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ajiki T, Kawamoto Y, Ueno M, Okusaka T, Furuse J: Feasibility of adjuvant S-1 chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202. Poster Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  46. Okuno T, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ikeda M, Ozaka M, Sugimori K, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Sano K, Tobimatsu K, Katanuma A, Gotoh K, Yamaguchi H, Ishii H, Ueno M, Furuse J: The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113. Poster Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  47. Morizane C, Nozomu Machida, Yoshitaka Honma, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Kitagawa Y, Terashima M, Furuse J: Randomized phase III study of etoposide plus cisplatinversus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213). Rapid Abstract Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  48. Okusaka T, Ikeda M, Ioka T, Ueno M, Teng Z, Furuya M, Furuse J: Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer: Additional safety report of randomized Japanese phase 2trial. Poster Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  49. Ueno M, Morizane C, Ikeda M, Sudo K, Hirashima Y, Kuroda M, Fukuyama Y, Okusaka T, Furuse J: A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. Poster Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  50. Ohba A, Ozaka M, Mizusawa J, Katayama H, Okusaka T, Kobayashi S, Ikeda M, Kaneko S, Sasahira N, Okano N, Furukawa M, Miki I, Mizuno N, Yasuda I, Fujimori N, Kataoka T, Ueno M, Ishii H, Fukuda H, Furuse J: Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE). Poster Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 21st. 2022.
  51. Kenro Hirata, Yasuo Hamamoto, Hirokazu Shoji, Hiroki Hara, Chihiro Kondoh, Hisateru Yasui, Takeshi Kajiwara, Eishi Baba, Takayuki Ando, Naotoshi Sugimoto, Naohiro Okano, Hisato Kawakami, Hiroo Katsuya, Michitaka Nagase, Toshikazu Moriwaki, Kenichi Yoshimura, Masahiko Ando, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro: A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT). Poster Session. 2022 ASCO Gastrointestinal Cancers Symposium. USA・ January 20th-22nd. 2022.
  52. 古瀬純司，上野誠，木村綾，丸山大，福田治彦：患者市民参画から得られること－JCOGの活動から．国民・患者の臨床研究への参画を目指して．第3回日本臨床試験学会学術集会．東京・オンライン．2022年2月4日．
  53. 古瀬純司：肝胆膵領域がんの薬物療法-開発にかかわった30年の軌跡．中外製薬社内勉強会．2022年2月14日．
  54. 池田公史，井岡達也，上野誠，奥坂拓志，Teng Zhaoyang，古屋桃子，古瀬純司：Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer-Additional safety report of randomized Japanese phase 2 trial. Mini-oral Session. 第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月17日．
  55. 河合桐男，林雅人，廣田玲，西岡真理子，前園知宏，岡野尚弘，水谷友紀，長島文夫，滝智彦，古瀬純司：NTRK3融合遺伝子とBRAFＶ600遺伝子変異を同時に有するＳ状結腸癌の一例．第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月17日．
  56. 木村綾，福田治彦，中村健一，柴田大朗，江場淳子，片岡智子，山本精一郎，水谷友紀，上野誠，枝園忠彦，丸山大，吉川貴己，古瀬純司：JCOGにおける患者・市民参画の取り組み．第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月17日．
  57. 長島文夫：がん薬物療法を受ける高齢者に対するチーム医療．日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月17日．
  58. 戸髙明子，仲地耕平，池田公史，小西大，野村尚吾，片山宏，片岡智子，柳本泰明，森永聡一郎，和田浩志，島田和明，高橋祐，中郡聡夫，後藤邦仁，鎌田研，清水泰博，上野誠，石井浩，奥坂拓志，古瀬純司：A phase III trial of adjuvant S-1 vs. observation for resected biliary tract cancer: JCOG1202, ASCOT. 第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月18日．
  59. 池田公史，森實千種，上野誠，須藤研太郎，平島詳典，黒田将任，福山祐紀，奥坂拓志，古瀬純司：A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. Oral Session. 第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月19日．
  60. 西岡真理子，林雅人，廣田玲，前園知宏，河合桐男，岡野尚弘，水谷友紀，長島文夫，古瀬純司： Anamorelin in patients with advanced pancreatic cancer and cancer cachexia: Experience of a single institute. 第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月19日．
  61. 小笠原定久，池田公史，山下竜也，工藤正俊，稲葉吉隆，森本学，土谷薫，清水怜，小島康志，平岡淳，能祖一裕，相方浩，沼田和司，佐藤俊哉，奥坂拓志，古瀬純司：Lenvatinib plus HAIC with cisplatin for advanced hepatocellular carcinoma: multicenter phase II trial (LEOPARD). 第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月19日.
  62. 森実千種，町田望，本間義崇，奥坂拓志，朴成和，加藤健，野村尚吾，平岡伸介，関根茂樹，谷口浩和，岡野尚弘，山口研成，佐藤琢爾，池田公史，水野伸匡，尾阪将人，片岡智子，寺島雅典，北川雄光，古瀬純司：Randomized phase III study of etoposide/cisplatin versus irinotecan/cisplatin in advanced digestive NEC: JCOG1213．第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月19日．
  63. 高原楠昊，中井陽介，藤澤聡郎，佐々木隆，森根裕二，渡邊一雄，上野誠，井岡達也，金井雅史，近藤俊輔，岡野尚弘，伊佐山浩通，小池和彦：A prospective multicenter phase II study of FOLFIRINOX in patients with advanced and recurrent biliary tract cancer．第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月19日．
  64. Kentaro Yamazaki, Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Yu Sunakawa, Manabu Shiozawa, Hisateru Yasui, Naoki Takahashi, Hironaga Satake, Kazuhiro Yoshida, Akiyoshi Kanazawa, Tetsuya Hamaguchi, Masahiro Goto, Naohiro Okano, Kaname Yamashita, Akihito Tsuji, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Takayuki Yoshino :Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC 血清VEGF-A, VEGF-D, PlGFが転移性結腸直腸癌における二次化学療法＋血管新生阻害薬の有効性に与える影響：GI-SCREEN CRC Ukit. 第19回日本臨床腫瘍学会学術集会．京都・オンライン．2022年2月19日．
  65. 古瀬純司：膵癌薬物療法の最前線－2022年新たな動向．第18回臨床消化器病フォーラム．オンライン．2022年2月19日．
  66. Kenro Hirata, Yasuo Hamamoto, Hirokazu Shoji, Hiroki Hara, Chihiro Kondoh, Hisateru Yasui, Takeshi Kajiwara, Eishi Baba, Takayuki Ando, Naotoshi Sugimoto, Naohiro Okano, Hisato Kawakami, Hiroo Katsuya, Michitaka Nagase, Toshikazu Moriwaki, Kenichi Yoshimura, Masahiko Ando, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro : Phase II trial of RAM combined with PTX vs nab-PTX for gastric cancer with peritoneal dissemination．第94回胃癌学会総会．横浜・オンライン．2022年3月4日．
  67. 古瀬純司：肝胆膵がんの治療開発 オンコロジーの“これまで”と“これから”, 30年の経験を振り返って．オンライン．2022年3月10日．
  68. 古瀬純司：特別講演・肝細胞がんの薬物療法 “これまで”と“これから”．HCC Expert Meeting in South OSAKA．オンライン．2022年3月11日．
  69. 古瀬純司：神経内分泌腫瘍の診療現場から．ノバルティスファーマ社内勉強会．オンライン．2022年3月14日．
  70. 古瀬純司：特別講演　膵・消化管神経内分泌腫瘍の治療選択.－薬物療法の位置づけと使い分け．膵・消化管神経内分泌腫瘍のWebセミナー．オンライン．2022年3月17日.
  71. 河合桐男，廣田玲，林雅人，西岡真理子，前園知宏，岡野尚弘，水谷友紀，長島文夫，古瀬純司：杏林大学病院におけるがん薬物療法中のオンコロジーエマージェンシーへの対応．第58回日本腹部救急医学会総会．東京・オンライン．2022年3月24日-25日.

論　文

欧文

  1. Azemoto N1,2, Ueno M3, Yanagimoto H4, Mizuno N5, Kawamoto Y6, Maruki Y7, Watanabe K8, Suzuki R9, Kaneko J10, Hisada Y7, Sato H11, Kobayashi S3, Miyata H12, Furukawa M13, Mizukami T14, Miwa H15, Ohno Y16, Tsuji K17, Tsujimoto A18, Nagano H19, Okuyama H20, Asagi A2, Okano N, Ishii H18, Morizane C7, Ikeda M8, Furuse J (1Matsuyama Red Cross Hospital, 2National Hospital Organization Shikoku Cancer Center, 3Kanagawa Cancer Center, 4Kobe University Graduate School of Medicine, 5Aichi Cancer Center Hospital, 6Hokkaido University Hospital, 7National Cancer Center Hospital, 8National Cancer Center Hospital East, 9Fukushima Medical University School of Medicine, 10Shizuoka Cancer Center, 11Asahikawa Medical University,12Ehime Prefecture Central Hospital, 13National Hospital Organization Kyushu Cancer Center, 14St Marianna University School of Medicine, 15Yokohama City University Medical Center, 16 Uwajima Municipal Hospital, 17Ishikawa Prefectural Central Hospital, 18Chiba Cancer Center, 19Yamaguchi University Graduate School of Medicine, 20Kagawa University Hospital) : Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study. Jpn J Clin Oncol. 52(2). 134-142. 2022.
  2. Okabe N1, Kobayashi T2, Furuse J, Fujiwara M3, Kamma H3 (1Jichi Medical University Saitama Medical Center, 2Home Clinic for Everyone, 3 Department of Pathology, Kyorin University School of Medicine) : An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma. Pathol Int . 71(12). 831-836. 2021.
  3. Kobayashi S1, Ueno M1, Ogawa G2, Fukutomi A3, Ikeda M4, Okusaka T5, Sato T6, Ito Y7, Kadota T2, Ioka T8, Sugimori K9, Sata N10, Nakamori S11, Shimizu K12, Mizuno N13, Ishii H14, Furuse J (1Kanagawa Cancer Center, 2National Cancer Center Hospital, 3Shizuoka Cancer Center, 4National Cancer Center Hospital East, 5National Cancer Center Hospital, 6Kyoto University School of Public Health, 7Showa University School of Medicine, 8Osaka International Cancer Center, 9 Yokohama City University Medical Center, 10Jichi Medical University, 11Osaka National Hospital, 12Tokyo Women’s Medical University Hospital, 13Aichi Cancer Center Hospital, 14 Chiba Cancer Center) : Impact of renal function on S-1 + radiotherapy for locally advanced pancreatic cancer: an integrated analysis of data from 2 clinical trials. 50(7). 965-971. 2021.
  4. Okano N, Mizutani T, Nagashima F, Furuse J : Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer. Lancet Oncol. 22(10). e423. 2021.
  5. Furuse J, Ueno M1, Ikeda M2 (1Kanagawa Cancer Center, 2National Cancer Center Hospital East) : Systemic therapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 51(9). 1363-1371. 2021.
  6. Kudo M1, Motomura K2, Wada Y3, Inaba Y4, Sakamoto Y5, Kurosaki M6, Umeyama Y7, Kamei Y7, Yoshimitsu J7, Fujii Y7, Aizawa M7, Robbins PB8, Furuse J(1 Kindai University, 2 Aso Iizuka Hospital, 3Kyushu Medical Center, 4Aichi Cancer Center Hospital, 5National Cancer Center Hospital, 6Musashino Red Cross Hospital, 7 Pfizer R&D Japan, 8Pfizer) : Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer. 10(3). 249-259. 2021.
  7. Ueno M1, Morizane C2, Okusaka T2, Mizusawa J2, Kataoka T2, Ikeda M3 Ozaka M4,Okano N, Sugimori K5, Todaka A6, Shimizu S7, Mizuno N8, Yamamoto T9 Sano K10 Tobimatsu K11 , Katanuma A12 , Miyamoto A13 , Yamaguchi H14 , Nishina T15, Shirakawa H16, Kojima Y17, Oono T18, Kawamoto Y19, Furukawa M20, Iwai T21 Sudo K22 , Miyakawa H23 Yamashita T24 , Yasuda I25, Takahashi H26, Kato N27, Shioji K28, Shimizu K29, Nakagohri T30 , Kamata K31 , Ishii H21 , Furuse J (1Kanagawa Cancer Center, 2National Cancer Center Hospital, 3National Cancer Center Hospital East, 4 Cancer Institute Hospital of Japanese Foundation for Cancer Research, 5Yokohama City University Medical Center, 6;Shizuoka Cancer Center、７Saitama Cancer Center, 8Aichi Cancer Center Hospital, 9Kansai Medical University Hospital, 10Teikyo University School of Medicine, 11Kobe University Graduate School of Medicine, 12 Teine Keijinkai Hospital, 13Osaka National Hospital, 14Jichi Medical University, 15National Hospital Organization Shikoku Cancer Center, 16Tochigi Cancer Center, 17National Center for Global Health and Medicine, 18Kyushu University, 19Hokkaido University Hospital, 20National Hospital Organization Kyushu Cancer Center, 21 Kitasato University Hospital, 22Chiba Cancer Center, 23Sapporo-Kosei General Hospital, 24Kanazawa University, 25University of Toyama, 26Osaka International Cancer Institute, 27Chiba University, 28Niigata Cancer Center Hospital, 29Tokyo, Women’s Medical University, 30Tokai University School of Medicine, 31Kindai University) members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG) : Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. Sci Rep. 11(1).12885. 2021.
  8. Hijioka S1, Morizane C1, Ikeda M2, Ishii H3, Okusaka T1, Furuse J(1National Cancer Center Hospital, 2National Cancer Center Hospital East, 3Chiba Cancer Center) : Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol. 51(8). 1185-1196. 2021.
  9. Imaoka H1, Ikeda M1, Maehara K2, Umemoto K3, Ozaka M4, Kobayashi S5, Terashima T6, Inoue H7, Sakaguchi C8, Tsuji K9, Shioji K10, Okamura K11, Tsujimoto A12, Nakamura I13, Shirakawa H14, Furukawa M15, Ueno M5, Morizane C2, Furuse J(1National Cancer Center Hospital East, 2National Cancer Center Hospital, 3 Marianna University School of Medicine, 4Cancer Institute Hospital Japanese Foundation for Cancer Research, 5 Hepatobiliary and Pancreatic Medical Oncology Division, 6Kanazawa University Hospital, 7Shizuoka Cancer Center, 8Shikoku Cancer Center, 9Ishikawa Prefectural Central Hospital, 10Niigata Cancer Center Hospital, 11JA Sapporo Kohsei Hospital, 12Chiba Cancer Center, 13Hyogo College of Medicine, 14Tochigi Cancer Center, 15National Hospital Organization Kyushu Cancer Center) : Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas. Pancreatology. 21(4). 738-745. 2021.
  10. Ikeda M1, Okusaka T2, Ohno I1, Mitsunaga S1, Kondo S2, Ueno H2, Morizane C2, Gemmoto K3, Suna H3, Ushida Y3, Furuse J(1National Cancer Center Hospital East , 2National Cancer Center Hospital , 3Ono Pharmaceutical Co ) : Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy .13(5). 371-385. 2021.
  11. Tomoko Jogo1,2, Yoshiaki Nakamura1,, Kohei Shitara1, Hideaki Bando3, Hisateru Yasui 4, Taito Esaki5, Tetsuji Terazawa 6, Taroh Satoh 7, Eiji Shinozaki 8, Tomohiro Nishina9, Yu Sunakawa10, Yoshito Komatsu11, Hiroki Hara12, Eiji Oki2, Nobuhisa Matsuhashi13, Takashi Ohta14, Takeshi Kato15, Koushiro Ohtsubo16, Takeshi Kawakami17, Naohiro Okano, Yoshiyuki Yamamoto18, Takanobu Yamada19, Akihito Tsuji 20, Justin I Odegaard 21, Hiroya Taniguchi1,, Toshihiko Doi1, Satoshi Fujii22 ,23, Takayuki Yoshino1 (1National Cancer Center Hospital East, 2Kyushu University, 3Aichi Cancer Center Hospital,4Kobe City Medical Center General Hospital, 5National Hospital Organization Kyushu Cancer Center, 6Osaka Medical College Hospital, 7Osaka University, 8Cancer Institute Hospital of Japanese Foundation for Cancer Research, 9National Hospital Organization Shikoku Cancer Center, 10 Marianna University School of Medicine, 11Hokkaido University Hospital, 12Saitama Cancer Center, 13Gifu University, 14Kansai Rosai Hospital, 15National Hospital Organization Osaka National Hospital, 16Kanazawa University, 17Shizuoka Cancer Center, 18University of Tsukuba Hospital, 19Kanagawa Cancer Center, 20Kagawa University Hospital, 21Guardant Health, 22Yokohama City University Graduate School of Medicine, 23National Cancer Center) : Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.Clin Cancer Res. 27(20). 5619-5627. 2021.
  12. Matsuki R1, Okano N, Arai T1, Yoshiike S2, Kogure M1, Suzuki Y1, Shibahara J2, Furuse J, Sakamoto Y1 (1Department of Hepato-Biliary-Pancreatic Surgery Division, Kyorin University, 2Department of pathology, Kyorin University) : Regression of tumor thrombus in the suprahepatic vena cava of hepatocellular carcinoma and conversion hepatectomy induced by lenvatinib. Liver Cancer. 2021. DOI : 10.1159/000520822.
  13. Naito T1, Uchino J2, Kojima T3, Matano Y4, Minato K5, Tanaka K6, Mizukami T7, Atagi S8, Higashiguchi T9, Muro K10, Takayama K2, Furuse J, Morishima E11, Takiguchi T11, Tamura K12 (1Shizuoka Cancer Center, 2Kyoto Prefectural University of Medicine, 3 Fukui Prefectural Hospital, 4Komatsu Municipal Hospital, 5Gunma Prefectural Cancer Center, 6Kyushu University, 7 Marianna University, 8National Hospital Organization Kinki-Chuo Chest Medical Center, 9Yonaha Okanoue Hospital, 10Aichi Cancer Center, 11Ono Pharmaceutical Co, Ltd, 12Fukuoka University) : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer. 128(10). 2025-2035. 2022. Epub ahead of print.
  14. Kudo M1,2,3, Ikeda M2,4, Ueshima K1,2, Sakamoto M2,5, Shiina S6, Tateishi R7, Nouso K8, Hasegawa K9, Furuse J, Miyayama S10, Murakami T11, Yamashita T12, Kokudo N3,13(1 Kindai University Faculty of Medicine, 2 National Center for Global Health and Medicine, 3 the Committee for Response Evaluation Criteria in Cancer of the Liver, 4National Cancer Center Hospital East, 5Keio University School of Medicine, 6Juntendo University School of Medicine, 7The University of Tokyo, 8Okayama City Hospital, 9Graduate School of Medicine, University of Tokyo, 10Fukuiken Saiseikai Hospital, 11Kobe University Graduate School of Medicine, 12Kanazawa University, Graduate School of Medical Science, 13the Committee for General Rules for the Clinical and Pathological Study of Primary Liver Cancer) : Response evaluation criteria in cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version). Hepatol Res. 52(4). 329-336. 2022. Epub ahead of print.
  15. Nagashima F, Furuse J : Treatments for elderly cancer patients and, 19 reforms to social security systems in Japan. Int J Clin Oncol. 27(2). 310-315. 2022. Epub ahead of print.
  16. Yamada I1, Morizane C2, Okusaka T2, Mizusawa J2, Kataoka T2, Ueno M3, Ikeda M4, Okano N, Todaka A5, Shimizu S6, Mizuno N7, Sekimoto M8, Tobimatsu K9, Yamaguchi H10, Nishina T11, Shirakawa H12, Kojima Y13, Oono T14, Kawamoto Y15, Furukawa M16, Iwai T17, Sudo K18, Okamura K19, Yamashita T20, Kato N21, Shioji K22, Shimizu K23, Nakagohri T24, Kamata K25, Ishii H18, Furuse J (1Cancer Institute Hospital of Japanese Foundation for Cancer Research, 2National Cancer Center Hospital, 3Kanagawa Cancer Center, 4National Cancer Center Hospital East, 5Shizuoka Cancer Center, 6Saitama Cancer Center, 7Aichi Cancer Center Hospital, 8Kansai Medical University Hospital, 9Kobe University Graduate School of Medicine, 10Jichi Medical University, 11National Hospital Organization, 12Tochigi Cancer Center, 13National Center for Global Health and Medicine, 14Kyushu University, 15 Hokkaido University Hospital, 16National Hospital Organization Kyushu Cancer Center, 17 Kitasato University School of Medicine, 18Chiba Cancer Center, 19 Sapporo Kousei General Hospital, 20Kanazawa University, 21Chiba University, 22Niigata Cancer Center Hospital, 23 Tokyo Women’s Medical University, 24Tokai University School of Medicine, 25Kindai University Faculty of Medicine) : JCOG-HBPOG. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. Sci Rep. 12(1). 987. 2022.
  17. Todaka A1, Nara S2, Motoi F3,4, Morinaga S5, Toshiyama R6, Higuchi R7, Konishi M8, Shirakawa H9, Tsumura H10, Okuyama H11, Nagano H12, Shioji K13, Sugimachi K14, Asagi A15, Mizuno N16, Furuse J (1Shizuoka Cancer Center, 2 National Cancer Center Hospital, 3 Tohoku University Graduate School of Medicine, 4 Yamagata University Graduate School of Medical Science, 5Kanagawa Cancer Center, 6National Hospital Organization Osaka National Hospital, 7 Tokyo Women’s Medical University, 8National Cancer Center Hospital East, 9Tochigi Cancer Center, 10Hyogo Cancer Center, 11Kagawa University, 12Yamaguchi University Graduate School of Medicine, 13Niigata Cancer Center Hospital, 14National Hospital Organization Kyushu Cancer Center, 15National Hospital Organization Shikoku Cancer Center, 16Aichi Cancer Center Hospital) : Postoperative treatment of resectable pancreatic cancer with positive peritoneal lavage cytology: a multicentre retrospective study. Anticancer Res . 42(2). 893-902. 2022.
  18. Yau T1, Park JW2, Finn RS3, Cheng AL4, Mathurin P5, Edeline J6, Kudo M7, Harding JJ8, Merle P9, Rosmorduc O10, Wyrwicz L11, Schott E12, Choo SP13, Kelley RK14, Sieghart W15, Assenat E16, Zaucha R17, Furuse J, Abou-Alfa GK8, El-Khoueiry AB18, Melero I19, Begic D20, Chen G20, Neely J20, Wisniewski T20, Tschaika M20, Sangro B21 (1University of Hong Kong, 2National Cancer Center, 3University of California、4National Taiwan University Cancer Center and National Taiwan University Hospital, 5Centre Hospitalo-Universitaire Claude Huriez, 6Centre Eugène Marquis, 7Kindai University Faculty of Medicine, 8Memorial Sloan Kettering Cancer Center, 9Croix-Rousse Hospital, 10Hôpital Pitié-Salpétrière-Université Pierre et Marie Curie, 11M Skłodowska-Curie Memorial National Cancer Research Institute, 12 Helios Klinikum Emil von Behring GmbH, 13National Cancer Centre Singapore, 14UCSF Helen Diller Family Comprehensive Cancer Center, 15Medical University Vienna, 16Centre Hospitalier Universitaire de Montpellier, 17Medical University of Gdańsk, 18University of Southern California, 19Clinica Universidad de Navarra and CIBERONC, 20Bristol Myers Squibb, 21Clinica Universidad de Navarra-IDISNA and CIBEREHD) : Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 23(1). 77-90. 2022.
  19. Ohki A1, Koba T2, Tsurumi M2, Hashimoto Y2, Nagao G2, Takeuchi H2, Okano N, Fujiwara M3, Shibahara J3, Abe N2 (1Department of Gastroenterological and General Surgery, Kyorin University, 2Department of Pathology) : Early-stage gastric cancer with solitary brain metastasis four years after curative surgery: a case report and literature review. Clin J Gastroenterol. 15(1). 90-94. 2022.
  20. Masato Hayashi, Naohiro Okano, Tomonori Mizutani : Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer. JAMA Oncology. 8(2). 304-305. 2022.
  21. Muro K1, Kojima T2, Moriwaki T3, Kato K4, Nagashima F, Kawakami H5, Ishihara R6, Ogata T7, Satoh T8, Iwakami K9, Han S9, Yatsuzuka N9, Takami T9, Bhagia P10, Doi T2 (1Aichi Cancer Center Hospital, 2National Cancer Center Hospital East, 3University of Tsukuba, 4National Cancer Center Hospital, 5Kindai University, 6Osaka International Cancer Institute, 7Kanagawa Cancer Center, 8Osaka University Suita, 9MSD K.K, 10Merck & Co., Inc.)：Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus. 19(1). 137-145. 2022.
  22. Nakamura Y1, Okamoto W1,2, Denda T3, Nishina T4, Komatsu Y 5, Yuki S5, Yasui H 6, Esaki T7, Sunakawa Y8, Ueno M9, Shinozaki E10, Matsuhashi N11, Ohta T12, Kato K13, Ohtsubo K14, Bando H1 ,15, Hara H16, Satoh T17, Yamazaki K18, Yamamoto Y19, Okano N, Terazawa T20, Kato T21, Oki E22, Tsuji A23, Horita Y24, Hamamoto Y25, Kawazoe A1, Nakajima H1, Nomura S2, Mitani R1, Yuasa M1, Akagi K26, Yoshino T1 (1National Cancer Center Hospital East, 2Hiroshima University Hospital, 3Chiba Cancer Center, 4National Hospital Organization Shikoku Cancer Center, 5Hokkaido University Hospital, 6Kobe City Medical Center General Hospital, 7National Hospital Organization Kyushu Cancer Center, 8St Marianna University School of Medicine, 9Kanagawa Cancer Center, 10Cancer Institute Hospital of Japanese Foundation for Cancer Research, 11Gifu University, 12Kansai Rosai Hospital, 13National Cancer Center Hospital, 14Kanazawa University, 15Aichi Cancer Center, 16Saitama Cancer Center, 17Osaka University, 18Shizuoka Cancer Center, 19University of Tsukuba Hospital, 20Osaka Medical College Hospital, 21National Hospital Organization Osaka National Hospital, 22Kyushu University, 23Kagawa University Hospital, 24Saitama Medical University International Medical Center, 25Keio University School of Medicine, 26Saitama Cancer Center) : Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO Precis Oncol. 2022. DOI : 10.1200/PO.21.00383.

和文

  1. 古瀬純司：免疫チェックポイント阻害薬の有効性と安全性．日消誌．118（5）．400-406．
  2. 古瀬純司，土岐真朗1，立石秀勝2，柴原純二3，阪本良弘4 (1杏林大・医・消化器内科，2杏林大・医・放射線医学教室，3杏林大・医・病理部，4杏林大・医・肝胆膵外科)：杏林大学病院での胆膵疾患に対する診療科横断的チーム医療．胆と膵．42(5)．427-431．2021．
  3. 古瀬純司：膵癌に対する化学療法．Medical Science Digest．47(7)．367-371．
  4. 古瀬純司：膵がん抗がん薬治療の進歩．日医雑誌．150 (5)．807-811．2021．
  5. 西岡真理子，長島文夫，古瀬純司：分子標的薬 小分子化合物 PARP阻害薬．腫瘍内科．28 (2)．135-140．2021．
  6. 岡野尚弘，古瀬純司：切除不能胆道癌における2次薬物療法．胆と膵．42臨時増刊特大号．1145-1151．2021．
  7. 河合桐男，古瀬純司：がん悪液質に対する薬物療法 病態の基本的な事項と対策．胆と膵．42臨時増刊特大号．1253-1258．2021．
  8. 廣田玲，林雅人，西岡真理子，前園知宏，河合桐男，水谷友紀，長島文夫，古瀬純司：膵癌に対する治療戦略、治療効果判定 膵癌に対する化学療法の進歩．肝胆膵．84(2)．189-197．2022．
  9. 長島文夫，古瀬純司：高齢がん患者の治療と支援．日本老年医学会雑誌．59 (1)．1-8．2022．
  10. 古瀬純司，高山浩一1，岸和田昌之2，光永修一3，天野晃滋4 (1京都府立医科大・医・内科学呼吸器内科，2三重大学医学部付属病院・肝胆膵移植外科，3国立がん研究センター東病院・肝胆膵内科，4国立がん研究センター中央病院・緩和医療科)：膵・胆道がんにおける悪液質の病態と治療．胆膵Oncology Forum．2(2)．4-10．2022．
  11. 長島文夫，榎本健太郎1，古瀬純司 (1厚生労働省大臣官房審議官)：超高齢社会における腫瘍学．癌と化学療法．49(1)．8-12．2022．

著　書

  1. 河合桐男，前園知宏，西岡真理子，古瀬純司 (分担執筆)：肝内胆管癌．希少がん・難治がん診療ハンドブック．石岡千加史監修，元雄良治編集．南江堂．2021．169-174．
  2. 古瀬純司 (分担執筆)：アテゾリズマブ・ベバシズマブ併用療法のnetwork meta-analysis．アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療．工藤正俊総監修．アークメディア．2021．133-137．
  3. 前園知宏，古瀬純司 (分担執筆)：膵癌化学療法の進歩．専門医のための消化器病学第3版．下瀬川徹，渡辺守監修．医学書院．2021．678-682．
  4. 古瀬純司 (分担執筆)：カボザンチニブの海外ランダム化第2相試験の概要．カボザンチニブによる肝細胞癌治療．工藤正俊総監修．アークメディア．2022．51-54．
  5. 岡野尚弘 (分担執筆)：胆道癌．新臨床腫瘍学第6版．南江堂．2021．452-456.

その他

  1. 岡野尚弘：第10回杏林医学会研究奨励賞受賞．First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.

講　演

  1. Finn RS, Kelley RK, Furuse J, Edeline J, Ren Z, Su SC, Malhotra U, Siegel AB, Valle JW: KEYNOTE-966 : A randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma. AACR. Online. April 24th,.2020.
  2. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, He Y, Soni N, Benhadji KA, Bridgewater JA: FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
  3. Ohba A, Nakamura Y,Taniguchi H, Ikeda M, Bando H, Mizuno N, Kato K, Morizane C, Nishina T, Ueno M, Furuse J, Hara H, Denda T, Kawakami H, Esaki T, Moriwaki T, Yasui H, Komatsu Y, Yoshino T, Ohtsu A: Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis. 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
  4. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Ogawa G, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T: Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
  5. Park W, O’Reilly EM, Furuse J, Kunieda F, Jie F, Kindler HL: Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC). 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
  6. Nakamura Y, Taniguchi H, Bando H, Esaki T, Komatsu Y, Kato K, Takahashi N, Kagawa Y, Kato T, Nishina T, Satoh T, Oki E, Sunakwa Y, Ueno M, Yamamoto Y, Kawakami H, Denda T, Furuse J, Ohtsu A, Yoshino T: Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients (pts) with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. Poster Discussion abstr #4071. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th.2020.
  7. Ohba A, Nakamura Y, Taniguchi H, Ikeda M, Bando H, Mizuno N, Kato K, Morizane C, Nishina T, Ueno M, Furuse J, Hara H, Denda T, Kawakami H, Esaki T, Moriwaki T, Yasui H, Komatsu Y, Yoshino T, Ohtsu A: Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. Poster Discussion abstr #3516. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th. 2020.
  8. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Ogawa G, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T : Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2 positive unresectable or recurrent biliary tract cancer — HERB trial. General Poster abstr #TPS4654. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th. 2020.
  9. Park W, O’Reilly EM, Furuse J, Kunieda F, Jie F, Kindler HL: Phase II, Open-Label, Randomized Study of First-line Zolbetuximab Plus Gemcitabine and Nab-Paclitaxel (GN) in Claudin 18.2–Positive Metastatic Pancreatic Cancer (mPC). General Poster abstr #TPS4667. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th.2020.
  10. Akihiro Ohba, Chigusa Morizane, Makoto Ueno, Satoshi Kobayashi, Yasuyuki Kawamoto, Yoshito Komatsu, Masafumi Ikeda, Mitsuhito Sasaki, Naohiro Okano, Junji Furuse, Nobuyoshi Hiraoka, Hiroshi Yoshida, Aya Kuchiba, Gakuto Ogawa, Kenichi Nakamura, Naoko Matsui, Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, Takuji Okusaka : Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 28th-31st. 2020.
  11. Vogel A, Finn RS, Kelley RK, Furuse J, Edeline J, Ren Z, Su SC, Malhotra U, Abby B. Siegel AB, Valle JW : Pembrolizumab in Combination With Gemcitabine and Cisplatin for the Treatment of Advanced Biliary Tract Cancer: Phase 3 KEYNOTE-966 Trial in Progress. ESMO World Congress on Gastrointestinal cancer 2020. Online. July 1st-4th. 2020.
  12. 長島文夫：高齢がん患者の治療選択について考える. 山口大学講演会．オンライン  ．2020年7月21日．
  13. Borad MJ, Bridgewater JA, Morizane C, Shroff RT, Oh DY, Moehler M, Furuse J, Benhadji KA, He Y, Valle JW : An open-label, randomized phase 3 study of futibatinib (TAS-120) versus gemcitabine-cisplatin chemotherapy as first-line treatment for patients with advanced cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene rearrangements (FOENIX-CCA3). Cholangiocarcinoma Foundation． Online． July 22th． 2020.
  14. 長島文夫 ： 高齢者のがん薬物療法ガイドライン.第62回日本老年医学会学術集会．オンライン．2020年8月4日‐6日.
  15. Izumi N, Kudo M, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Motomura K, Furuse J, Ikeda M, Morimoto M, Kuroda S, Kimura A: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: A Phase II multicenter study (Cabozantinib-2003).第56回日本肝臓学会．オンライン．2020年8月28日．
  16. 長島文夫：高齢者がん薬物療法の考え方.桜山がん診療包括ケアカンファレンス．オンライン名古屋Web  ．2020年9月3日．
  17. Furuse J : PC-Cure-1: a retrospective study of Conversion Surgery for unresectable Pancreatic Cancer. Update of FACO Clinical Trials. 13th Annual Meeting of the Korean Society of Medical Oncology & 2020 International Conference (KSMO 2020), 8th International Conference of the Federation of Asian Clinical Oncology (FACO)．Online． Sep 4th．2020.
  18. Kelly RK, Vogel A, Finn RS, Furuse J, Edeline J, Ren Z, Su SC, Malhotra U, Siege AB, Valle JW: Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer : Phase 3 KEYNOTE-966 trial in progress. International Liver Cancer Association 2020.Online. Sep 11th. 2020.
  19. Furuse J : Pancreatic canc.er treatments Asian perspective. Joining efforts across the borders in improving mPDAC patient outcomesSymposium organized by Servier. ESMO2020.Online. Sep 18th. 2020.
  20. 古瀬純司：肝胆膵領域がんにおける最近の動向．会長企画シンポジウム 2 ASCO2020、ESMO2020の総括と新たな診療の構築1 －消化管・肝胆膵・呼吸器・頭頸部－．第58回日本癌治療学会学術集会．京都．2020年10月22日．
  21. 長島文夫：高齢がんにおけるウェアラブルデバイスを用いた生体情報採録システムの実施可能性試験．第58回日本癌治療学会学術集会．京都．2020年10月22日．
  22. Furuse J, Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Kelley RK, Cassier PA, Klümpen HJ, Uboha NV, Mahipal A, Mitchell E, Ahn E, Chang HM, Masuda K, He Y, Benhadji KA, Bridgewater JA: Efficacy, Safety, and Quality of Life With Futibatinib in Patients With Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements: FOENIX-CCA2. Mini Oral Session. ESMO-Asia 2020. Online. Nov 20th. 2020.
  23. 古瀬純司：膵がん化学療法の最新情報－オニバイド®（nal-IRI)を中心に. 新潟消化管研究会．新潟．2020年10月17日．
  24. 古瀬純司：膵がん化学療法の最新情報－オニバイド®（nal-IRI)を中心に．新潟消化管研究会. 仙台．2020年11月13日．
  25. 長島文夫：高齢者大腸がん患者における現状と課題. 高齢者がん患者に関わる多職種連携セミナー．オンライン東京Web  ．2020年11月17日．
  26. 古瀬純司：肝癌におけるがんサポーティブケア．第56回日本肝癌研究会．オンライン．2020年12月23日.
  27. 古瀬純司：特別発言．パネルディスカッション 3 切除不能膵癌に対する集学的治療．第51回日本膵臓学会大会．オンライン．2021年1月8日．
  28. 古瀬純司：ランチョンセミナー 4. 膵癌の薬物療法最前線~2次治療を見据えた治療戦略．第51回日本膵臓学会大会．オンライン．2021年1月8日．
  29. 古瀬純司：教育セミナー．膵癌薬物療法．第51回日本膵臓学会大会．オンライン．2021年1月8日．
  30. Kudo M, Ueshima K, Ikeda M, Torimura T, Aikata H, Izumi N, Yamasaki T, Hino K, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yoshimura K, Okusaka T, Furuse J, Arai Y: TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium 2021. Online. January 15th-17th.2021.
  31. Okano N, Morizane C, Okusaka T, Sadachi R, Kataoka T, Ueno M, Ikeda M, Ozaka M, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Yamaguchi H, Ishii H, Furuse J : Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113. Gastrointestinal Cancers Symposium 2021. Online. January 15th-17th.2021.
  32. McNamara MG, Bridgewater JA, Goyal L, Goldstein D, Shroff RT, Moehler MH, Lowery MA, Bekaii-Saab TS, Kelley RK, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox JJ, Valle JW: Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC). Gastrointestinal Cancers Symposium 2021. Online. January 15th-17th.2021.
  33. Suzuki E, Morizane C, Ogawa G, Kataoka T, Okano N, Okusaka T, Ueno M, Ikeda M, Ozaka M, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Fukuda H, Ishii H, Furuse J: Impact of liver cirrhosis in patients with intrahepatic cholangiocarcinoma receiving systemic chemotherapy: a subgroup analysis of the JCOG1113 randomized phase III trial. Poster # J-16, The Asian Pacific Association for the Study of the Liver (APASL) 2021. Online. Feb 4th-6th. 2021.
  34. 上野誠，森實千種，井岡達也，田近正洋，池田公史，山口研成，原浩樹，薮崎裕，宮本敦史，岩佐悟，武藤学，高島勉，三梨桂子，小松嘉人，仁科智裕，中島貴子，佐原貴寿，上原泰介，船坂勢津雄，八代正和，古瀬純司: Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090. MO38-3．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
  35. Ogasawara S, Yamashita T, Kurosaki M, Numata K, Morimoto N, Ohkawa K, Arakawa T, Manabu Morimoto M, Muromatsu R, Ishigami M, Furuse J, Ogawa K, Hiroshi Aikata H, Hasegawa K, Sawako U, Tsutomu Takatsuki T, Yoshida T, Han S, Malhotra U, Kudo M: Effect of pembrolizumab on hepatitis viral load and ALT levels in Japanese patients with hepatocellular carcinoma．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
  36. Oh DY, Braud FD, Bridgewater J, Furuse J, Hsu CH, Ikeda M, Lee S, Moehler M, Park JO, Shen L, Yoo C, Helwig C, Osada M, Borad M: Phase 2/3 study of bintrafusp alfa with gemc-itabine plus cisplatin as first-line treatment of bil-iary tract cancer．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
  37. 今岡大，池田公史，前原耕介，梅本久美子，尾阪将人，小林智，寺島健志，井上博登，坂口智紘，辻国広，塩路和彦，岡村圭也，川本泰之，鈴木玲，白川博文，永野浩昭，上野誠，森實千種，古瀬純司：Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
  38. 木村綾，福田治彦，中村健一，柴田大朗，江場淳子，片岡智子，山本精一郎，水谷友紀，上野誠，枝園忠彦，小島崇宏，吉川貴己，丸山大，古瀬純司：JCOGにおける患者・市民参画の取り組み．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
  39. Satoshi Yuki, Yoshiaki Nakamura, Hiroya Taniguchi, Tadamichi Denda, Tomohiro Nishina, Yasuo Hamamoto, Hiroki Hara, Taito Esaki, Hisato Kawakami, Atsuo Takashima, Taroh Satoh, Yu Sunakawa, Toshiki Masuishi, Eiji Shinozaki, Toshikazu Moriwaki, Izumi Miki, Kohei Shitara, Takayuki Yoshino : Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
  40. 長島文夫：SIOG-JSMO joint symposium 第3期がん対策推進基本計画における今後の課題と持続可能な社会として目指すもの．第18回日本臨床腫瘍学会学術集会．2021年2月18日‐20日．
  41. 古瀬純司：大きく変わった肝細胞がんの薬物療法.－免疫チェックポイント阻害の時代へ．西東京市医師会学術講演会．オンライン．2021年1月19日．
  42. 長島文夫：高齢者に対するがん薬物療法．第17回日本消化管学会総会学術集会．オンライン．  2021年2月19日‐21日．
  43. 古瀬純司: がん悪液質とアナモレリン（エドルミズ錠®）のエビデンス. 最新医療研究会. オンライン. 2021年2月25日．
  44. 古瀬純司：特別講演. 切除不能膵癌におけるconversion surgeryの動向．第49回九州膵研究会．オンライン．2021年3月6日．
  45. 長島文夫：AMEDロボット介護機器開発・標準化事業（効果測定・評価事業）成果報告会．オンライン．  2021年3月27日.

論　文

欧文

  1. Okano N, Furuse J, Ueno M1, Morizane C2, Yamanaka T3, Ojima H4, Ozaka M5, Sasaki M6, Takahara N7, Nakai Y7, Kobayashi S1, Morimoto M1, Hosoi H2, Maeno S, Nagashima F, Ikeda M8, Okusaka T2 (1Kanagawa Cancer Center, 2National Cancer Center Hospital,3Yokohama City University School of Medicine, 4Keio University School of Medicine, 5The Cancer Institute of JFCR, 6National Cancer Center Hospital East, 7The University of Tokyo) : Multicenter phase II trial of axitinib monotherapy for gemcitabine-based chemotherapy refractory advanced biliary tract cancer (AX-BC Study). Oncologist. 2020. DOI: 10.1002/onco.13547. [Epub]
  2. Ueno M1, Nakamori S2, Sugimori K3, Kanai M4, Ikeda M5, Ozaka M6, Furukawa M7, Okusaka T8, Kawabe K9, Furuse J, Komatsu Y10, Ishii H11, Sato A12, Shimizu S13, Chugh P14, Tang R15, Ioka T16. (1Kanagawa Cancer Center, 2NHO Osaka National Hospital, 3Yokohama City University Medical Center, 4Kyoto University Hospital, 5National Cancer Center Hospital East, 6Cancer Institute Hospital of JFCR , 7NHO Kyushu Cancer Center, 8National Cancer Center Hospital, 9Kyushu University,10Hokkaido University Hospital Cancer Center,11Chiba Cancer Center, 12Hirosaki University Hospital, 13Saitama Cancer Center , 14Servier Pharmaceuticals , 15Osaka International Cancer Institute) : nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med. 9(24). 9396-9408. 2020.
  3. Nara S1, Esaki M1, Ban D1, Takamoto T1, Shimada K1, Ioka T2, Okusaka T3, Ishii H4, Furuse J (1National Cancer Center Hospital, 2Yamaguchi University Graduate School of Medicine, 3National Cancer Center Hospital, 4Chiba Cancer Center) : Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. Jpn J Clin Oncol. 50(12).1353-1363. 2020.
  4. Nakamura Y1, Taniguchi H1, Ikeda M1, Bando H2, Kato K3, Morizane C3, Esaki T4, Komatsu Y5, Kawamoto Y6, Takahashi N7, Ueno M8, Kagawa Y9, Nishina T10, Kato T11, Yamamoto Y12, Furuse J, Denda T13, Kawakami H14, Oki E15, Nakajima T16, Nishida N17, Yamaguchi K18, Yasui H19, Goto M20, Matsuhashi N21, Ohtsubo K22, Yamazaki K23, Tsuji A24, Okamoto W1,25, Tsuchihara K1,26, Yamanaka T1, Miki I1, Sakamoto Y1, Ichiki H1, Hata M1, Yamashita R26, Ohtsu A1, Odegaard JI27, Yoshino T1(1 National Cancer Center Hospital East, 2National Cancer Center Hospital East, 3Aichi Cancer Center Hospital,4National Cancer Center Hospital, 5National Hospital Organization Kyushu Cancer Center, 6Hokkaido University Hospital, 7Saitama Cancer Center, 8Kanagawa Cancer Center, 9Kansai Rosai Hospital, 10National Hospital Organization Shikoku Cancer Center, 11National Hospital Organization Osaka National Hospital, 12University of Tsukuba Hospital, 13Chiba Cancer Center, 14Kindai University Hospital, 15Kyushu University, 16St. Marianna University School of Medicine, 17Osaka University, 18Cancer Institute Hospital of Japanese Foundation for Cancer Research, 19Kobe City Medical Center General Hospital, 20Osaka Medical College Hospital, 21Gifu University, 22Kanazawa University, 23Shizuoka Cancer Center, 24Kagawa University Hospital, 25Hiroshima University Hospital,26National Cancer Center, 27Guardant Health, Redwood City) : Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 26(12). 1859-1864. 2020.
  5. Okuyama H1,2, Ikeda M2, Okusaka T3, Furukawa M4, Ohkawa S5, Hosokawa A6, Kojima Y7, Hara H8, Murohisa G9, Shioji K10, Asagi A11, Mizuno N12, Kojima M13, Yamanaka T14 (1Kagawa University, 2National Cancer Center Hospital East, 3National Cancer Center Hospital, 4National Hospital Organization Kyushu Cancer Center, 5Kanagawa Cancer Center,6Faculty of Medicine University of Toyama, Toyama, 7National Center for Global Health and Medicine, 8Saitama Cancer Center, 9Seirei Hamamatsu General Hospital, 10Niigata Cancer Center Hospital, 11National Hospital Organization Shikoku Cancer Center, 12Aichi Cancer Center Hospital, 13Exploratory Oncology Research and Clinical Trial Center, 14Yokohama City University Graduate School of Medicine) : A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology. 110(11-12). 988-993. 2020.
  6. Tanaka H1, Hijioka S2, Hosoda W3, Ueno M4, Kobayashi N5, Ikeda M6, Ito T7, Kodama Y8, Morizane C9, Notohara K10, Taguchi H11, Kitano M12, Komoto I13, Tsuji A14, Hashigo S15, Kanno A16, Miyabe K17, Takagi T18, Ishii H, Kojima Y19, Yoshitomi H20, Yanagimoto H21, Mizuno N3 (1Suzuka General Hospital, 2National Cancer Center Hospital, 3Aichi Cancer Center Hospital, 4Kanagawa Cancer Center,5Yokohama City University Hospital, 6National Cancer Center Hospital East,7Fukuoka Sannno Hospital, 8Kobe University Graduate School of Medicine, 9National Cancer Center Hospital, 10Kurashiki Central Hospital, 11Saiseikai Sendai Hospital, 12Wakayama Medical University, 13Kansai Electric Power Hospital, 14Kagawa University, 15Kumamoto University, 16Tohoku University Graduate School of Medicine, 17Japanese Red Cross Nagoya Daini Hospital, 18Fukushima Medical University School of Medicine, 19Chiba Cancer Center, 20Center Hospital of the National Center for Global Health and Medicine, 21Chiba University, 22Kobe University Graduate School of Medicine) : Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology. 20(7). 1421-1427. 2020.
  7. Bekaii-Saab TS1, Valle JW2, Cutsem EV3, Rimassa L4,5, Furuse J, Ioka T6, Melisi D7, Macarulla T8, Bridgewater J9, Wasan H10, Borad MJ1, Abou-Alfa GK11,12, Jiang P13, Lihou CF13, Zhen H13, Asatiani E14, Féliz L14, Vogel A15 (1Mayo Clinic, 2University of Manchester , The Christie Hospital NHS Foundation Trust, The University of Manchester, 3University of Leuven, 4Humanitas Clinical and Research Center-IRCCS, 5Humanitas University, 7Osaka International Cancer Institute, 8University of Verona, 9Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, 10UCL Cancer Institute, University College London, 11Hammersmith Hospital, Imperial College Health Care Trust, 12Memorial Sloan Kettering Cancer Center, 13Weill Medical College, Cornell University, 14Incyte Corporation, Wilmington, 15Incyte Biosciences International Sàrl, Morges, 16Hannover Medical School) : FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 16(30). 2385-2399. 2020.
  8. Okano N, Hana K1, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H1, Furuse J : (1J-Pharma Co) : Biomarker analyses in patients with advanced solid tumors treated with the LAT1 Inhibitor JPH203. In Vivo. 34(5). 2595-2606. 2020.
  9. Kudo M1, Morimoto M2, Moriguchi M3, Izumi N4, Takayama T5, Yoshiji H6, Hino K7, Oikawa T8, Chiba T9, Motomura K10, Kato J11, Yasuchika K12, Ido A13, Sato T14, Nakashima D14, Ueshima K1, Ikeda M15, Okusaka T16, Tamura K17, Furuse J (1Kindai University, 2Kanagawa Cancer Center, 3Kyoto Prefectural University of Medicine, 4Musashino Red Cross Hospital, 5Tokushima University Graduate School of Biomedical Sciences, 6Nara Medical University, 7Kawasaki Medical School, 8Iwate Medical University, 9Chiba University, 10Aso Iizuka Hospital, 11Juntendo University School of Medicine, 12Kyoto University Graduate School of Medicine, 13Kagoshima University Medical and Dental Hospital, 14Kyowa Kirin Co., 15National Cancer Center Hospital East, 16National Cancer Center Hospital, 17Fukuoka University) : A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci. 111(10). 3759-69. 2020.
  10. Imaoka H1, Ikeda M1, Maehara K2, Umemoto K3, Ozaka M4, Kobayashi S5, Terashima T6, Inoue H7, Sakaguchi C8, Tsuji K9, Shioji K10, Okamura K11, Kawamoto Y12, Suzuki R13, Shirakawa H14, Nagano H15, Ueno M5, Morizane C2, Furuse J (1National Cancer Center Hospital East, 2National Cancer Center Hospital , 3St.Marianna University School of Medicine , 4Cancer Institute Hospital Japanese Foundation for Cancer Research , 5Kanagawa Cancer Center ,6Kanazawa University Hospital ,7Shizuoka Cancer Center ,8Shikoku Cancer Center ,9Ishikawa Prefectural Central Hospital, 10Niigata Cancer Center Hospital ,11JA Sapporo Kohsei Hospital ,12Hokkaido University Hospital, 13Fukushima Medical University School of Medicine ,14Tochigi Cancer Center ,15Yamaguchi University Graduate School of Medicine ) : Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a
  11. Okano N, Morizane C1, Nomura S2, Takahashi H3, Tsumura H4, Satake H5, Mizuno N6, Tsuji K7, Shioji K8, Asagi A9, Yasui K10, Kitagawa S11, Kashiwada T12, Ishiguro A13, Kanai M14, Ueno M15, Ogura T16, Shimizu S17, Tobimatsu K18, Motoya M19, Nakashima K20, Ikeda M3, Okusaka T1, Furuse J (1National Cancer Center Hospital, 2National Cancer Center, 3National Cancer Center Hospital East,4Hyogo Cancer Center, 5Kobe City Medical Center General Hospital,6Aichi Cancer Center Hospital,7Ishikawa Prefectural Central Hospital,8Niigata Cancer Center Hospital,9National Hospital Organization Shikoku Cancer Center,10Kyoto Prefectural University of Medicine,11Sapporo Kosei General Hospital, 12Saga University, 13Teine Keijinkai Hospital,14Kyoto University,15Kanagawa Cancer Center, 16St. Marianna University School of Medicine, 17Saitama Cancer Center,18Kobe University Graduate School of Medicine,19Sapporo Medical University School of Medicine,20University of Miyazaki Hospital) : Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). Int J Clin Oncol. 25(10). 1835-1843. 2020.
  12. Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H1, Furuse J (1J-Pharma Co) : First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 38(5). 1495-1506. 2020.
  13. Kudo M1, Ueshima K1, Ikeda M2, Torimura T3, Tanabe N4, Aikata H5, Izumi N6, Yamasaki T7, Nojiri S8, Hino K9, Tsumura H10, Kuzuya T11, Isoda N12, Yasui K13, Aino H14, Ido A15, Kawabe N16, Nakao K17, Wada Y18, Yokosuka O19, Yoshimura K20, Okusaka T21, Furuse J, Kokudo N22, Okita K23, Johnson PJ24, Arai Y21; TACTICS study group (1Kindai University Faculty of Medicine,2National Cancer Center Hospital East,3Kurume University School of Medicine, 4National Hospital Organisation Sendai Medical Center,5Hiroshima University,6Musashino Red Cross Hospital,7Yamaguchi University Graduate School of Medicine,8Nagoya City University Graduate School of Medical Sciences,9Kawasaki Medical School,10Hyogo Cancer Center,11Nagoya University Graduate School of Medicine,12Jichi Medical University,13Kyoto Prefectural University of Medicine,14Social Insurance Tagawa Hospital,15Kagoshima University Graduate School of Medical and Dental Sciences,16Fujita Health University School of Medicine,17Nagasaki University Graduate School of Biomedical Sciences,18National Hospital Organization Kyushu Medical Center,19Chiba University,20Hiroshima University,21National Cancer Center Hospital,22National Center for Global Health and Medicine,23Shunan Memorial Hospital, 24University of Liverpool) : Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 69(8). 1492-1501. 2020.
  14. Ikeda M1, Morizane C2, Hijioka S3, Matsumoto S4, Konishi T5, Komoto I6, Aoki T7, Ito T8, Furuse J, Sasano H9, Doi R10 (1National Cancer Center Hospital East,2National Cancer Center Hospital,3Kyoto University,4Cancer Institute Hospital of the Japanese Foundation for Cancer Research,5Kansai Electric Power Hospital,6Dokkyo Medical University,7Fukuoka Sanno Hospital,8Tohoku University School of Medicine,9Otsu Red Cross Hospital) : Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology. 20(5). 944-950. 2020.
  15. Sangro B1, Melero I2, Wadhawan S3, Finn RS4, Abou-Alfa GK5, Cheng AL6, Yau T7, Furuse J, Park JW8, Boyd Z3, Tang HT3, Shen Y3, Tschaika M3, Neely J3, El-Khoueiry A9 (1Clinica Universidad de Navarra-IDISNA and CIBEREHD, 2Universidad de Navarra and CIBERONC,3Bristol Myers Squibb,4University of California, 5Memorial Sloan Kettering Cancer Center ,Weill Medical College at Cornell University 6National Taiwan University Hospital,7University of Hong Kong, 8National Cancer Center, 9USC Norris Comprehensive Cancer Center) : Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 73(6).1460-1469. 2020.
  16. Shimoyama R1, Hijioka S1, Mizuno N2, Ogawa G1, Kataoka T1, Katayama H1, Machida N3, Honma Y1, Boku N1, Hamaguchi T4, Fukuda H1, Terashima M3, Kanemitsu Y1, Furuse J (1National Cancer Center Hospital, 2Aichi Cancer Center Hospital,3Shizuoka Cancer Center,4Saitama Medical University International Medical Center) : Stomach Cancer Study Group/Colorectal Cancer Study Group/Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology. 20(6). 1183-1188. 2020.
  17. Matsuki R1, Kawai K, Suzuki Y1, Kogure M1, Nakazato T1, Naruge D, Okano N, Seki S1, Ohmori Y1, Kawamura N1, Kamma H1, Hisamatsu T1, Shibahara J1, Mori T1, Furuse J, Sakamoto Y1 (1Kyorin University Hospital ): Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma. Liver Cancer. 9(3). 358-360.2020.
  18. Kudo M1, Okusaka T2, Motomura K3, Ohno I4, Morimoto M5, Seo S6, Wada Y7, Sato S8, Yamashita T9, Furukawa M10, Aramaki T11, Nadano S12, Ohkawa K13, Fujii H14, Kudo T15, Furuse J, Takai H16, Homma G16, Yoshikawa R16, Zhu AX17 (1Kindai University Faculty of Medicine, 2National Cancer Center Hospital,3Aso Iizuka Hospital,4National Cancer Center Hospital East, 5Kanagawa Cancer Center,6Kyoto University, 7Kyushu Medical Center,8Kyoundo Hospital,9Kanazawa University,10National Hospital Organization Kyushu Cancer Center,11Shizuoka Cancer Center Hospital,12National Hospital Organization Shikoku Cancer Center,13Osaka International Cancer Institute,14Jichi Medical University,15Osaka University,16Eli Lilly Japan K.K,17Massachusetts General Hospital Cancer Center, Harvard Medical School) : Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol. 55(6). 627-639. 2020.
  19. Yamamoto N1, Ryoo BY2, Keam B3, Kudo M4, Lin CC5, Kunieda F6, Ball HA6, Moran D6, Komatsu K7, Takeda K6, Fukuda M7, Furuse J, Morita S8, Doi T9 (1National Cancer Center Hospital,2Asan Medical Center, University of Ulsan,3Seoul National University Hospital,4Kindai University,5National Taiwan University Hospital,6Astellas Pharma Global Development,7Astellas Pharma,8Kyoto University, 9National Cancer Center Hospital East) : A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. Invest New Drugs.38(2). 445-456. 2020.
  20. Okusaka T1, Furuse J(1National Cancer Center Hospital) : Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 55(4). 369-382. 2020.
  21. U0eno M1, Ikeda M2, Sasaki T3, Nagashima F, Mizuno N4, Shimizu S5 , Ikezawa H6, Hayata N7, Nakajima R8, Morizane C9 (1Kanagawa Cancer Centre Hospital,2National Cancer Center Hospital East,3Cancer Institute Hospital of JFCR,4Aichi Cancer Centre Hospital,5Saitama Cancer Centre,6Eisai Co. Ltd,7Eisai Inc,8National Cancer Centre Hospital) : Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 20(1). 1105. 2020.
  22. Kobayashi N1, Omae K2, Horita Y3, Ueno H4, Mizuno N5, Uesugi K6, Sudo K7, Ozaka M8, Hayashi H9, Okano N, Kamei K10, Yamaguchi A11, Kobayashi S12, Suzuki S13, Ishihara S14, Uchiyama T15, Todaka A16, Fukutomi A16 (1Yokohama City University Hospital,2Shizuoka Cancer Center,3Toyama Prefectural Central Hospital,4National Cancer Center Hospital,5Aichi Cancer Center, 6National Hospital Organization Shikoku Cancer Center,7Chiba Cancer Center,8Cancer Institute Hospital of Japanese Foundation for Cancer Research,9Hokkaido University Graduate School of Medicine,10Kindai University Hospital,11Kure Medical Center and Chugoku Cancer Center,12Kanagawa Cancer Center,13Yamagata University Faculty of Medicine,14Fujita Health University,15Kikugawa General Hospital,16Shizuoka Cancer Center) : FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Pancreatology.20(7). 1519-1525. 2020.
  23. Imaoka H1, Ikeda M1, Maehara K2, Umemoto K3, Ozaka M4, Kobayashi S5, Terashima T6, Inoue H7, Sakaguchi C8, Tsuji K9, Shioji K10, Okamura K11, Tsujimoto A12, Nakamura I13, Shirakawa H14, Furukawa M15, Ueno M3, Morizane C2, Furuse J (1National Cancer Center Hospital East,2National Cancer Center Hospital,3St. Marianna University School of Medicine,4Cancer Institute Hospital Japanese Foundation for Cancer Research,5Kanagawa Cancer Center,6Kanazawa University Hospital,7Shizuoka Cancer Center,8Shikoku Cancer Center,9Ishikawa Prefectural Central Hospital,10Niigata Cancer Center Hospital,11JA Sapporo Kohsei Hospital,12Chiba Cancer Center,13Hyogo College of Medicine,14Tochigi Cancer Center,15National Hospital Organization Kyushu Cancer Center) : Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas. Pancreatology. 2021. DOI: 10.1016/j.pan.2021.02.008. [Epub]
  24. Takai E1, Nakamura H2, Chiku S3, Kubo E4, Ohmoto A4, Totoki Y2, Shibata T2, Higuchi R5, Yamamoto M5, Furuse J, Shimizu K5, Takahashi H6, Morizane C4, Furukawa T7, Yachida S1 (1Osaka University,2National Cancer Center Research Institute,3Mizuho Information and Research Institute,4National Cancer Center Hospital,5Tokyo Women’s Medical University,6National Cancer Center Hospital East,7Tohoku University Graduate School of Medicine) : Whole-exome sequencing reveals new potential susceptibility genes for Japanese familial pancreatic cancer. Ann Surg. 2020. DOI : 10.1097/SLA.0000000000004213. Online ahead of print.
  25. Maruki Y,1 Morizane C1, Arai Y2, Ikeda M3, Ueno M4, Ioka T5, Naganuma A6, Furukawa M7, Mizuno N8, Uwagawa T9, Takahara N10, Kanai M11, Asagi A12, Shimizu S13, Miyamoto A14, Yukisawa S15, Kadokura M16, Kojima Y17, Furuse J, Nakajima TE18,19, Sudo K20, Kobayashi N21, Hama N22, Yamanaka T23, Shibata T24, Okusaka T1 (1National Cancer Center Hospital, 2National Cancer Center Research Institute,3National Cancer Center Hospital East,4Kanagawa Cancer Center,5Yamaguchi University Hospital,6National Hospital Organization Takasaki General Medical Center,7National Hospital Organization Kyushu Cancer Center,8Aichi Cancer Center Hospital, 9The Jikei University School of Medicine,10The University of Tokyo,11Kyoto University,12National Hospital Organization Shikoku Cancer Center,13Saitama Cancer Center,14National Hospital Organization Osaka National Hospital,15Tochigi Cancer Center,16Kofu Municipal Hospital,17National Center for Global Health and Medicine,18St.Marianna University School of Medicine,19Kyoto University Hospital,20Chiba Cancer Center,21Yokohama City University School of Medicine, 22Yokohama City University Graduate School of Medicine) : Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). J Gastroenterol. 56(3). 297. 2021.
  26. Ueno M1, Morizane C2, Furukawa M3, Sakai D4, Komatsu Y5, Nakai Y6, Tsuda M7, Ozaka M8, Mizuno N9, Muto M10, Fukutomi A11, Ikeda M12, Tsuji A13, Katanuma A14, Moriwaki T15, Kajiwara T16, Ishii H17, Negoro Y18, Shimizu S19, Nemoto N20, Kobayashi S20, Makino K20, Furuse J (1Kanagawa Cancer Center,2National Cancer Center Hospital,3National Hospital Organization Kyushu Cancer Center,4Osaka University Graduate School of Medicine,5Hokkaido University Hospital,6The University of Tokyo,7Hyogo Cancer Center,8Cancer Institute Hospital of the Japanese Foundation for Cancer Research,9Aichi Cancer Center Hospital,10Kyoto University Hospital,11Shizuoka Cancer Center,12National Cancer Center Hospital East,13Kagawa University,14Teine-keijinkai hospital,15University of Tsukuba,16National Hospital Organization Shikoku Cancer Center,17Chiba Cancer Center,18Kochi Health Sciences Center,19Saitama Cancer Center,20Yakult Honsha Co.)：A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. Cancer Med. 10(6). 2088-2099. 2021.
  27. Yokokawa A1, Kaneko S1, Endo S1, Minowa Y1, Ayukawa H1, Hirano R1, Nagashima F, Naruge D, Okano N, Kobayashi T, Kawai K, Furuse J, Furuta T1, Shibasaki H1 (1Tokyo University of Pharmacy and Life Sciences) : Effect of UGT1A1, CYP3A and CES activities on the pharmacokinetics of irinotecan and its metabolites in patients with UGT1A1 gene polymorphisms. Eur J Drug Metab Pharmacokinet. 46(2). 317-324. 2021.
  28. Umemoto K1,2, Takahashi H1, Morizane C1, Yamada I3, Shimizu S4, Shioji K5, Yoshida Y6, Motoya M7, Mizuno N8, Kojima Y9, Terashima T10, Uesugi K11, Ueno M12, Furuse J, Akimoto T1,2, Ikeda M1(1National Cancer Center Hospital East,2Juntendo University Graduate School of Medicine,3Cancer Institute Hospital, Japanese Foundation For Cancer Research,4Saitama Cancer Center,5Niigata Cancer Center Hospital,6Shizuoka Cancer Center,7Sapporo Medical University,8Aichi Cancer Center Hospital,9National Center for Global Health and Medicine,10Kanazawa University Hospital,11National Hospital Organization Shikoku Cancer Center,12Kanagawa Cancer Center) : FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer Chemother Pharmacol. 87(3). 397-404. 2021.
  29. Ioka T1,2, Furuse J, Fukutomi A3, Mizusawa J4, Nakamura S5, Hiraoka N4, Ito Y4, Katayama H4, Ueno M6, Ikeda M7, Sugimori K8, Okano N, Shimizu K9, Yanagimoto H10, Okusaka T4, Ozaka M11, Todaka A4, Nakamori S12, Tobimatsu K13, Sata N14, Kawashima Y15, Hosokawa A16, Yamaguchi T17, Miyakawa H18, Hara H19, Mizuno N20, Ishii H17, Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG)(1Osaka International Cancer Institute, 2Yamaguchi University Hospital, 3Shizuoka Cancer Center,4National Cancer Center Hospital, 5Kansai Medical University Hospital, 6Kanagawa Cancer Center, 7National Cancer Center Hospital East, 8Yokohama City University Medical Center, 9Tokyo Women’s Medical University, 10Kansai Medical University, 11Cancer Institute Hospital,12Osaka National Hospital,13Kobe University Graduate School of Medicine,14Jichi Medical University School of Medicine,15Tokai University School of Medicine,16University of Toyama,17Chiba Cancer Center,18Sapporo Kosei General Hospital,19Saitama Cancer Center,20Aichi Cancer Center Hospital ) : Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol. 51(2). 235-243. 2021.
  30. Kudo M1, Tsuchiya K2, Kato N3, Hagihara A4, Numata K5, Aikata H6, Inaba Y7, Kondo S8, Motomura K9, Furuse J, Ikeda M10, Morimoto M11, Achira M12, Kuroda S13, Kimura A14 (1Kindai University ,2Musashino Red Cross Hospital ,3Chiba University , 4Osaka City University ,5Yokohama City University Medical Center,6Hiroshima University,7Aichi Cancer Center Hospital,8National Cancer Center Hospital ,9IIZUKA HOSPITAL,11National Cancer Center Hospital East,12Kanagawa Cancer Center ,13PRA Development Center KK ,14Takeda Pharmaceutical Company Limited ) : Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol. J Gastroenterol. 56(2). 181-190. 2021.
  31. Ueno M1, Morinaga S1, Hashimoto Y2, Umemoto K2, Sasahira N3, Saiur A3, Seyama Y4, Honda G5, Ioka T6, Takahashi H7, Miyamoto A8, Nakamori S8, Unno M9, Takadate T9, Mizuno N10, Shimizu Y10, Ueno H11, Sugiyama M12, Fukutomi A13, Shimizu S14, Okusaka T11, Furuse J (1Kanagawa Cancer Center,2National Cancer Center Hospital East,3Cancer Institute Hospital of Japanese Foundation for Cancer Research,4Bokuto Hospital,5Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 6Yamaguchi University,7Osaka International Cancer Institute, 8National Hospital Organization Osaka National Hospital,9Tohoku University Graduate School of Medicine,10Aichi Cancer Center Hospital,11National Cancer Center Hospital,12Department of Surgery, Kyorin University,13Shizuoka Cancer Center,14Saitama Cancer Center) : Tolerability of nab-paclitaxel plus gemcitabine as adjuvant setting in Japanese patients with resected pancreatic cancer: phase I study. Pancreas.50(1).83-88. 2021.
  32. Nagino M1, Hirano S2, Yoshitomi H3, Aoki T3, Uesaka K4, Unno M5, Ebata T6, Konishi M7, Sano K8, Shimada K9, Shimizu H10, Higuchi R11, Wakai T12, Isayama H13, Okusaka T9, Tsuyuguchi T14, Hirooka Y15, Furuse J, Maguchi H16, Suzuki K17, Yamazaki H18, Kijima H19, Yanagisawa A20, Yoshida M21,Yokoyama Y6, Mizuno T6, Endo I22 (1Aichi Cancer Center,2Hokkaido University,3Dokkyo Medical University,4Shizuoka Cancer Center,5Tohoku University Graduate School of Medicine,6Nagoya University Graduate School of Medicine,7National Cancer Center Hospital East,8Teikyo University School of Medicine,9Tokyo National Cancer Center Hospital,10Teikyo University Chiba Medical Center,11Tokyo Women’s Medical University,12Niigata University Graduate School of Medical and Dental Sciences,13Juntendo University,14Chiba Prefectural Sawara Hospital,15 Fujita Health University,16Teine-Keijinkai Hospital,17Aichi Medical University,18Kyoto Prefectural University of Medicine,19Hirosaki University Graduate School of Medicine, 20Japanese Red Cross Kyoto Diichi Hospital,21International University of Health and Welfare,22Yokohama City University) : Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition . J Hepatobiliary Pancreat Sci. 28(1). 26-54. 2021.
  33. Yamamoto M1, Yoshida M2, Furuse J, Sano K3, Ohtsuka M4, Yamashita S1, Beppu T5, Iwashita Y6, Wada K3, Nakajima TE7.8, Sakamoto K9, Hayano K10, Mori Y11, Asai K12, Matsuyama R13, Hirashita T1, Hibi T14, Sakai N4, Tabata T15, Kawakami H16, Takeda H7, Mizukami T7, Ozaka M17, Ueno M18, Naito Y19, Okano N, Ueno T20, Hijioka S21, Shikata S22, Ukai T23, Strasberg S24 , Sarr MG25, Jagannath P26, Hwang TL27, Han HS28, Yoon YS28, Wang HJ29, Luo SC30, Adam R31 , Gimenez M32,33, Scatton O34, Oh DY35, Takada T3 (1Tokyo Women’s Medical University,2International University of Health and Welfare,3Teikyo University School of Medicine,4Chiba University,5Yamaga City Medical Center,6Oita University Faculty of Medicine,7St. Marianna University School of Medicine,8Kyoto University Hospital,9Ehime University Graduate School of Medicine,10Chiba University,11Kyushu University,12Toho University Ohashi Medical Center,13Yokohama City University Graduate School of Medicine,14Kumamoto University Graduate School of Medical Sciences,15Kindai University Faculty of Medicine,16Cancer Institute Hospital of the Japanese Foundation for Cancer Research,17Kanagawa Cancer Center,18National Cancer Center Hospital East,19Cancer Institute Hospital, 20National Cancer Center Hospital,21Mie Prefectural Ichishi Hospital,22Osaka Institute of Public Health,23Washington University in St. Louis,24Mayo Clinic, 25Lilavati Hospital & SL Raheja Hospital,26Chang Gung Memorial Hospital at Linkou, Chang Gung University,27Seoul National University Bundang Hospital, Seoul National University College of Medicine,28Ajou University School of Medicine,29Taichung Veterans General Hospital,30AP HP Paul Brousse Hospital, University Paris Sud,31University of Buenos Aires, 32Institute of Image-Guided Surgery,33APHP Pitié-Salpêtrière Hospital, Sorbonne Université,34Seoul National University Hospital Cancer Research Institute,35Seoul National University College of Medicine)：Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci. 28(1).1-25. 2021.
  34. Takahashi H1, Ikeda M1, Shiba S2, Imaoka H3, Todaka A4, Shioji K5, Yane K6, Kojima Y7, Kobayashi S8, Asagi A9, Ozaka M10, Takada R11, Nagashio Y12, Horiguchi S13, Kasuga A14, Suzuki E15, Terashima T16, Ueno M8, Morizane C2, Furuse J（1National Cancer Center Hospital East,2National Cancer Center Hospital,3Aichi Cancer Center Hospital,4Shizuoka Cancer Center,5Niigata Cancer Center Hospital,6Teine-Keijinkai Hospital,7National Center for Global Health and Medicine,8Kanagawa Cancer Center, 9National Hospital Organization Shikoku Cancer Center,10Cancer Institute Hospital of Japanese Foundation for Cancer Research,11Osaka International Cancer Institute,12National Kyushu Cancer Center,13Okayama University Graduate School of Medicine,14Cancer Institute Hospital of the Japanese Foundation for Cancer Research,15Chiba University,16Kanazawa University Hospital）: Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 50(1). 77-82. 2021.
  35. Inomata K1, Yokoi H1 ,Fujiwara M1, Kimura Y2, Matsumoto Y1, Naito S1, Ohara A3, Okano N, Kanmma H2, Saito K1(1Department of Otolaryngology-Head and Neck Surgery, Kyorin University School of Medicine,2Department of Pathology , Kyorin University School of Medicine,3Department of Radiology, Kyorin University School of Medicine) : Case of thyroid transcription factor-1-positive neuroendocrine carcinoma of the sphenoid sinus with bone　metastases. Human Pathology. Case Reports.24. 2021. https://doi.org/10.1016/j.ehpc.2021.200492.
  36. Tsubata Y1, Shinomiya S2, Inoue K3, Ishikawa N4, Saito R5, Nakashima K1, Hotta K6, Hamada A7, Nagashima F, Ando Y8, Morita S9, Kobayashi K2, Isobe T6 (1Shimane University Faculty of Medicine,2Saitama Medical University International Medical Center,3Ehime Prefectural Central Hospital,4Hiroshima Prefectural Hospital,5Tohoku University Hospital,6Okayama University Hospital,7National Cancer Center Research Institute,8Nagoya University Hospital,9Kyoto University Graduate School of Medicine) : Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study. BMC Geriatr. 21(1). 74. 2021.

和文

  1. 古瀬純司 : 切除不能膵癌に対する臨床試験のup-to-date. 胆と膵. 42(1). 67-71. 2021.
  2. 古瀬純司 : 肝細胞がんに対する薬物療法の進歩. がん分子標的治療 18(2). 151-156. 2021.
  3. 岡野尚弘, 長島文夫, 古瀬純司：各臓器がんのゲノム診療の現状　消化器がん．腫瘍内科．27(1)．73-80．2021．
  4. 岡野尚弘，西岡真理子，杉浦ちとせ，前園知宏，河合桐男，小林敬明，水谷友紀，長島文夫，古瀬純司：進行膵癌の化学療法．進行胆道癌・膵癌の治療限界を打ち破る－症例から学ぶ究極の治療．胆と膵．41(5)．487-492．2020．
  5. 西岡真理子，長島文夫，古瀬純司：膵がん治療の最前線―化学療法―．膵炎・膵がん診療のUp To Date．臨牀と研究．97(5)．548-555．2020．
  6. 古瀬純司：肝細胞癌に対する治療薬の今後の展望．肝臓クリニカルアップデート 6(1)．85-90．2020.
  7. 古瀬純司：膵癌悪液質患者への栄養サポート－アナモレリンの特徴．胆と膵．41(7)．679-682．2020．
  8. 長島文夫，水谷友紀，岡野尚弘，西岡真理子，河合桐男，前園知宏，杉浦ちとせ，廣田玲，小林敬明，前野聡子，佐々木ヱリ，古瀬純司 : 高齢者のがん診療について．新薬と臨牀．69(8)．998-1003．2020．
  9. 前園知宏，古瀬純司： 胆膵疾患治療の最前線 パラダイムシフトも含めて 切除不能膵癌に対する化学療法  . Medical Practice. 37(8). 1291-1296．2020．
  10. 古瀬純司：肝・胆道・膵癌におけるConversion surgeryの意義－腫瘍内科医の立場から．手術．74(10)．1413-1418．2020.
  11. 古瀬純司：免疫チェックポイント阻害剤同士の併用療法 デュルバルマブ＋トレメリムマブ併用療法のupdate (Study 22)－肝細胞癌治療のパラダイムチェンジ－進化する薬物療法2020 Update Part1－（免疫療法）．肝胆膵．81(4)．713-717．2020．
  12. 岡野尚弘，長島文夫，古瀬純司：進行肝癌の1st line試験（RATIONALE-301, HIMARAYA, CM-9DW, LEAP-002,COSMIC-312）の概要  ．肝細胞癌治療のパラダイムチェンジ－進化する薬物療法2020 Update Part1－（免疫療法）．肝胆膵．81(4)．729-735．2020．
  13. 岡野尚弘，廣田玲，西岡真理子，杉浦ちとせ，前園知宏，河合桐男，水谷友紀，長島文夫，古瀬純司：胆道癌薬物療法の最新動向．臨床外科．75(13)．1484-1488．2020．
  14. 古瀬純司：肝細胞がんに対する薬物療法の進歩．がん分子標的治療．18(2)．151-156．2021.
  15. 古瀬純司：肝細胞がん 薬物療法．THE GI FOREFRONT．16(2)．114-117．2020．
  16. 古瀬純司 : IPMNに対する化学療法：術後補助療法および切除不能例に対する化学療法レジメンの選択. 胆と膵. 41. 1351-1353. 2020.
  17. 松井敏史，須藤珠水，永田あかね，山中崇，木棚究，水木麻衣子，長島文夫，前野聡子，佐々木ヱリ，池村健，裵東海，武久敬洋：要介護高齢者のロボットリハビリテーション. 老年内科. 3(2). 191-204. 2020.
  18. 長島文夫，桶川隆嗣1 (1杏林大・医・泌尿器科学)：特集「ここまできたがん免疫療法」対談「がん免疫療法の現状と展望」. 杏林医学会雑誌. 51(4).279-282.2020.
  19. 岡野尚弘：大腸癌の術後補助療法-最適な使い分け-．消化器内科．3(3)．12-20．2021．

著　書

  1. 古瀬純司(総監修)：膵癌診療の動向-序文に代えて．日本膵臓学会50周年記念誌．膵臓病学 臨床・研究の50年－日本膵臓学会と膵癌診療のあゆみ－．アークメデイア．2021．
  2. 小林智，石井浩，古瀬純司：薬物療法．膵癌．高齢者がん医療Q&A 臓器別編．日本がんサポーティブケア学会編集．金原出版．2020．144-154．
  3. 古瀬純司：膵疾患の治療・処置総論．抗癌薬治療．膵臓病診療ガイドブック．日本膵臓学会 教育委員会編集．診断と治療社．2020．146-150．
  4. 古瀬純司：肝細胞癌に対するラムシルマブ2次治療の第Ⅲ相試験（REACH試験）の総括．ラムシルマブによる肝細胞がん治療．工藤正俊監修．アークメディア．2020．43-47．
  5. 古瀬純司（編集）:．消化器ナーシング　臓器別消化器がん 化学療法・薬物療法．メディカ出版．2020．
  6. 岡野尚弘（分担執筆）：レゴラフェニブ．がん化学療法の薬はや調べノート．メディカ出版．2020．62-63.
  7. 岡野尚弘（分担執筆）：バンデタニブ．がん化学療法の薬はや調べノート．メディカ出版．2020．64-65．
  8. 岡野尚弘（分担執筆）：オラパリブ．がん化学療法の薬はや調べノート．メディカ出版．2020．150-151．
  9. 岡野尚弘（分担執筆）：ゲムシタビン．がん化学療法の薬はや調べノート．メディカ出版．2020．176-177．
  10. 岡野尚弘（分担執筆）：パクリタキセル．がん化学療法の薬はや調べノート．メディカ出版．2020．272-273．
  11. 岡野尚弘（分担執筆）：ナブパクリタキセル．がん化学療法の薬はや調べノート．メディカ出版．2020．274-275．
  12. 岡野尚弘（分担執筆）：ドセタキセル．がん化学療法の薬はや調べノート．メディカ出版．2020．276-277．
  13. 岡野尚弘（分担執筆）：胆道癌一次治療、二次治療．オンコロジークリニカルガイド　消化器癌化学療法改訂5版．室圭・大村健二編集．南山堂．2020．P288-293．

報告書

  1. 長島文夫：患者・家族の意思決定能力に応じた適切な意思決定支援の実践に資する簡便で効果的な支援プログラムの開発に関する研究．厚生労働科学研究費補助金(がん対策推進総合研究事業)2020年度　分担研究報告書．
  2. 長島文夫：高齢者がん診療指針策定に必要な基盤整備に関する研究．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2020年度　分担研究報告書．

その他

【座長・司会・主催】

  1. 長島文夫：切除不能進行胃がん高齢患者の治療．GI Cancer Cutting Edge　Web座談会．オンライン．2020年8月20日.
  2. 長島文夫：老年腫瘍学セミナー. オンライン．2021年2月27日.
  3. 長島文夫：東日本大震災から10年災害に備えるまちづくりを考える．第9回杏林CCRCフォーラム．オンライン．2021年3月13日.

 

講　演

  1. 長島文夫：高齢者前立腺癌治療 監視療法からCRPCまで 高齢者における癌治療について 本邦における老年腫瘍学．第107回日本泌尿器科学会総会，名古屋，2019年4月18日.
  2. Furuse J: Up-To-Date systemic treatments for hepatocellular carcinoma. 8th International Forum of the Japanese Society of Gastroenterology. 第105回日本消化器病学会総会，金沢，2019年5月9日.
  3. 岡野尚弘，松木亮太，土岐真朗，立石秀勝，渡邉俊介，鈴木裕，柴原純二，阪本良弘，杉山政則，古瀬純司：Borderline resectable膵癌に対する術前治療としてのゲムシタビン+ナブパクリタキセル療法のfeasibility試験．第105回日本消化器病学会総会，金沢，2019年5月10日．
  4. 古瀬純司 : 最新の膵癌治療の動向－薬物療法の進歩．第22回湖南・東近江消化器カンファレンス，近江八幡，2019年5月16日．
  5. 古瀬純司：MSI-High膵癌・胆道癌における新たな治療戦略－免疫チェックポイント阻害剤登場. Oncologyインターネット講演会，東京，2019年5月23日．
  6. Nara S, Shimada K, Uesaka K, Konish M, Ohtsuka M, Hirono S, Unno M, Yanagimoto H, Nomura T, Sata N, Wada H, Hatano E, Sakamoto H, Ohta T, Fujino Y, Morinaga S, Tahara M, Ambo Y, Ohta K, Fujii T, Shirakawa H, Nagano H, Miyamoto A, Takeda K, Sugimachi K, Furuse J : The assessment of preoperative diagnostic accuracy of multidetector-row computed tomography (MDCT) for resectable biliary tract cancer- multi-institutional validity study in Japan. Digestive Disease Week 2019, USA, May 18th-21st, 2019.
  7. Shibasaki-Hirano H, Usukura C, Katsumata S, Hirahara Y, Hirano R, Yokokawa A, Maesono T, Kawai K, Nishioka M, Kobayashi T, Okano N, Nagashima F, Furuse J : Simultaneous measurement of regorafenib and its metabolites in human plasma using HPLC and pharmacokinetics in Japanese patients. 日本TDM学会学術集会，東京，2019年5月25-26日．
  8. Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J: First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100). ASCO2019, USA, June 3rd, 2019.
  9. 古瀬純司 : 肝細胞癌に対する薬物療法：最近の話題と今後の展望．第31回日本肝胆膵外科学会学術集会，高松，2019年6月14日．
  10. Furuse J, Kawakami H, Mizukami T, Ozaka M, Okano N, Ueno M, Hijioka S, Ueno T, Naito Y, Nakajima TE: International clinical practice guidelines for metastatic liver tumors: Interim report. The 31st Meeting of Japan Society of Hepato-Biliary-Pancreatic Surgery, 高松，2019年6月14日．
  11. 長島文夫：高齢者がん診療の考え方　高齢者機能評価と意思決定支援を含めて．第1回地域がん医療連携研修会，横浜，2019年6月25日．
  12. 池田公史，工藤正俊，奥坂拓志，本村健太，大野泉，森本学，瀬尾智，和田幸之，佐藤新平，山下竜也，古川正幸，新槇剛，灘野成人，大川和良，藤井博文，工藤敏啓，古瀬純司，髙井弘基，本間剛介，吉川麗月，Andrew X. Zhu：ソラフェニブ後のAFP高値進行肝細胞癌に対するラムシルマブ：2つの国際共同無作為化第3相試験の併合解析における日本人患者の有効性と安全性．第20回日本肝がん分子標的治療研究会，長崎，2019年6月29日．
  13. 古瀬純司，泉並木，工藤正俊，本村健太，薮下和久，稲葉吉隆，片村嘉男，近藤泰輝：切除不能な肝細胞癌患者に対するレンバチニブ投与の多施設観察研究-中間報告-．第20回日本肝がん分子標的治療研究会，長崎，2019年6月29日．
  14. 古瀬純司 : バイオマーカー．（特別発言）第55回日本肝癌研究会，東京，2019年7月5日.
  15. 古瀬純司 : 膵癌の薬物療法-これまでとこれから．第50回日本膵臓学会大会，東京，2019年7月12-13日.
  16. 古瀬純司，福冨晃，水野伸匡，尾阪将人，井岡達也，奥坂拓志 : 切除不能膵癌に対する化学療法．膵癌診療ガイドライン2019．膵癌診療の進歩値明日への提言．第50回日本膵臓学会大会，東京，2019年7月12-13日．
  17. 庄司広和，工藤千恵，高石官均，高橋直樹，傳田忠道，川上武志，山口研成，古瀬純司，森脇俊和，高野利美，澤田亮一，宮本敬大，今関洋，青木一教，室圭，朴成和：標準治療に不応不耐進行胃癌患者に対するNivoluamb療法のBiomarker研究．第17回日本臨床腫瘍学会学術集会，京都，2019年7月18日．
  18. 津村英隆，森実千種，野村尚吾，高橋秀明，岡野尚弘，水野伸匡，佐竹悠良，辻国広，塩路和彦，浅木彰則，安居幸一郎，宮川浩之，石黒敦，小倉孝，上野誠，飛松和俊，寺島健志，池田公史，奥坂拓志，古瀬純司：Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
  19. Morizane C, Ikeda M, Ueno M, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J: Open-label, phase I study of nivolumab or nivolumab/cisplatin/gemcitabine in patients with unresectable/recurrent biliary tract cancer. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
  20. Ikeda M, Okuyama H, Okusaka T, Furuse J, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T: Everolimus for advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based chemotherapy. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日．
  21. 岡野尚弘：好中球減少に対するマネジメント．第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
  22. 古瀬純司，丸山大，木村綾，中村健一，福田治彦 : JCOGにおける患者参画の取り組みと展望．臨床試験への患者参画．第17回日本臨床腫瘍学会学術集会，京都，2019年7月20日．
  23. 古瀬純司 : 肝細胞癌の治療戦略-薬物療法の動向と今後の展望．第2回Digestive Expert Forum in Osaka，大阪，2019年7月26日．
  24. 長島文夫：高齢者のがん診療の考え方．第28回多摩骨軟部腫瘍研究会，三鷹，2019年8月24日．
  25. Furuse J: Molecular targeted therapy for advanced HCC: review of the clinical trials results. Molecular Targeted Therapy: Regional Difference of Treatment Strategy for Intermediate/Advanced stage HCC Patients in a Era of Multi-Targeted Agents Era. The 10th Asia-Pacific Primary Liver Cancer Expert Meeting. 札幌，2019年8月31日．
  26. 古瀬純司：肝細胞癌の薬物療法ー1次治療から2次治療へのエビデンス．NEXT Web conference，東京，2019年9月4日．
  27. 古瀬純司：肝細胞癌の治療戦略-薬物療法の動向と今後の展望．第15回広島肝胆膵研究会，広島，2019年9月6日.
  28. 佐々木ヱリ，前野聡子，河合桐男，小林敬明，岡野尚弘，北村浩，古瀬純司，長島文夫：がん従事者に対するロボット介護機器のアンケ―ト調査．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
  29. 前野聡子，佐々木ヱリ，河合桐男，小林敬明，岡野尚弘，北村浩，古瀬純司，長島文夫：高齢がん患者における脆弱性の評価と介入を行った症例～各種ガイドラインの活用．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
  30. 佐々木哲哉，前野聡子，佐々木ヱリ，長島文夫：殺細胞性抗癌薬の添付文書に掲載される依存症治療薬との薬物間相互作用の評価．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
  31. 古瀬純司：膵癌化学療法の進歩と期待．第164回福岡膵懇話会学術講演会，福岡，2019年9月11日．
  32. 長島文夫：高齢者のがん薬物治療の考え方．東京都病院薬剤師会臨床薬学研究会，八王子，2019年9月19日．
  33. 古瀬純司：膵がん薬物療法の進歩－がんゲノム医療でどう変わる？．第71回日本消化器画像診断研究会，和歌山，2019年9月21日．
  34. Okano N, Ueno M, Morizane C, Yamanaka T, Ojima H, Ozaka M, Sasaki M, Takahara N, Kobayashi S, Morimoto M, Hosoi H, Nakai Y, Ikeda M, Maeno S, Nagashima F, Okusaka T, Furuse J : Multicenter phase II trial　of　axitinib　monotherapy　for　advanced　biliary　tract　cancer　refractory　to　gemcitabine-based chemotherapy. ESMO2019, Spain, September 27th-October 1st, 2019.
  35. Hashimoto Y, Hijioka S, Hirooka Y, Ohno E, Ioka T, Kobahashi S, Okusaka T, Maruki Y, Yashika J, Ashida R, Furuse J, Ikeda M, Kasuya H, Tanaka M, Ueno M : Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer. ESMO2019, Spain, September 27th-October 1st, 2019.
  36. Hijioka S, Ueno M, Ioka T, Hirooka Y, Ohno E, Ozaka M, Okusaka T, Maruki Y, Kobahashi S, Ashida R, Yashika J, Furuse J, Ikeda M, Kasuya H, Tanaka M, Hashimoto Y: Phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer. ESMO2019, Spain, September 27th-October 1st, 2019.
  37. Okamoto W, Nakamura Y, Shiozawa M, Komatsu Y, Denda T, Hara H, Kagawa Y, Narita Y，Kawakami H, Esaki T, Nishina T, Izawa N, Ando K, Moriwaki T, Kato T, Nagashima F, Satoh T, Nomura S, Yoshino T，Akagi K：Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer. ESMO 2019，Spain，September 27th- October 1st，2019．
  38. Kawamoto Y, Nakamura Y, Ikeda M, Bando H, Esaki T, Ueno M, Nishino T, Kagawa Y. Oki E, Denta T, Mizukami T, Tkahashi N, Okano N, Miki I, Sakamoto Y, M.Lefterova, J.Odegaard, Taniguchi H, Morizane C, Yoshino T : Biological difference of tumor mutational burden(TMB)and microsatellite instability(MSI)status in patients with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal(GI)cancers using cell-free DNA(cfDNA)sequencing analysis in the GOZILA study. ESMO 2019，Spain，September 27th- October 1st，2019．
  39. 古瀬純司，奥坂拓志，小西大，山崎秀哉：胆道癌診療ガイドライン改訂のポイント：胆道癌に対する化学療法・放射線療法．第55回日本胆道学会学術集会，名古屋，2019年10月3-4日．
  40. 長島文夫：高齢者のがん医療の考え方．Nagasaki Hematology Seminar，長崎，2019年10月4日.
  41. 長島文夫：高齢者のがん診療の考え方：第多摩エリアの化学療法を考える会．調布，2019年10月11日．
  42. Nakajima TE, Mizukami T, Takeda H, Kawakami H, Okano N, Ueno M, Hijioka S, Ozaka M, Ueno T, Naito Y, Furuse J: Chemotherapy. International clinical practice guidelines for metastatic liver tumors. 第57回日本癌治療学会学術集会，福岡，2019年10月24日．
  43. 長島文夫，岡野尚弘，河合桐男，前園知宏，西岡真理子，杉浦ちとせ，小林敬明，水谷友紀,古瀬純司：高齢者に対するがん治療の適応と限界：日本における老年腫瘍学の現状．第57回日本癌治療学会学術集会，福岡，2019年10月24日.
  44. 中島貴子，水上拓郎，武田弘幸，川上尚人，岡野尚弘，上野誠，肱岡範，尾坂将人，上野貴之，内藤陽一，古瀬純司：転移性肝腫瘍国際診療ガイドライン中間報告．第57回日本癌治療学会学術集会，福岡，2019年10月24日.
  45. 古瀬純司：がん腫別に考える体重減少とその要因：膵癌．第57回日本癌治療学会学術集会，福岡，2019年10月25日．
  46. 西岡真理子，古瀬純司：当院のゲムシタビン不応膵癌に対するゲムシタビン＋ナブパクリタキセル併用療法の治療成績．第57回日本癌治療学会学術集会，福岡，2019年10月25日.
  47. Furuse J, Okano N, Ueno M, Kawai M, Yamanaka T, Yamaue H: Conversion Surgery for unresectable Pancreatic Cancer. 第57回日本癌治療学会学術集会，福岡，2019年10月26日.
  48. 河合桐男，古瀬純司 : 50%以上の肝占拠病変もしくは門脈本幹浸潤Vp4の肝細胞癌にレンバチニを使用した3例．第57回日本癌治療学会学術集会，福岡，2019年10月26日．
  49. 前園知宏，古瀬純司：切除可能膵癌への術後補助療法S-1後に再発した切除不能膵癌へのFOLFIRINOX療法の検討．第57回日本癌治療学会学術集会，福岡，2019年10月26日．
  50. 長島文夫：高齢者がん診療の考え方―国内外のガイドラインを参考に―．第15回GI-Net Club学術講演会，大阪，2019年10月26日．
  51. 長島文夫：高齢者のがん薬物療法の考え方―国内外のガイドラインを参考に―．第4回栃木県がん領域薬剤師フォーラム，宇都宮，2019年10月28日．
  52. 長島文夫：高齢者のがん治療．杏林大学公開講演会，三鷹，2019年11月2日．
  53. Hiraoka Y, Nakamura Y, Kawamoto Y, Ikeda M, Bando H, Esaki T, Ueno M, Nishina T, Kagawa Y, Oki E, Denda T, Migita O, Takahashi N, Okano N, Ogata Y, Lefterova M, Odegaaed J, Taniguchi H, Morizane C, Yoshino T, Kuwata T: Purative Germline BRCA1/2 Mutations in Patients(pts)with Advanced Gastrointestinal(GI)Cancers Using Circulating Cell-Free Tumor DNA(cfDNA) Analysis in the GOZAILA study. NSGC38th Annual Conference, USA, November 5th-8th, 2019.
  54. Maesono T, Nishioka M, Sugiura C, Kawai K.Okano N, Kobayashi T, Mizutani T, Nagashima F, Shibahara J, Sakamoto Y, Furuse J: A Case of Unresectable Pancreatic Cancer with BRCA1 Gene Mutation Effectively Worked by modified FOLFIRINOX after Gemcitabine plus nab-Paclitaxel Refractory. APA-JPS joint meeting in 2019, USA, November 7th, 2019.
  55. Matsuoka A, Tsubata Y, Mizutani T, Takahashi M, Shimodaira H, Hamamoto Y, Nagashima F, Ando Y：Development and Distribution of the Japanese Edition of SIOG Educational Materials, 19th Conference of the international Society of Geriatric Oncology, Switzerland, November 14th-16th, 2019.
  56. 黒澤貴志，岡野尚弘，松木亮太，西岡真理子，前園知宏，河合桐男，小林敬明，鈴木裕，長島文夫，柴原純二，阪本良弘，古瀬純司：切除不能膵癌に対するconversion surgery後の再発と治療選択について．JDDW2019，第61回日本消化器病学会大会，神戸，2019年11月21日.
  57. 古瀬純司：肝細胞がんにおける薬物療法－最近の動向．JDDW2019，第23回日本肝臓学会大会，神戸，2019年11月22日．
  58. 岡野尚弘：胆膵癌化学療法最新の知見．第27回日本消化器関連学会週間，神戸，2019年11月23日.
  59. 古瀬純司：がんゲノム医療の現状と動向ー今何ができるか．多摩エリア大腸がんeセミナー，立川，2019年11月28日．
  60. 坂田好美，古瀬純司：VTE Expert meeting in MITAKA，三鷹，2019年11月29日．
  61. Ioka T, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Rui Tang R, Seraj J, Ueno M: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC). ESMO-Asia 2019, Singpore, November 22nd-24th, 2019.
  62. 古瀬純司：膵・胆道癌 薬物療法の最近の動向とJCOG肝胆膵グループの取り組み．第7回関西肝胆道オンコロジーグループ学術集会，山口，2019年12月21日．
  63. 古瀬純司：膵がん治療の最前線－がんゲノム医療は膵がん治療を変える．パンキャンジャパン膵臓がん勉強会クリスマス・スペシャル，東京，2019年12月22日．
  64. 古瀬純司，吉岡祐亮：ゲノム医療の時代におけるリキッドバイオプシーの役割．第4回リキッドバイオプシー研究会，東京，2020年1月17-18日.
  65. Nakamura Y, Taniguchi H, Bando H, Kato K, Esaki T, Komatsu Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Sunakawa Y, Satoh T, Yoshino T, Ohtsu A: Utility of Circulating Tumor DNA (ctDNA) versus Tumor Tissue Clinical Sequencing for Enrolling Patients with Advanced Gastrointestinal (GI) Cancer to Matched Clinical Trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  66. Morizane C, Ueno M, Ioka T, Tajika M, Ikeda M, Yamaguchi K, Hara H, Yabusaki H, Miyamoto A, Iwasa S, Muto M, Takashima T, Minashi K, Komatsu Y, Nishina T, Nakajima TE, Sahara T, Funasaka S, Yashiro M, Furuse J: Expansion part of phase 1 study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  67. Yoshida Y, Fukutomi A, Ueno M, Mori K, Watanabe K, Ohba A, Kobayashi S, Furuta M, Tsujimoto A, Osaka M, Okano N, Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K, Asagi A, Furuse J: Efficacy of chemotherapy for patients with unresectable or recurrent pancreatic adenosquamous carcinoma: a multicenter retrospective analysis. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  68. Todaka A, Nara S, Motoi F, Morinaga S, Hama N, Higuchi R, Konishi M, Shirakawa H, Tsumura H, Okuyama H, Matsui H, Shioji K, Sugimachi K, Asagi A, Mizuno N, Fukutomi A, Furuse J: Multicenter retrospective observational study of pancreatic cancer with positive peritoneal lavage cytology intended for surgical resection. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  69. Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater JA, Wasan HS, Borad MJ, Lihou CF, Zhen H, Luis Féliz L, Asatiani E, Jiang P, Vogel A: FIGHT-302: Phase 3 Study of First-line Pemigatinib Versus Gemcitabine Plus Cisplatin for Cholangiocarcinoma With FGFR2 Fusions or Rearrangements. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  70. Borad MJ, Bridgewater JA, Morizane C, Shroff RT, Oh DY, Moehler M, Furuse J, Benhadji KA, He Y, Valle JW: An open-label, randomized phase 3 study of futibatinib (TAS-120) versus gemcitabine-cisplatin chemotherapy as first-line treatment for patients with advanced cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene rearrangements (FOENIX-CCA3). 2020 Gastrointestinal cancers symposium, January 23rd-25th, 2020.
  71. 古瀬純司：膵がん薬物療法の進歩－がんゲノム医療でどう変わる?．T-CORE college 2020, 仙台，2020年2月8日.
  72. Furuse J: Patient and Public Involvement, PPI. JCOG-EORTC symposium, Tokyo, February 15th, 2020.
  73. 長島文夫：高齢がん患者の治療選択について考える. 第34回日本がん看護学会学術集会，東京，2020年2月22日.

論　文

欧文

  1. Kudo M1, Ueshima K1, Ikeda M2, Torimura T3, Tanabe N4, Aikata H5, Izumi N6, Yamasaki T7, Nojiri S8, Hino K9, Tsumura H10, Kuzuya T11, Isoda N12, Yasui K13, Aino H14, Ido A15, Kawabe N16, Nakao K17, Wada Y18, Yokosuka O19, Yoshimura K20, Okusaka T21, Furuse J, Kokudo N22, Okita K23, Johnson PJ24, Arai Y21(1Kindai University Faculty of Medicine, 2National Cancer Center Hospital East, 3Kurume University School of Medicine, 4National Hospital Organisation Sendai Medical Center, 5Hiroshima University, 6Musashino Red Cross Hospital, 7Yamaguchi University Graduate School of Medicine, 8Nagoya City University Graduate School of Medical Sciences, 9Kawasaki Medical School, 10Hyogo Cancer Center, 11Nagoya University Graduate School of Medicine, 12Jichi Medical University, 13Kyoto Prefectural University of Medicine, 14Social Insurance Tagawa Hospital, 15Kagoshima University Graduate School of Medical and Dental Sciences, 16Fujita Health University School of Medicine, 17Nagasaki University Graduate School of Biomedical Sciences, 18National Hospital Organization Kyushu Medical Center, 19Chiba University, 20Hiroshima University, 21National Cancer Center Hospital, 22National Center for Global Health and Medicine, 23Shunan Memorial Hospital, 24University of Liverpool, TACTICS study group): Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2019. DOI: 10.1136/gutjnl-2019-318934. [Epub ahead of print]
  2. Koyama T1, Shimizu T1, Iwasa S1, Fujiwara Y1, Kondo S1, Kitano S1, Yonemori K1, Shimomura A1, Iizumi S1, Sasaki T2, Furuse J, Yamamoto N1(1National Cancer Center Hospital, 2Eisai): First-in-human phase I study of E7090, a novel selective FGFR inhibitor, in patients with advanced solid tumors. Cancer Sci 111(2): 571-579, 2019.
  3. Ueno M1, Morizane C2, Ikeda M3, Okusaka T2, Ishii H4, Furuse J (1Kanagawa Cancer Center,2National Cancer Center Hospital, 3National Cancer Center Hospital East, 4Chiba Cancer Center): A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. Jpn J Clin Oncol 249(12): 1073-1082, 2019.
  4. Morizane C1, Okusaka T1, Mizusawa J1, Katayama H2, Ueno M3, Ikeda M4, Ozaka M5, Okano N, Sugimori K6, Fukutomi A7, Hara H8, Mizuno N9, Yanagimoto H10, Wada K11, Tobimatsu K12, Yane K13, Nakamori S14, Yamaguchi H15, Asagi A16, Yukisawa S17, Kojima Y18, Kawabe K19, Kawamoto Y20, Sugimoto R21, Iwai T22, Nakamura K23, Miyakawa H24, Yamashita T25, Hosokawa A26, Ioka T27, Kato N28, Shioji K29, Shimizu K30, Nakagohri T31, Kamata K32, Ishii H23, Furuse J (1National Cancer Center Hospital, 2Kanagawa Cancer Center, 3National Cancer Center Hospital East, 4Cancer Institute Hospital of Japanese Foundation for Cancer Research, 5Yokohama City University Medical Center, 6Shizuoka Cancer Center, 7Saitama Cancer Center, 8Aichi Cancer Center Hospital, 9 Kansai Medical University Hospital, 10Teikyo University School of Medicine, 11Department of Internal Medicine Kobe University Graduate School of Medicine, 12Teine Keijinkai Hospital, 13 National Hospital Organization Osaka National Hospital, 14Jichi Medical University, 15National Hospital Organization Shikoku Cancer Center, 16Tochigi Cancer Center, 17National Center for Global Health and Medicine, 18Kyushu University, 19Hokkaido University Hospital, 20 National Hospital Organization Kyushu Cancer Center, 21Kitasato University Hospital, 22Chiba Cancer Center, 23Sapporo Kousei General Hospital, 24Kanazawa University, 25University of Toyama, 26Osaka International Cancer Institute, 27Chiba University, 28Niigata Cancer Center Hospital, 29Tokyo Women’s Medical University, 30Tokai University School of Medicine, 31Tokai University School of Medicine, 32Kindai University Faculty of Medicine) : Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial. Ann Oncol 30(12):1950-1958, 2019.
  5. Hamauchi S1, Furuse J, Takano T2, Munemoto Y3, Furuya K4, Baba H5, Takeuchi M6, Choda Y7, Higashiguchi T8, Naito T9, Muro K10, Takayama K11, Oyama S12, Takiguchi T12, Komura N12, Tamura K13(1Shizuoka Cancer Center, 2Toranomon Hospital, 3Fukui-ken Saiseikai Hospital, 4Hokkaido Hospital, 5Kumamoto University, 6Nagaoka Red Cross Hospital, 7Hiroshima Citizens Hospital, 8Fujita Health University School of Medicine, 9Shizuoka Cancer Center, 10Aichi Cancer Center Hospital, 11Kyoto Prefectural University of Medicine, 12Ono Pharmaceutical Company, 13Fukuoka University) : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125(23):4294-4302, 2019.
  6. Furuse J: Paradigm shifting of systemic chemotherapy for unresectable pancreatic cancer in Japan. J Clin Med 8(8): 1170, 2019.
  7. Hamaguchi T1, Denda T2, Kudo T3, Sugimoto N4, Ura T5, Yamazaki K6, Fujii H7, Kajiwara T8, Nakajima TE9, Takahashi S10, Otsu S11, Komatsu Y12, Nagashima F, Moriwaki T13, Esaki T14,Sato T15, Itabashi M16, Oki E17, Sasaki T18, Chiron M19, Yoshino T20 (1National Cancer Center Hospital, 2Chiba Cancer Center, 3Osaka University Graduate School of Medicine, 4Osaka Medical Center for Cancer and Cardiovascular Disease, 5Aichi Cancer Center Hospital, 6Shizuoka Cancer Center, 7Jichi Medical University Hospital, 8Shikoku Cancer Center, 9 Marianna University School of Medicine Hospital, 10Tohoku University Hospital, 11Oita University Hospital, 12Hokkaido University Hospital, 13University of Tsukuba Hospital. 14National Kyushu Cancer Center, 15Kitasato University East Hospital, 16Tokyo Women’s Medical University Hospital, 17Kyushu University Hospital, 18Sanofi K. K, 19Sanofi, 20National Cancer Center Hospital East): Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci 110(11): 3565-3572, 2019.
  8. Ueno M1, Nagashima F, Ueno H2, Ikeda M3, Ohkawa S1, Mizuno N4, Ioka T5, Omuro Y6, Nakajima TE7 Furuse J (1Kanagawa Cancer Center, 2National Cancer Center Hospital, 3National Cancer Center Hospital East, 4Aichi Cancer Center Hospital, 5Osaka International Cancer Institute, 6Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 7 Marianna University School of Medicine Hospital) : Phase I/II study: experience with the late onset of acute pancreatitis after the start of chemotherapy with gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Intern Med 58(20): 2957-2962, 2019.
  9. Kudo M1, Ikeda M2, Ueshima K1, Sakamoto M3, Shiina S4, Tateishi R2, Hasegawa K5, Furuse J, Miyayama S6, Murakami T7, Yamashita T8, Kokudo N9(1Kindai University Faculty of Medicine, 2National Cancer Center Hospital East, 3Keio University School of Medicine, 4Juntendo University, 5University of Tokyo, 6Fukuiken Saiseikai Hospital, 7Kobe University Graduate School of Medicine, 8Kanazawa University, 9National Center for Global Health and Medicine) : Response evaluation criteria in cancer of the liver version 5 (RECICL 2019 revised version). Hepatol Res 49(9): 981-989, 2019.
  10. Ueno M1, Ikeda M2, Morizane C3, Kobayashi S1, Ohno I2, Kondo S3, Okano N, Kimura K4, Asada S4, Namba Y4, Okusaka T3, Furuse J (1Kanagawa Cancer Center, 2National Cancer Center Hospital East, 3National Cancer Center Hospital,4Ono Pharmaceutical Co, Ltd): Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol :4(8):611-621, 2019.
  11. Hidaka H1, Izumi N2, Aramaki T3, Ikeda M4, Inaba Y5, Imanaka K6, Okusaka T7, Kanazawa S8, Kaneko S9, Kora S10, Saito H11, Furuse J, Matsui O12, Yamashita T9, Yokosuka O13, Morita S14, Arioka H15, Kudo M16, Arai Y7(1Kitasato University School of Medicine, 2Musashino Red Cross Hospital, 3Shizuoka Cancer Center, 4National Cancer Center Hospital East, 5Aichi Cancer Center Hospital, 6Osaka International Cancer Institute,7National Cancer Center Hospital, 8Okayama University Medical School, 9Kanazawa University Hospital, 10Fukuoka University, 11Asahikawa Kosei General Hospital, 12Kanazawa University Graduate School of Medical Science, 13Chiba University, 14 Kyoto University Graduate School of Medicine, 15Yokohama Rosai Hospita, 16Kindai University Faculty of Medicine)：Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Med Oncol 36(6): 52, 2019.
  12. Yamamoto N1, Ryoo BY2, Keam B3, Kudo M4, Lin CC5, Kunieda F6, Ball HA6, Moran D6, Komatsu K7, Takeda K6, Fukuda M7, Furuse J, Morita S8, Doi T9(1National Cancer Center Hospital, 2University of Ulsan, 3Seoul National University Hospital, 4Kindai University, 5 National Taiwan University Hospital, 6Astellas Pharma Global Development, Inc, 7Astellas Pharma, 8Kyoto University, 9National Cancer Center Hospital East) : A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid Invest New Drugs, 2019. DOI: 10.1007/s10637-019-00780-w. [Epub ahead of print]
  13. Kaibori M1, Yoshii K2, Yokota I2, Hasegawa K3, Nagashima F, Kubo S4, Kon M5, Izumi N6, Kadoya M7, Kudo M8, Kumada T9, Sakamoto M10, Nakashima O11, Matsuyama Y12, Takayama T13, Kokudo N14(1Kansai Medical University, 2Kyoto Prefectural University of Medicine, 3 The University of Tokyo , 4Osaka City University Graduate School of Medicine , 5Musashino Red Cross Hospital, 6Shinshu University School of Medicine , 7Kinki University School of Medicine , 8Ogaki Municipal Hospital , 9Keio University School of Medicine, 10Kurume University Hospital,11School of Public Health University of Tokyo, 12 Nihon University School of Medicine, 13National Center for Global Health and Medicine, Liver Cancer Study Group of Japan) : Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey. Ann Surg 269(4): 692-699, 2019.
  14. Mizutani T1, Nakamura K1, Fukuda H1, Ogawa A2, Hamaguchi T3, Nagashima F (1 National Cancer Center Hospital, 2National Cancer Center Hospital East, 3Saitama Medical University International Medical Center, Geriatric Study Committee/Japan Clinical Oncology Group) Geriatric Research Policy: Japan Clinical Oncology Group (JCOG) policy. Japanese Journal of Clinical Oncology 49(10) :901-910, 2019.
  15. Okusaka T1, Nakamura M2, Yoshida M3, Kitano M4, Uesaka K5, Ito Y6, Furuse J, Hanada K7, Okazaki K8 (1National Cancer Center Hospital, 2Kyushu University, 3International University of Health and Welfare, 4Wakayama Medical University, 5Shizuoka Cancer Center, 6Showa University School of Medicine, 7JA Onomichi General Hospital, 8Kansai Medical University) Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society: Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 49(3) :326-335, 2020.
  16. Kudo M1, Okusaka T2, Motomura K3, Ohno I4, Morimoto M5, Seo S6, Wada Y7, Sato S8, Yamashita T9, Furukawa M10, Aramaki T11, Nadano S12, Ohkawa K13, Fujii H14, Kudo T15, Furuse J, Takai H16, Homma G16, Yoshikawa R16, Zhu AX17(1Kindai University Faculty of Medicine, 2National Cancer Center Hospital, 3Aso Iizuka Hospital, 4National Cancer Center Hospital East, 5Kanagawa Cancer Center, 6Kyoto University, 7National Hospital Organization Kyushu Medical Center, 8Kyoundo Hospital, Sasaki Institute, 9Kanazawa University, 10National Hospital Organization Kyushu Cancer Center, 11Shizuoka Cancer Center Hospital,12National Hospital Organization Shikoku Cancer Center, 13Osaka International Cancer Institute, 14Jichi Medical University, 15Osaka University, 16Eli Lilly Japan K.K, 17Massachusetts General Hospital Cancer Center) : Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol 2020. DOI:10.1007/s00535-020-01668-w. [Epub ahead of print]
  17. Okuyama H1,2, Ikeda M2, Okusaka T3, Furukawa M4, Ohkawa S5, Hosokawa A6, Kojima Y7, Hara H8, Murohisa G9, Shioji K10, Asagi A11, Mizuno N12, Kojima M13, Yamanaka T14, Furuse J (1Kagawa University, 2National Cancer Center Hospital East, 3National Cancer Center Hospital, 4National Hospital Organization Kyushu Cancer Center, 5Kanagawa Cancer Center, 6Faculty of Medicine University of Toyama, 7National Center for Global Health and Medicine, 8Saitama Cancer Center, 9Seirei Hamamatsu General Hospital, 10Niigata Cancer Center Hospital, 11National Hospital Organization Shikoku Cancer Center, 12Aichi Cancer Center Hospital, 13National Cancer Center, 14Yokohama City University Graduate School of Medicine) : A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology 2020. DOI: 10.1159/000505550. [Epub ahead of print]
  18. Naito Y1, Mishima S1, Akagi K2, Igarashi A3, Ikeda M1, Okano S1, Kato S4, Takano T5, Tsuchihara K1, Terashima K6, Nishihara H7, Nishiyama H8, Hiyama E9, Hirasawa A10, Hosoi H11, Maeda O12, Yatabe Y13, Okamoto W9, Ono S14, Kajiyama H12, Nagashima F, Hatanaka Y15, Miyachi M11, Kodera Y12, Yoshino T1, Taniguchi H1（1National Cancer Center Hospital East, 2Saitama Cancer Center, 3Yokohama City University School of Medicine, 4Juntendo University, 5Tohoku University, 6National Center for Child Health and Development, 7Keio University, 8Tsukuba University, 9Hiroshima University Hospital, 10Okayama University, 11Kyoto Prefectural University of Medicine, 12Nagoya University Hospital, 13National Cancer Center Hospital, 14Jichi Medical University, 15Hokkaido University Hospital）：Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol 25(3) :403-417, 2020.
  19. Okusaka T1, Nakamura M2, Yoshida M3, Kitano M4, Uesaka K5, Ito Y6, Furuse J, Hanada K7, Okazaki K8(1National Cancer Center Hospital, 2Kyushu University, 3International University of Health and Welfare, 4Wakayama Medical University, 5Shizuoka Cancer Center, 6Showa University School of Medicine, 7JA Onomichi General Hospital, 8Kansai Medical University, Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society): Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 49(3): 326-335, 2020.
  20. Kitamura H, Nagashima F, Andou M1, Furuse J (1Nagoya University): Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer. Intern Med 59(1): 15-22, 2020.
  21. Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H1, Furuse J (1J-Pharma Co): First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020. DOI: 10.1007/s10637-020-00924-3. [Epub ahead of print]
  22. Kitamura H, Nagashima F, Andou M1, Furuse J (1Nagoya University): Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer. Intern Med 59(1): 15-22, 2020.

和文

  1. 古瀬純司：ラムシルマブとほかの二次治療薬との使い分け．特集／進化する肝細胞癌の薬物療法―2019 Update (Part 1)．肝胆膵 79(2): 344-349, 2019.
  2. 古瀬純司，上野誠1，石井浩2 (1神奈川県立がんセンター・消化器内科，2千葉県がんセンター・治験臨床研究センター)：がん治療における患者参画．医師の立場からの期待．癌と化学療法 46(8): 1230-1234, 2019.
  3. 岡野尚弘，古瀬純司：アテゾリズマブ + ベバシズマブ併用Phase Ib試験のUpdated data. 特集／進化する肝細胞癌の薬物療法―2019 Update (Part 2). 肝胆膵 79(3): 587-591, 2019.
  4. 古瀬純司：レンバチニブ+ ペムブロリズマブ併用療法の第Ⅰb相試験-Updated data. 特集／進化する肝細胞癌の薬物療法―2019 Update (Part 2)．肝胆膵 79(2): 597-600, 2019.
  5. 古瀬純司：胆道癌・膵癌に対する免疫療法の現状と展望．消化器・肝臓内科 6(3): 218-223, 2019.
  6. 古瀬純司：第55回米国臨床腫瘍学会(ASCO2019) meeting report. The Liver Cancer Journal 11(2): 55-58, 2019.
  7. 古瀬純司：術前治療としての化学療法の動向．胆と膵 40(11): 957-961, 2019.
  8. 岡野尚弘，長島文夫，古瀬純司：消化器癌のゲノム医療．杏林医学会誌50(4): 191-197, 2019.

著　書

  1. 古瀬純司（分担執筆）：膵癌．膵腫瘍と嚢胞性膵疾患．消化管・腹膜疾患 肝・胆道・膵疾患. 内科学書改訂第9版. 南学正臣総編集．東京，中山書店，2019．475-479．
  2. 古瀬純司，岡野尚弘（分担執筆）：胆道癌に対するアキシチニブ単独療法の治療開発(B44)．先進医療NAVIGATOR．がん先進医療の最前線．先進医療フォーラム編集．東京，日本医学出版，2019．60-64.
  3. 長島文夫（ガイドライン作成統括委員会副委員長）：高齢者のがん薬物療法ガイドライン．日本臨床腫瘍学会/日本癌治療学会編．東京，南江堂，2019．
  4. 長島文夫（評価委員）：成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン第2版．日本癌治療学会/日本臨床腫瘍学会編．東京，金原出版，2019．
  5. 岡野尚弘（分担執筆）：XELOX(CapeOX)療法．消化器ナーシング. 東京，メディカ出版， p. 35-37.
  6. 岡野尚弘（分担執筆）：アテゾリズマブ＋ベバシズマブ併用phase Ib試験のuodated data.　肝胆膵．東京，アークメディア，2019．587-591.
  7. 岡野尚弘（分担執筆）：GEM＋CDDP (GC). 消化器がん化学療法副作用マネジメントプロのコツ改訂第2版．東京，メジカルビュー社，2019．168-171.
  8. 岡野尚弘（分担執筆）：GEM＋S-1(GS)．消化器がん化学療法副作用マネジメントプロのコツ改訂第2版．東京，メジカルビュー社，2019．172-175.
  9. 岡野尚弘（分担執筆）：胆道癌におけるFGFR遺伝子異常とFGFR阻害薬の開発．胆と膵．東京，医学図書出版，2019．1347-1350.
  10. 岡野尚弘（分担執筆）：肝・胆・膵がんにおけるMSI検査の位置づけ．腫瘍内科．東京，化学評論社，2019．219-224．

報告書

  1. 長島文夫：高齢がん患者に対する簡便で効果的な診療プログラムの開発．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2019年度　分担研究報告書．
  2. 長島文夫：高齢者がん診療指針策定に必要な基盤整備に関する研究．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2019年度　分担研究報告書．

その他

【座長・司会・主催】

  1. 古瀬純司（座長）：外来化学療法カンファレンス. 武蔵野, 2019年4月5日.
  2. 窪田敬一、古瀬純司（司会）: Borderline resectable膵がんに対する治療戦略.金沢, 第105回日本消化器病学会総会, 金沢, 2019年5月10日.
  3. 古瀬純司、廣岡芳樹 (座長)：膵疾患に対する造影超音波検査の有用性と今後の展開. Ultrasonic Week 2019. 日本超音波医学会第92回学術集会, 東京, 2019年5月24日.
  4. 古瀬純司（司会）：ランチョンセミナー. 第108回日本消化器内視鏡学会関東支部例会, 東京, 2019年6月8日.
  5. 古瀬純司 (座長)：Gastric Cancer I-O Seminar in Tama. Lecture. 立川, 2019年6月24日.
  6. 古瀬純司 (座長)：GEP-NET Web Seminar. 東京, 2019年6月26日.
  7. 古瀬純司 (座長)：Colorectal Cancer Conference. 立川, 2019年6月27日.
  8. 古瀬純司、永井英成（司会）: レンバチニブによる新たな肝細胞癌治療ストラテジー. 第20回日本肝がん分子標的治療研究会, 長崎, 2019年6月29日.
  9. 古瀬純司 (司会): ランチョンセミナー 第55回日本肝癌研究会, 東京, 2019年7月5日.
  10. 古瀬純司（司会）: 特別講演 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  11. 高折恭一、古瀬純司（司会）: PanCan Award. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  12. Furuse J（司会）: Guidelines for pancreatic cancer, Japan vs. USA. Luncheon Seminar. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  13. 岡崎和一、古瀬純司（司会）: 日本膵臓学会-昨日から明日へ. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  14. 古瀬純司（司会）: 英語発表上達のコツ. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  15. 長島文夫 (司会) : 膵癌に対する内視鏡治療～疼痛・症状緩和を目指して～. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  16. Furuse J, Ueno M(司会) : New evidence of chemotherapy in biliary tract and pancreatic cancers and introduction them to the practice. 第17回日本臨床腫瘍学会学術集会, 京都, 2019年7月19日.
  17. 古瀬純司 （司会）：メディカルセミナー 第17回日本臨床腫瘍学会学術集会, 京都, 2019年7月19日.
  18. Cheng AL, Furuse J (座長) : Sponsored Symposium 2. The role of Systemic Therapy for uHCC. The 10th Asia-Pacific Primary Liver Cancer Expert Meeting, 札幌, 2019年8月31日.
  19. 古瀬純司 (主催)：第50回日本膵臓学会大会　市民公開講座. 東京，2019年8月4日．
  20. 古瀬純司（Opening remarks）： がん包括マネジメントセミナー. 三鷹, 2019年9月18日.
  21. 古瀬純司（司会）: 膵癌診療ガイドライン改訂後のこれからの治療戦略. 高齢者膵癌に対する治療戦略を考える. 第57回日本癌治療学会学術集会, 福岡, 2019年10月24日.
  22. 山本雅一、吉田雅博、古瀬純司（司会）: 転移性肝癌国際診療ガイドライン公聴会. 第57回日本癌治療学会学術集会, 福岡, 2019年10月24日.
  23. 矢永勝彦、古瀬純司: 臓器別シンポジウム Borderline Resectable膵癌に対する治療戦略. 第57回日本癌治療学会学術集会, 福岡, 2019年10月25日.
  24. 古瀬純司（司会）：血管新生阻害薬, 東京, 2019年10月31日.
  25. Furuse J, Brand R（座長）: Mini Symposium IV. Genomics of exocrine pancreatic disorders. APA-JPS joint meeting in 2019, USA, November 7th-9th,2019.
  26. Qin S, FuruseJ, Paark JO: Hepatobiliary-Pancreatic Cancer Session. 7th Federation of Asian Clinical Oncology (FACO) Academic Conference, China, December 6th,2019.
  27. 古瀬純司（司会）：10周年特別企画2．第21回日本肝がん分子標的治療研究会，東京，2020年1月11日．
  28. 古瀬純司、吉岡祐亮（司会）: ゲノム医療の時代におけるリキッドバイオプシーの役割. 第4回リキッドバイオプシー研究会. 東京, 2020年1月17-18日.
  29. 古瀬純司（司会）: Patient and Public Involvement, PPI. JCOG-EORTC symposium. 東京, 2020年2月15日.
  30. 古瀬純司（座長）：がん疼痛セミナー, がん疼痛治療の最前線. 三鷹, 2019年2月28日.

 

【新聞掲載】

  1. 長島文夫：「質問なるほドリ、乳がんになる高齢者って多いの？」にて解説，毎日新聞，2019年8月31日．
  2. 長島文夫：「医療の意思決定、高齢者のがん・後編」にて解説，読売新聞，2019年11月25日．
  3. 長島文夫：「がん5年生存率病期・年代別公表」にて解説，朝日新聞，2019年12月14日．

講　演

  1. 古瀬純司 : 膵・消化管神経内分泌腫瘍の薬物療法-多様な治療をどう使い分ける？．膵・消化管神経内分泌腫瘍を考える,新潟,2018年4月12日.
  2. Furuse J : Adjuvant therapy experience-including S-1. Pancreas 2018, USA, April 26th-28th, 2018.
  3. 古瀬純司 : 肝細胞がんの化学療法ー新時代への展望. LENVIMA-HCC　適応追加記念講演会, 長崎, 2018年5月16日.
  4. 古瀬純司：消化器がんにおけるPrecision Medicine.GI-SCREENと多摩地区の現状と今後.第6回KDOG meeting, 町田, 2018年5月19日.
  5. 古瀬純司：神経内分泌腫瘍に対する薬物療法ー最新の情報と今後の展望.第10回Tohoku-NET WORK, 仙台, 2018年5月26日.
  6. Okano N, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J： First-in-human phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  7. Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi A, Yoshino T: REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  8. Ueno M, Morizane C, Okusaka T, Mizusawa J, Katayama H, Ikeda M, Ozaka M, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Yukisawa S, Ishii H, Furuse J: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  9. Kudo M, Ueshima K, Torimura T, Tanabe N, Ikeda M, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Isoda N, Yasui K, Kuzuya T, Okusaka T, Furuse J, Kokudo N, Okita K, Yoshimura K, Arai Y, TACTICS Trial Group: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. ASCO 2018 annual meeting, USA, June 1st-6th,2018.
  10. Abou-Alfa GK, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Negro A, Sangro B: A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  11. Okano N, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J: First-in-human

phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.

  1. 古瀬純司, 奥坂拓志, 小西大 : 胆道癌診療ガイドライン公聴会. 化学療法. 第30回日本肝胆膵外科学会学術集会, 横浜, 2018年6月7-9日.
  2. 古瀬純司 : 肝細胞癌の分子標的治療：ソラフェニブ単独から多様な治療選択へ. 第30回日本肝胆膵外科学会学術集会, 横浜, 2018年6月7-9日.
  3. Furuse J: The 2nd line chemotherapy in Japan and future perspectives. The 11th International Pancreatic Cancer Conference, Commemorative Lecture of Pin-Wen Lin and 2018 Cancer Biology Symposium, Taiwan, June 8th-10th, 2018.
  4. Furuse J: The experience of FOLFIRINOX in advanced pancreatic cancer. Japanese experience. Satellite Symposium in the 11th International Pancreatic Cancer Conference, Taiwan, June 8th-10th, 2018.
  5. 古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望. LENVIMA-HCC AE Management Forum in Dokkyo, 栃木, 2018年6月13日.
  6. 長島文夫 : 高齢者のがん患者を診療するにあたっての考え方. 第60回日本老年医学会学術集会, 京都, 2018年6月16日.
  7. 古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望. Lenvatinib適応追加記念講演会, 金沢, 2018年6月21日.
  8. 岡部直太, 小林敬明, 千葉知宏, 大窪泰弘, 古瀬純司, 草間博 : 食道悪性黒色腫に対するnivolumab治療中にリンパ球性下垂体炎を来した剖検症例の一例. 第107回日本病理学会総会, 札幌, 2018年6月21-23日
  9. 長島文夫 ： 高齢者に抗がん剤は効果なし”は本当なのか?. 日本臨床腫瘍学会市民公開講座, 大阪, 2018年6月24日.
  10. 古瀬純司 : 切除不能膵癌における治療方針－conversion surgeryの是非－. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  11. 岡野尚弘, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 長島文夫, 古瀬純司 : 遠隔転移を有する膵癌における化学療法によるconversion surgery. 切除不能膵癌における治療方針－conversion surgeryの是非－. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  12. 古瀬純司 : 切除不能膵癌に対する化学療法-ガイドラインにおける課題. 特別企画2膵癌ガイドラインの諸問題と今後の課題. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  13. 西岡真理子, 岡野尚弘, 前園知宏, 河合桐男, 小林敬明, 長島文夫, 古瀬純司: FOLFIRINOXとGEM耐性後、GEM+na-PTX療法が奏効した肝転移を伴う膵癌の1例. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  14. 前園知宏, 岡野尚弘, 西岡真理子, 河合桐男, 小林敬明, 長島文夫, 古瀬純司: GEM+nab-PTX不応後にmodified FOLFIRINOXが著効したBRCA1遺伝子変異を有した切除不能膵癌の1例. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  15. 山内芳也, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 岡野尚弘, 長島文夫, 古瀬純司 : 切除不能・再発膵腺扁平上皮癌に対する併用薬物療法施行例の検討. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  16. 古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望.鹿児島LENVIMA-HCC適応追加記念講演会, 鹿児島, 2018年7月4日.
  17. Furuse J, Chan SL, Sangro B, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Xu Y, Negro A, Abou-Alfa GK, on behalf of the HIMALAYA investigators: HIMALAYA study: a randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). the 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2018), Korea, July 6th-8th, 2018.
  18. Furuse J, Hamauchi S, Takano T, Munemoto Y, Furuya K, Baba H, Takeuchi M, Choda Y, Higashiguchi T, Naito T, Muro K, Takayama K, Tamura K: A multicenter, open-label, uncontrolled study of ONO-7643/anamorelin in cachexia patients with gastrointestinal cancer. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  19. 山内理海, 設楽紘平, 山中竹春,傳田忠道, 辻靖, 小松嘉人, 小林良充, 古瀬純司, 加藤健志, 沖英次, 安藤高志, 萩原康博, 大橋靖雄, 吉野孝之: REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan: Quality of Life Analysis. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  20. 奥坂拓志, 池田公史, 大野泉, 高橋秀明, 近藤俊輔, 森実千種, 古瀬純司 : 肝細胞がん患者を対象としたGPC3, WDRPUH及びNEIL3由来ペプチドワクチンの第1相試験における最終解析. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  21. 小山隆文, 清水俊雄, 藤原豊, 近藤俊輔, 北野滋久, 米盛勧, 下村昭彦, 飯泉桜, 佐々木達也, 古瀬純司, 山本昇 : 新規FGFR選択的阻害薬E7090の進行固形癌患者を対象とした第1相臨床試験. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  22. 工藤敏啓, 川本泰之, 奥坂拓志, 高橋秀明, 小林智, 古瀬純司, 伊藤心二, 清水怜, 中村和貴, 鎌田研, 衣斐寛倫, 伊藤直樹, 水野伸匡, 石井浩, 森実千種,吉野孝之 : The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN (GI-SCREEN 2015-01-Non CRC) Advanced Biliary Tract Cancer Cohort. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  23. 長島文夫, 古瀬純司 : JSMO-SIOG symposium All oncologists are geriatric oncologists Geriatric Oncology in Japan. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  24. 清水怜, 高橋秀明, 上野誠, 大場彬博, 村中徹人, 須藤研太郎, 岡野尚弘, 水上拓郎, 伊藤心二, 石井浩, 賀川義規, 鎌田研, 工藤敏啓, 森実千種, 吉野孝之 : The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Advanced Pancreatic Cancer Cohort. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  25. 山内芳也, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 岡野尚弘, 成毛大輔, 北村浩, 女屋博昭, 長島文夫, 古瀬純司 : 高齢者膵がんにおけるCTを利用した筋肉の評価と薬物療法の臨床的アウトカムに関する研究. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  26. 古瀬純司 : 膵がんの基礎知識と治療の最新情報. ONCOLO Meets Cancer Experts eminar, 東京, 2018年7月27日.
  27. 古瀬純司 : 消化器癌化学療法の最新情報. ASCO 2018より. 三鷹キャンサーネット, 三鷹, 2018年8月2日.
  28. 古瀬純司 : 膵・消化管神経内分泌腫瘍の新たな展開ー診断から治療まで. 膵・消化管神経内分泌腫瘍セミナー, 宮崎,2018年8月3日.
  29. 古瀬純司 : 肝細胞がんの薬物療法ー新時代への展望.滋賀LENVIMA適正使用講演会, 草津,2018年8月30日.
  30. 北村浩, 長島文夫, 岡野尚弘, 中澤潤一, 有馬志穂, 古瀬純司 : Gemcitabine baseの化学療法を行った高齢者膵がんにおける有害事象と高齢者機能評価について．第3回日本がんサポーティブケア学会, 福岡, 2018年8月31日.
  31. 前野聡子, 長島文夫, 河合桐男, 前園知宏, 黒澤貴志, 小林敬明, 岡野尚弘, 北村浩, 有馬志穂, 古瀬純司：海外高齢者がん診療ガイドライン活用の工夫 － 認知症をもつがん患者の実地症例から－. 第3回日本がんサポーティブケア学会, 福岡, 2018年8月31日.
  32. Sangro B, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Xu Y, Negro A, Abou-Alfa G: A Randomized, Multicenter Phase 3 Study of Durvalumab (D) and Tremelimumab (T) as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (HCC): HIMALAYA Study. ILCA Annual Conference, UK, September 14th-16th, 2018.
  33. Ueshima K, Kudo M, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Arai Y and TACTICS study group: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. ILCA Annual Conference, UK, September 14th-16th, 2018.
  34. Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Ueno M, Morizane C, Mizuno N, Ikeda M, Furuse J: Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and ILCA Annual Conference, UK, September 14th-16th, 2018.
  35. 古瀬純司, 奥坂拓志, 小西大, 山崎秀哉 : 胆道癌診療ガイドライン公聴会. 化学療法、放射線療法. 第54回日本胆道学会学術集会, 千葉, 2018年9月27-28日.
  36. Furuse J: Systemic treatment for advanced HCC－Current status and future perspectives. Taiwan Digestive Disease Week 2018. Taiwan, September 29th-30th, 2018.
  37. 古瀬純司：最新のがん治療：ゲノム医療の幕開け. 杏林大学病院がんセンター「がんと共にすこやかに生きる」講演会シリーズ第4回, 三鷹, 2018年10月13日.
  38. 古瀬純司, 岡野尚弘, 黒澤貴志 : 初診時切除不能膵癌に対するconversion surgery
    －内科の立場から. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
  39. Furuse J: Cohort study of patients with initially unresectable pancreatic cancer of conversion surgery after FOLFIRINOX or GEM plus nab-PTX (PC-CURE-1). 6th International Conference of FACO. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
  40. Denda T, Shitara K, Yamanaka T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Kato T, Ohashi Y, Yoshino T: REVERCE: A Randomized Phase II of Regorafenib- Cetuximab for mCRC previously treated with chemotherapy: serum protein biomarker analysis. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18日-20日.
  41. Kitamura H, Nagashima F, Andou M, Nakazawa J, Arima S, Okano N, Furuse J: Cancer-Specific Geriatric Assessment(CSGA)を用いた高齢者膵癌化学療法の第二相試験. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
  42. Izawa N, Morizane C, Takahashi H, Ueno M, Kawamoto Y, Okano N, Shimizu S, Sudo K, Itoh S, Asagi A, Y. Kagawa, K. Kamata, T. Kudo, S. Nomura, T. Kuwata, S. Fujii, W. Okamoto, K. Shitara, A. Ohtsu, T. Yoshino: The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer. ESMO 2018, Germany, October 19th-23rd, 2018.
  43. Takahashi H, Morizane C, Nomura S, Okano N, Tsuda M, Mizuno N, Satake K, Tsuji K, Shioji K, Ishii H, Yasui K, Miyakawa H, Ishiguro A, Ogura T, Ueno M, Ikeda A, Terashima T, Ikeda M, Okusaka T, Furuse J: Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). ESMO 2018, Germany, October 19th-23rd,2018.
  44. Okuyama H, Ikeda M, Okusaka T, Furuse J, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Yamaguchi K, Murohisa G, Shioji K, Ishii H, Mizuno N, Kojima M, Yamanaka T: A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy. Germany, ESMO 2018, October 19th-23rd, 2018.
  45. 長島文夫 : 本当!? 「高齢者に抗がん剤は“効果なし?”」. ちゃやまちキャンサーフォーラム2018, 大阪, 2018年10月27日.
  46. 古瀬純司 : 膵癌治療の最前線―エビデンスとプラクティス. 第16回日本消化器外科学会大会, 神戸, 2018年11月1-4日.
  47. 古瀬純司 : 切除不能肝内胆管癌の化学療法―現状と今後の展望. 第16回日本消化器外科学会大会, 神戸, 2018年11月1-4日.
  48. 古瀬純司 : 膵癌の化学療法ー最新の動向と今後の展望. Osaka GI Oncology Forum, 大阪, 2018年11月16日.
  49. 古瀬純司 : 膵癌の化学療法ー最新の動向と今後の展望. 第15回京都消化器癌化学療法研究会, 京都, 2018年11月22日.
  50. FuruseJ: Chemotherapy for unresectable pancreatic cancer－Current status and future perspectives. The 8th Japan-China Hepato-Pancreato-Biliary Symposium,,Tokyo, November 22ed-23rd, 2018.
  51. 古瀬純司 : 膵・胆道癌化学療法の最新情報ーがんゲノム医療の導入は？．第17回大阪消化器化学療法懇話会, 大阪, 2018年12月1日.
  52. 古瀬純司 : 特別講演.膵癌化学療法の最新の知見. Pancreatic Cancer and Neuroendocrine tumor FORUM in Chiba, 千葉, 2018年12月14日.
  53. 古瀬純司：消化器癌化学療法の最近の話題-ESMO2018 in Munich. 三鷹キャンサーネット, 三鷹, 2018年12月20日.
  54. 古瀬純司：膵がん治療の最前線－新しいガイドラインと今後の期待. パンキャンジャパン膵がん勉強会クリスマス・スペシャル, 東京, 2018年12月22日.
  55. Chow PKH, Li L, Li J, Jia F, Wang HJ, Hasegawa K, Yang JM, Tan PS, Qin S, Han KH, Goh B, Han HS, Furuse J, Zhu X, Ling JZJ, Gandhi M: Differences in Presentation and Management Patterns in Patients with Hepatocellular Carcinoma (HCC): Data from HCC Registry in Asia. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th,2019.
  56. Kobayashi S, Ueno M, Ogawa G, Fukutomi A, Ikeda M, Okusaka T, Sato T, Ito Y, Kadota T, Ioka T, Sugimori K, Sata N, Nakamori S, Shimizu K, Mizuno N, Ishii H, Furuse J: Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer: an integrated exploratory analysis of JCOG1106 and LAPC-S1RT. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th, 2019.
  57. Ikeda M, Ueno M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J: A multicentre open-label, phase 1 study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th, 2019.
  58. Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX: Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following First-Line Sorafenib: Pooled Efficacy and Safety in Japanese Patients Across Two Global Randomized Phase 3 Studies (REACH-2 and REACH). 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  59. Yamada I, Morizane C, Okusaka T, Ogawa G, Sato Y, Ueno M, Ikeda M, Sugimori K, Fukutomi A, Shimizu S, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Nishina T, Ishii H, Furuse J: The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory analysis of JCOG1113. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  60. Ueno M, Morizane C, Okusaka T, Ogawa G, Sato Y, Ikeda M, Ozaka M, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Nishina T, Ishii H, Furuse J: The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory analysis of JCOG1113. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  61. Goyal L, Bahleda R, Furuse J, Valle J, Markus Moehler M, Oh DY, Chang HM, Kelley RK, Javle M, Borad M, Chen LT, Uboha N, Klümpen HJ, O’Dwyer PJ, Li D, Morizane C, Huang J, Bridgewater JA: FOENIX-CCA2 (FOENIX-101): A phase 2 trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions and other rearrangements. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  62. 長島文夫 : 高齢者のがん治療. 健康長寿講演会（三鷹市老人クラブ連合会）, 三鷹, 2019年2月5日.
  63. 長島文夫 : みんなで支えるがん医療「超高齢社会とがん、杏林CCRC研究所の取り組み」. 杏林CCRCフォーラム公開講演会, 三鷹, 2019年2月23日.
  64. 長島文夫 : 高齢者とがん. 杏林大学講演会シリーズ第7回「がんと共にすこやかに生きる」, 三鷹, 2019年3月2日.
  65. 古瀬純司 : 消化器がんに対するがんゲノム医療. 日本癌治療学会第18回アップデート教育コース, がん治療とゲノム医療, 三鷹, 2019年3月9日.
  66. Furuse J: Consolidating the Treatment Guidelines of Chemotherapy for Cholangiocarcinoma between the East and West. Lecture. 3rd Asian-Pacific Cholangiocarcinoma Conference. Taiwan, March 15th-16th, 2019.
  67. 長島文夫 : 第2回老年腫瘍学セミナー. 日本臨床腫瘍学会,東京, 2019年3月21日.

 

論　文

欧文

  1. Kitahara H1, Honma Y1, Ueno M2, Kanemitsu Y1, Ohkawa S2, Mizusawa J1, Furuse J, Shimada Y3, Colorectal Cancer Study Group and Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (1National Cancer Center Hospital, 2Kanagawa Cancer Center, 3Kochi Health Sciences Center) : Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD). Jpn J Clin Oncol, 2018. DOI:10.1093/jjco/hyy188. [Epub ahead of print]
  2. Doi T1, Yoh K1, Shitara K1, Takahashi H1, Ueno M2, Kobayashi S2, Morimoto M2, Okusaka T1, Ueno H1, Morizane C1, Okano N, Nagashima F, Furuse J (1National Cancer Center Hospital East, 2Kanagawa Cancer Center)：First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. Invest New Drugs, 2018. DOI: 10.1007/s10637-018-069 7-3. [Epub ahead of print]
  3. Shiba S1, Imaoka H2, Shioji K3, Suzuki E4, Horiguchi S5, Terashima T6, Kojima Y7, Okuno T8, Sukawa Y9, Tsuji K10, Umemoto K11, Asagi A12, Todaka A13, Ueno M14, Ikeda M11, Morizane C1, Furuse J（1National Cancer Center Hospital, 2Aichi Cancer Center Hospital, 3Niigata Cancer Center Hospital, 4Chiba University, 5Okayama University Graduate School of Medicine, 6Kanazawa University Hospital, 7National Center for Global Health and Medicine, 8Kinki University, 9Keio University, 10Teine Keijinkai Hospital, 11National Cancer Center Hospital East, 12Shikoku Cancer Center, 13Shizuoka Cancer Center, 14 Kanagawa Cancer Center）：Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer 18(1) : 993,2018.
  4. Tak WY1, Ryoo BY2, Lim HY3, Kim DY4, Okusaka T5, Ikeda M6, Hidaka H7, Yeon JE8, Mizukoshi E9, Morimoto M10, Lee MA11, Yasui K12, Kawaguchi Y13, Heo J14, Morita S15, Kim TY16, Furuse J, Katayama K17, Aramaki T18, Hara R19, Kimura T19, Nakamura O19, Kudo M20(1Kyungpook National University, 2University of Ulsan College of Medicine, 3Sungkyunkwan University , 4Yonsei University College of Medicine , 5National Cancer Center Hospital, 6National Cancer Center Hospital East , 7Kitasato University Hospital , 8Korea University Guro Hospital , 9Kanazawa University Hospital, 10Kanagawa Cancer Center, 11The Catholic University of Korea, 12Kyoto Prefectural University of Medicine , 13Saga-ken Medical Centre Koseikan , 14Pusan National University and Medical Research Institute , 15Kochi Health Sciences Center , 16Seoul National University Hospital , 17Osaka International Cancer Institute , 18Shizuoka Cancer Center, 19Yakult Honsha , 20Kindai University Hospital )：Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest New Drugs 36(6) : 1072-1084, 2018.
  5. Mizusawa J1, Fukutomi A2, Katayama H1, Ishii H3, Ioka T4, Okusaka T1, Ueno H1, Ueno M5, Ikeda M6, Mizuno N7, Ozaka M8, Fukuda H1, Furuse J, Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (1National Cancer Center Hospital, 2Shizuoka Cancer Center, Shizuoka, 3National Hospital Organization Shikoku Cancer Center, 4Osaka International Cancer Institute, 5Kanagawa Cancer Center, 6National Cancer Center Hospital East, 7Aichi Cancer Center Hospital, 8Cancer Institute Hospital of the Japanese Foundation for Cancer Research)：Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). Pancreatology 18(7) : 841-845,2018.
  6. Morizane C1, Ueno M2, Ikeda M3, Okusaka T2, Ishii H4, Furuse J (1National Cancer Center Hospital, 2Kanagawa Cancer Center, 3National Cancer Center Hospital East, 4National Hospital Organization Shikoku Cancer Center)：New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol 48(8) : 703-711,2018.
  7. Kobayashi S1, Terashima T2, Shiba S3, Yoshida Y4, Yamada I5, Iwadou S6, Horiguchi S7, Takahashi H8, Suzuki E9, Moriguchi M10, Tsuji K11, Otsuka T12, Asagi A13, Kojima Y14, Takada R15, Morizane C3, Mizuno N16, Ikeda M8, Ueno M1, Furuse J（1Kanagawa Cancer Center, 2Kanazawa University Hospital, 3National Cancer Center Hospital, 4 Shizuoka Cancer Center, 5Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 6Hiroshima City Hospital, 7Okayama University, 8National Cancer Center Hospital East, 9Chiba University, 10Kyoto Prefectural University of Medicine, 11Ishikawa Prefectural Central Hospital, 12Saga University Hospital, 13National Hospital Organization Shikoku Cancer Center, 14National Center for Global Health and Medicine, 15Osaka International Cancer Institute, 16Aichi Cancer Center Hospital）：Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 109(8) : 2549-2557,2018.
  8. Nakachi K1,2, Konishi M1, Ikeda M3, Shimada K3, Okusaka T3, Saiura A4, Ishii H4, Sugiyama M5, Furuse J, Sakamoto H5, Shimamura T5, Ohta T6 (1National Cancer Center Hospital East, 2Otaru General Hospital, 3National Cancer Center Hospital, 4Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 5Saitama Cancer Center, 6Tokyo Women’s Medical University)：Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Int J Clin Oncol 23(5) : 894-899,2018.
  9. Sato Y1,2, Ueno H3, Ioka T4, Ohkawa S5, Ikeda M6, Shimamura T7, Tsuji A8, Tsuchiya Y9, Furuse J10, Ishii H11, Furuya K12, Iguchi H13, Saito Y14, Kaniwa N14, Sawada JI14, Sakamoto H1, Sekine A2, Okusaka T3, Yoshida T1(1National Cancer Center Research Institute, 2Chiba University, 3National Cancer Center Hospital, 4Osaka Medical Center for Cancer and Cardiovascular Disease, 5Kanagawa Cancer Center, 6National Cancer Center Hospital East, 7East Medical Clinic, 8Kagawa University, 9Niigata Cancer Center Hospital, 10 Kyorin University, 11Cancer Institute Hospital, 12Hokkaido Social Insurance Hospital, 13Sasebo Kyosai Hospital, 14National Institute of Health Sciences) : GEST. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas 47(5):637-642，
  10. Furuse J, Shibahara J1, Sugiyama M2(1Department of Pathology, Kyorin university, 2 Department of Surgery, Kyorin university)：Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. J Hepatobiliary Pancreat Sci 25(5) : 261-268, 2018.
  11. Ozaka M1, Ishii H2, Sato T3, Ueno M4, Ikeda M5, Uesugi K6, Sata N7, Miyashita K8, Mizuno N9, Tsuji K10, Okusaka T10, Furuse J：（1Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 2National Hospital Organization Shikoku Cancer Center, 3Kyoto University School of Public Health, 4Kanagawa Cancer Center, 5National Cancer Center Hospital East, 6Jichi Medical University School of Medicine, 7Showa University Northern Yokohama Hospital, 8Aichi Cancer Center Hospital, 9Ishikawa Prefectural Central Hospital, 10 National Cancer Center Hospital）：A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81(6) : 1017-1023, 2018.
  12. Natsume M1, Watanabe K1, Matsumoto S2, Naruge D3, Hayashi K4, Furuse J, Kawamura M1, Jinno H1, Sano K1, Fukushima R1, Osawa G1, Aruga E1, Hashiguchi Y1, Tanaka A1, Takikawa H1, Seki N1（1Teikyo University, 2NTT Medical Center Tokyo,3 Kyorin University, 4Tokyo Women’s Medical University）：Factors influencing cancer patients’ choice of end-of-life care place. J Palliat Med 21(6) : 751-765,2018.
  13. Kojima Y1, Ohtsuka K2, Ohnishi H2, Abe N1, Furuse J, Watanabe T2, Sugiyama M1（1 Department of Surgery, Kyorin University, 2Department of Laboratory Medicine, Kyorin Univeresity）：APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas. Surg Today48(8) : 765-772, 2018.
  14. Suzuki E1, Kaneko S2 Okusaka T3, Ikeda M4, Yamaguchi K5, Sugimoto R6, Aramaki T7, Asagi A8, Yasui K9, Sano K10, Hosokawa A11, Kato N1, Ishii H8, Sato T12, Furuse J（1Chiba University, 2Kanazawa University School of Medical Science, 3National Cancer Center Hospital, 4National Cancer Center Hospital East, 5Saitama Cancer Center, 6Kyushu Cancer Center, 7Shizuoka Cancer Center, 8Shikoku Cancer Center, 9Kyoto Prefectural University of Medicine, 10Teikyo University School of Medicine, 11Faculty of Medicine University of Toyama, 12Kyoto University School of Public Health）: A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. Jpn J Clin Oncol 48(4) : 317-321, 2018.
  15. Nakachi K1, Konishi M2, Ikeda M2, Mizusawa J3, Eba J3, Okusaka T3, Ishii H4, Fukuda H3, Furuse J (1Otaru General Hospital, 2National Cancer Center Hospital East, 3National Cancer Center Hospital, 4National Hospital Organization Shikoku Cancer Center)：Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol 48(4) : 392-395, 2018.
  • J, Kurata T1, Okano N, Fujisaka Y1, Naruge D, Shimizu T1, Kitamura H, Iwasa T1, Nagashima F, Nakagawa K1(1Kindai University) : An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer chemotherapy and pharmacology, 2018.
  1. Sawaki M1, Tamura K2, Shimomura A2, Taki Y1, Nagashima F, Iwata H1(1Aichi Cancer Center Hospital, 2National Cancer Center Hospital) : Practice management for elderly patients with breast cancer: Findings from a survey by the Japan Breast Cancer Study Group. Nagoya Journal of Medical Science.80(2) : 217-26, 2018.
  2. Yamaguchi K1,2, Fujitani K3, Nagashima F, Omuro Y4, Machida N5, Nishina T6, Koue T7, Tsujimoto M7, (1Saitama Cancer Center, 2Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3Osaka General Medical Center, 4Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 5Shizuoka Cancer Center, 6National Hospital Organization Shikoku Cancer Center, 7Eli Lilly Japan, 8Osaka University Hospital)：Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. Gastric Cancer 21(6) : 1041-9, 2018.
  3. Hamamoto Y1,2, Sakakibara N1, Nagashima F, Kitagawa Y3, Higashi T1 (1National Cancer Center, 2Keio Cancer Center, 3Keio University School of Medicine)： Treatment selection for esophageal cancer: evaluation from a nationwide database. Esophagus15(2) : 109-14, 2018.
  4. Sawaki M1, Tamura K2, Shimomura A2, Taki Y1, Nagashima F, Iwata H1(1Aichi Cancer Center Hospital, 2National Cancer Center Hospital)：Practice management for elderly patients with breast cancer: Findings from a survey by the Japan Breast Cancer Study Group. Nagoya Journal of Medical Science 80(2) : 217-26, 2018.
  5. Furuse J, Kurata T1, Okano N, Fujisaka Y1, Naruge D, Shimizu T1, Kitamura H, Iwasa T1, Nagashima F1, Nakagawa K(1Kindai University Faculty of Medicine) : An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid Cancer Chemother Pharmacol.82(3):511-519, 2018.
  6. Todaka A1, Mizuno N2, Ozaka M3, Ueno H4, Kobayashi S5, Uesugi K6, Kobayashi N7, Hayashi H8, Sudo K9, Okano N, Horita Y10, Kamei K11, Yukisawa S12, Nakamori S13, Yachi Y14, Henmi T15, Kobayashi M16, Boku N1, Mori K1, Fukutomi A1(1Shizuoka Cancer Center, 2Aichi Cancer Center Hospital, 3The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 4National Cancer Center Hospital, 5Kanagawa Cancer Center Hospital, 6National Hospital Organization Shikoku Cancer Center, 7Yokohama City University Hospital, 8Hokkaido University Hospital, 9Chiba Cancer Center,10Toyama Prefectual Central Hospital,11Kindai University Faculty of Medicine, 12Tochigi Cancer Center, 13Osaka National Hospital,14DaiichiSankyo, 15Yakult Honsha,16Shizuoka Industrial Foundation Pharama Vally Center)：Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas47(5):631-636, 2018. DOI: 10.1097/MPA.0000000000001049.
  7. Yoshida T1,2, Hijioka S1,3, Hosoda W1,4, Ueno M5, Furukawa M6, Kobayashi N7, Ikeda M8, Ito T9, Kodama Y10, Morizane C3, Notohara K11, Taguchi H12, Kitano M13, Yane K14, Tsuchiya Y15, Komoto I16, Tanaka H17, Tsuji A18, Hashigo S19, Mine T20, Kanno A21, Murohisa G22, Miyabe K23, Takagi T24, Matayoshi N25, Sakaguchi M26, Ishii H27, Kojima Y28, Matsuo K29, Yoshitomi H30, Nakamori S31, Yanagimoto H32, Yatabe Y33, Furuse J, Mizuno N1 : (1Aichi Cancer Center Hospital, 2Kizawa Memorial Hospital, 3National Cancer Center Hospital, 4The Johns Hopkins University School of Medicine, 5Kanagawa Cancer Center, 6National Kyushu Cancer Center, 7Yokohama City University Hospital, 8National Cancer Center Hospital East, 9Kyushu University, 10Kyoto University, 11Kurashiki Central Hospital, 12Kagoshima University Graduate School of Medical and Dental Sciences, 13Kinki University, 14 Teine-Keijinkai Hospital, 15Niigata Cancer Center Hospital, 16Kansai Electric Power Hospital, 17Suzuka General Hospital, 18 Kobe City Medical Center General Hospital, 19Kumamoto University, 20Tokai University School of Medicine, 21Tohoku University Graduate School of Medicine, 22Seirei Hamamatsu General Hospital, 23Nagoya City University Graduate School of Medical Sciences, 24Fukushima Medical University School of Medicine, 25University of Occupational and Environmental Health, 26Saiseikai Kumamoto Hospital, 27Shikoku Cancer Center, 28Cancer Institute Hospital, 29Center Hospital of the National Center for Global Health and Medicine, 30Aichi Cancer Center Research Institute, 31Chiba University, 32National Hospital Organization Osaka National Hospital, 33Kansai Medical University Hospital)：Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Ann Surg Oncol. 26(5):1385-1393, 2019. DOI: 10.1245/s10434-019-07252-8. [Epub ahead of print]
  8. Furuse J: A PARP inhibitor in pancreatic cancer : Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?. EBioMedicine2019. DOI: 10.1016/j.ebiom.2019.01.039.
  9. Yasuda H1, Kataoka K1, Takeyama Y2, Takeda K3, Ito T4, Mayumi T5, Isaji S6, Mine T7, Kitagawa M8, Kiriyama S9, Sakagami J1, Masamune A10, Inui K11, Hirano K12, Akashi R13, Yokoe M14, Sogame Y1, Okazaki K15, Morioka C16, Kihara Y17, Kawa S18, Tanaka M4,Andoh A19, Kimura W20, Nishimori I21, Furuse J, Yokota I22, Shimosegawa T10 (1Kyoto Prefectural University of Medicine, 2Kindai University Faculty of Medicine, 3National Hospital Organization Sendai Medical Center, 4 Kyushu University, 5University of Occupational and Environmental Health, 6Mie University School of Medicine, 7Tokai University School of Medicine, 8Nagoya University of Arts and Sciences, 9Ogaki Municipal Hospital, 10Tohoku University Graduate School of Medicine, 11Fujita Health University Bantane Hospital, 12University of Tokyo, 13Kumamoto Regional Medical Center, 14Japanese Red Cross Nagoya Daini Hospital, 15Kansai Medical University, 16Nara Medical University, 17Kitakyushu General Hospital, 18Matsumoto Dental University, 19Shiga University of Medical Science, 20Yamagata University Faculty of Medicine, 21Kochi Medical School, 22Hokkaido University)：Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan. World J Gastroenterol 25(1) : 107-117, 2019.
  10. Motoi F1, Kosuge T2, Ueno H2, Yamaue H3, Satoi S4, Sho M5, Honda G6, Matsumoto I7, Wada K8, Furuse J, Matsuyama Y9, Unno M1, Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP) (1Tohoku University School of Medicine, 2National Cancer Center Hospital, 3Wakayama Medical University, 4Kansai Medical University, 5Nara Medical University, 6Tokyo Metropolitan Cancer and Infectious Diseases Center, 7Kindai University Faculty of Medicine, 8Teikyo University School of Medicine, 9University of Tokyo) : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49(2) : 190-194, 2019.
  11. Shitara K1, Yamanaka T2, Denda T3, Tsuji Y4, Shinozaki K5, Komatsu Y6, Kobayashi Y7, Furuse J, Okuda H8, Asayama M9, Akiyoshi K10, Kagawa Y11, Kato T12, Oki E13, Ando T14, Hagiwara Y15, Ohashi Y16, Yoshino T1 (1National Cancer Center Hospital East, 2Yokohama City University School of Medicine, 3Chiba Cancer Center, 4Tonan Hospital, 5Hiroshima Prefectural Hospital, 6Hokkaido University Hospital Cancer Center, 7Kushiro Rosai Hospital, 8Keiyukai Sapporo Hospital, 9Saitama Cancer Center, 10Osaka City General Hospital, 11Kansai Rosa Hospital, 12National Hospital Organization Osaka National Hospital, 13Kyushu University, 14University of Tsukuba, 15The University of Tokyo, 16Chuo University)：REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol 30(2) : 259-265, 2019.
  12. Ioka T1, Ueno M2, Ueno H3, Park JO4, Chang HM5, Sasahira N6, Kanai M7, Chung IJ8, Ikeda M9, Nakamori S10, Mizuno N11, Omuro Y12, Yamaguchi T13, Hara H14, Sugimori K15, Furuse J, Maguchi H16, Furukawa M17, Fukuzawa K18, Kim JS19, Yukisawa S20, Takeuchi M21, Okusaka T3, Boku N3, Hyodo I22 (1Osaka International Cancer Institute.2Kanagawa Cancer Center, 3National Cancer Center Hospital, 4Sungkyunkwan University School of Medicine, 5University of Ulsan College of Medicine, 6Cancer Institute Hospital of Japanese Foundation for Cancer Research, 7Kyoto University Hospital, 8Chonnam National University Hwasun Hospital, 9National Cancer Center Hospital East, 10National Hospital Organization Osaka National Hospital, 11Aichi Cancer Center Hospital, 12Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 13Chiba Cancer Center,14Saitama Cancer Center Hospital, 15Yokohama City University Medical Center, 16Teine-Keijinkai Hospital, 17National Hospital Organization Kyushu Cancer Center, 18Oita Red Cross Hospital, 19Korea University Guro Hospital, 20Tochigi Cancer Center, 21 Kitasato University, 22 University of Tsukuba)：TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer 106 : 78-88, 2019.
  13. Makishima H1, Yasuda S1, Isozaki Y1, Kasuya G1, Okada N1, Miyazaki M2, Mohamad O1,3, Matsufuji N1, Yamada S1, Tsuji H1, Kamada T1, Liver Cancer Working Group (1National Institute of Radiological Sciences Hospital, 2Mita Hospital, 3University of Texas Southwestern Medical center)：Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study. Cancer Sci 110(1) : 303-309,2019.
  14. Denda T1, Sakai D2, Hamaguchi T3, Sugimoto N4, Ura T5, Yamazaki K6 Fujii H7, Kajiwara T8, Nakajima TE9, Takahashi S10, Otsu S11, Komatsu Y12, Nagashima F, Moriwaki T13, Esaki T14, Sato T15, Itabashi M16, Oki E17, Sasaki T18, Sunaga Y18, Ziti-Ljajic S19, Brillac C19, Yoshino T20 (1Chiba Cancer Center, 2 Osaka University Graduate School of Medicine, 3 National Cancer Center Hospital, 4Osaka Medical Center for Cancer and Cardiovascular Disease, 5Aichi Cancer Center Hospital, 6Shizuoka Cancer Center, 7Jichi Medical University Hospital, 8Shikoku Cancer Center, 9 Marianna University School of Medical Hospital, 10Tohoku University Hospital, 11Oita University Hospital, 12Hokkaido University Hospital, 13University of Tsukuba Hospital, 14National Kyushu Cancer Center, 15Kitasato University East Hospital, 16Tokyo Women’s Medical University Hospital, 17Kyushu University Hospital, 18Sanofi K. K, 19Sanofi Oncology, 20National Cancer Center Hospital East) : Phase II trial of aflibercept with FOLFIRI as a second-line treatment , for Japanese patients with metastatic colorectal cancer. Cancer science, 2019.
  15. Shirasu H1, Todaka A1, Omae K2, Fujii H3, Mizuno N4, Ozaka M5, Ueno H6, Kobayashi S7, Uesugi K8, Kobayashi N9, Hayashi H10, Sudo K11, Okano N, Horita Y12, Kamei K13, Yukisawa S14, Kobayashi M15, Fukutomi A16 (1Shizuoka Cancer Center, 2Jichi Medical University Hospital, 3Aichi Cancer Center Hospital, 4The Cancer Institute Hospital of the Japanese Foundation For Cancer Research, 5National Cancer Center Hospital, 6Kanagawa Cancer Center, 7 National Hospital Organization Shikoku Cancer Center, 8Yokohama City University Hospital, 9 Hokkaido University Graduate School of Medicine, 10Chiba Cancer Center, 11Toyama Prefectural Central Hospital, 12 Kindai University, 13Tochigi Cancer Center, 14 Shizuoka Industrial Foundation Pharma Valley Center) : Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer Sci110(2) : 707-716, 2019. DOI: 10.1111, /cas.13883.

和文

  1. 北村浩1, 井戸田一朗1, 岡山香里2, 大河戸光章3, 佐野彰彦4, 佐野麻里子5, 小林治6, 河合伸4, 古瀬純司 (1しらかば診療所, 2群馬バース大・保・検査技術学, 3杏林大・保・ 臨床検査技術学, 4杏林大・医・総合医療学・5杏林大・医学部付属病院看護部, 6杏林大・保) : 拡大肛門鏡検査によるHIV陽性者の肛門管上皮内病変の診断と治療. 日本エイズ学会誌 20(1) : 25-31, 2018.
  2. 古瀬純司 : 切除不能膵癌に対する化学療法. 消化器外科 41(6):911-917, 2018.
  3. 古瀬純司 : 化学療法. 膵癌 臨牀消化器内科 33(7):167-173, 2018.
  4. 古瀬純司 : 切除不能膵癌に対する化学療法―現状と今後の展望. 癌の臨床 64(1) : 17-23, 2018.
  5. 古瀬純司 : 膵癌の治療. 化学療法と化学放射線療法. Current Therapy 36(6):23-28, 2018.
  6. 古瀬純司 : 急激に変貌する肝癌の薬物療法.免疫チェックポイント阻害薬（単剤）. Liver Cancer Journal 10(1):44-48, 2018.
  7. 古瀬純司 : 膵神経内分泌腫瘍の化学療法. 臨牀消化器内科 33(9):1177-1182, 2018.
  8. 古瀬純司 : 進行肝細胞癌に対する分子標的治療のオーバービュー. 消化器・肝臓内科 4(1):37-43, 2018.
  9. 古瀬純司 : Cabozantinibの第II相試験の振り返りと第III総試験結果. 肝胆膵 77(2):393-397, 2018.
  10. 古瀬純司 : ソラフェニブ不応進行肝細胞癌に対するレゴラフェニブの第Ⅲ相試験（RESORCE）の示唆すること. がん分子標的治療 16(3):78-81, 2018.
  11. 山内芳也, 長島文夫, 河合桐男, 岡野尚弘, 成毛大輔, 小林敬明, 古瀬純司：高齢がん患者の機能評価. 外科と代謝・栄養 52(1):17-22, 2018.
  12. 小林敬明, 前野聡子, 長島文夫：高齢者のがん診療〜実地医家の視点から〜 胃がん・大腸がん. 内科 121(4):887-891, 2018.
  13. 前野聡子, 長島文夫：がんとフレイル. 最新医学　別冊(フレイル):107-112, 2018.
  14. 前野聡子, 長島文夫：老年医学領域の高度医療・未来医療　高齢者のがん医療の進歩. 日本臨床76(増刊5 老年医学(上)):255-259, 2018.
  15. 岡野尚弘, 黒澤貴志, 西岡真理子, 前園知宏, 河合桐男, 小林敬明,長島文夫, 古瀬純司 : 切除不能胆道癌に対する二次治療　現状と今後の期待. 胆と膵39(10):869-874, 2018.
  16. 黒澤貴志, 前野聡子, 長島文夫：後期高齢者に対するがん薬物治療の問題点. 臨床腫瘍プラクティス 14(4):241-248, 2018.
  17. 長島文夫, 小林智1, 柳本泰明2, 中井陽介3(1神奈川県立がんセンター・消化器内科, 2関西医大・医・外科学講座, 3東京大・医・消化器内科)：膵・胆道癌高齢患者に対する積極的抗癌治療. 膵・胆道癌Frontier 7(2):64-71, 2018.
  18. 黒澤貴志, 岡野尚弘, 長島文夫, 古瀬純司 : 胆嚢癌の治療. 消化器内科 34(2):193-198, 2019.
  19. 古瀬純司 : 膵癌の予後改善に向けて. 医学のあゆみ 268(11):893, 2019.
  20. 岡野尚弘, 西岡真理子, 前園知宏, 黒澤貴志, 河合桐男, 小林敬明, 長島文夫, 古瀬純司 : 大腸がん化学療法の最近の潮流. 消化器・肝臓内科 5(1):1-9, 2019.
  21. 岡野尚弘：41st ESMO Congress 2016. 膵胆道癌FRONTIER 7(1):43-44, 2019.
  22. 岡野尚弘：切除不能膵癌に対するconversion surgery. 医学のあゆみ268(11):913-916, 2019.
  23. 前野聡子, 河合桐男, 黒澤貴志, 西岡真理子, 前園知宏, 北村浩, 小林敬明, 岡野尚弘, 長島文夫, 古瀬純司 : 高齢者に対する大腸癌化学療法の実際. 消化器・肝臓内科5(1):17-23, 2019.
  24. 前野聡子,長島文夫 ：高齢がん診療のあり方. Geriatric　Neurosurgery31：19-22, 2019.

 

著書

  1. 河合桐男,古瀬純司（分担執筆）: IV.　薬剤のマネージメント エベロリムス. 膵・消化管NETの診断と治療レジメン―治療に困った時に必ず役に立つ！―. 肱岡範, 奥坂拓志編集. 東京, 医学と看護社, 2018. p.92-96.
  2. 古瀬純司（分担執筆）:　肝癌, 胆道癌, 膵癌化学療法の最近の動向. エビデンスに基づいた癌化学療法ハンドブック 大津敦編集. 大阪, メディカルレビュー社, 2018. p.478-490.

 

 

 

 

  1. 岡野尚弘（分担執筆）: 膵癌　 エビデンスに基づいた癌化学療法ハンドブック2018. 大津敦編集. 大阪, メディカルレビュー社, 2018. p.511-513
  2. 岡野尚弘（分担執筆）: 膵癌　GEM＋Nab-PTX. エビデンスに基づいた癌化学療法ハンドブック 大津敦編集. 大阪, メディカルレビュー社, 2018. p.514-516
  3. 岡野尚弘（分担執筆）: 膵癌　GEM＋ エビデンスに基づいた癌化学療法ハンドブック2018. 大津敦編集. 大阪, メディカルレビュー社, 2018. p.521-523
  4. 岡野尚弘（分担執筆）： 大腸癌　UFT＋ 消化器がん化学療法レジメンブック4版. 室圭編著. 東京, 日本医事新報社, 2018. p.191-193.
  5. 岡野尚弘（分担執筆）： 大腸癌　IRI＋S-1/IRIS療法＋ベバシズマブ. 消化器がん化学療法レジメンブック4版. 室圭編著. 東京, 日本医事新報社, 2018. p.194-197.
  6. 古瀬純司（分担執筆）: ガイドライン外来診療膵癌. 東京, 日経メディカル開発, 2019. p.585-589.
  7. 古瀬純司（編者）: がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 大阪, メディカ出版，
  8. 古瀬純司（編者）: 膵癌の予後改善に向けて.医学のあゆみ.東京,医歯葉出版, 268(11), 2019
  9. 古瀬純司（編者）: 神経内分泌腫瘍の薬物療法.東京, 科学評論社, 23(3), 2019
  10. 岡野尚弘（分担執筆）: レゴラフェニブ. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.58-59.
  11. 岡野尚弘（分担執筆）: バンデタニブ. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.60-61.
  12. 岡野尚弘（分担執筆）: ゲムシタビン.化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.142-143.
  13. 岡野尚弘（分担執筆）: パクリタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.230-231.
  14. 岡野尚弘（分担執筆）: ナブパクリタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.232-233.
  15. 岡野尚弘（分担執筆）: ドセタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.234-235.
© Kyorin University All rights reserved.